| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Novavax, Inc.$9.33
-0.17 (-1.81%)
B 69Pipeline Score Undervalued Biotech · Commercial
Market Cap
1.51 B
EPS
-0.54
P/E Ratio
-
Value Trade
31.27 M
SEC Financials
Q1 2026Dilution Risk
Revenue
139.51 M
R&D Expenses
95.47 M
Operating CF
-32.42 M
Total Assets
1.04 B
Total Liabilities
1.19 B
Equity
-144.76 M
D/E Ratio
12,345
0.88 %
Week
7.85 %
1 Month
1.66 %
3 Month
47.36 %
6 Month
-93.62 %
5 Year
-88.49 %
All Time
Cash Data
Cash Position
790.33 M
Monthly Burn
10.81 M
Runway
71.2 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
5.10 M
52 Week Range
6.13 - 11.97
% held by Insiders
5.02 %
% held by Institutions
67.63 %
Enterprise Value
1.02 B
Total Shares
164.39 M
Short %
29.3 %
Float Shares
156.33 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Novavax, Inc.
1651Total events
3Upcoming
650Tier-1 (high impact)
2010 – 2027Coverage
Upcoming catalysts 3
Event history 1648
Q3 2026
◆Product LaunchPost-Market
Potential combination vaccine launch in fall 2026
COVID-19 and influenzasource ↗
Jun 4, 2026
May 13, 2026
Mar 30, 2026
Mar 11, 2026
Mar 10, 2026
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Fireside Chat
Mar 3, 2026
Feb 26, 2026
●Quarterly UpdateCorporate
Q4 and full year 2025 financial results and operational highlights
Jan 20, 2026
▲Partnership / LicenseCorporate
Novavax enters into license agreement with Pfizer for Matrix-M adjuvant
Jan 14, 2026
◆Oral PresentationPresentation
Novavax presentation at 44th Annual J.P. Morgan Healthcare Conference
Drug Pipeline Intelligence
B69
Pipeline Score $10.9B
Pipeline ValueUndervalued
Valuation Signal23
Drugs Scored15.0x
rNPV / MCap Top 93%
Micro Cap (rank 65 of 911)
Percentile RankNovavax, Inc. holds a solid B-grade pipeline (69/100), with $27.2B risk-adjusted pipeline value, led by SARS-CoV-2 rS/Matrix-M1 Adjuvant in SARS-CoV-2 Infection (Phase 3), across $122B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 rS/Matrix-M1 Adjuvant Monoclonal antibody | SARS-CoV-2 Infection | Phase 3 | NCT04533399 | 65% | $9.0B | COMPLETED | 19,607 | - | - | Jan 19, 2022 | - | Feb 17, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza | COVID-19 and Influenza | Phase 3 | 2025-06-11 | 2.4-5.7-fold over baseline | Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Both vaccine candidates indu Read More | |
COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza | COVID-19 and Influenza | Phase 3 | 2025-06-11 | 2.4-5.7-fold over baseline | Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Both vaccine candidates indu Read More | |
COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza | COVID-19 and Influenza | Phase 3 | 2025-06-11 | 2.4-5.7-fold over baseline | Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Both vaccine candidates indu Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NVAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NVAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NVAXNovavax to Participate in 2026 Jefferies Global Healthcare Conference
Novavax, Inc. has announced its participation in the 2026 Jefferies Global Healthcare Conference. The event will feature a fireside chat, with a webcast available for 30 days on the company's website. This participation highlights Novavax's commitment to addressing global health challenges through its innovative vaccine technologies.
Read more →NVAXNovavax to Participate in 2026 Jefferies Global Healthcare Conference Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference. Conference Details: Fireside...
Novavax, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 4, 2026. The event will include a fireside chat from 10:30 to 11:00 a.m. ET in New York, NY. A webcast of the chat will be available for 30 days on the company's website.
Read more →NVAXNovavax to Participate in BofA Securities 2026 Health Care Conference
Novavax, Inc. announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 13, 2026. The event includes a fireside chat and investor meetings, highlighting the company's ongoing engagement with stakeholders. A webcast of the chat will be available for 30 days post-event.
Read more →NVAX▲ +15.6%on this newsshared move
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
Novavax, Inc. reported its financial results for Q1 2026, highlighting significant progress in its corporate strategy, including a new licensing agreement with Pfizer for vaccine candidates. The company is also advancing its C. difficile vaccine candidate towards clinical trials. However, its revenue projections depend on Sanofi's forecasts, and regulatory approval uncertainties remain a concern.
Read more →NVAXNovavax to Report First Quarter 2026 Financial Results on May 6, 2026
Novavax, Inc. will announce its first quarter 2026 financial results on May 6, 2026, at 8:30 a.m. ET. The company will host a conference call to discuss operational highlights, with details available for participants to join. A replay of the call will be accessible for a limited time after the event.
Read more →NVAXNovavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Novavax has appointed Dr. Robert Walker as the new Executive Vice President and Head of R&D. Dr. Walker brings over 30 years of experience in drug and vaccine development, having previously served as Chief Medical Officer at Novavax. His appointment is seen as a strategic move to enhance the company's research and development capabilities.
Read more →NVAX▼ -9.4%on this news
Novavax to Participate in Upcoming Investor Conferences
Novavax, Inc. has announced its participation in several upcoming investor conferences. The company will provide webcasts of the events, which will be accessible on its website for 30 days. This initiative reflects Novavax's commitment to engaging with investors and sharing insights about its vaccine technology and growth strategies.
Read more →NVAX▲ +17.4%on this newsshared move
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Novavax, Inc. reported its financial results for Q4 and the full year 2025, highlighting significant progress in corporate strategy and partnerships. The company anticipates a revenue range of $230 million to $270 million for 2026, driven by collaborations with Sanofi and Pfizer. However, it faces challenges related to regulatory approvals and market acceptance of its vaccine candidates.
Read more →NVAX▲ +6.2%on this news
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Novavax, Inc. (Nasdaq: NVAX) announced that it will report its fourth quarter and full year 2025 financial results on February 26, 2026. The event will be accessible via a conference call starting at 8:30 a.m. Eastern Time. Replay details for the event and instructions for registration have also been provided, allowing stakeholders to participate or access the information later. Novavax aims to enhance its impact through cutting-edge vaccine technology and strategic partnerships.
Read more →NVAXNovavax Announces Entering into a License Agreement with Pfizer
Novavax has entered into a license agreement with Pfizer for its Matrix-M adjuvant, allowing Pfizer to use this technology in up to two disease areas. CEO John C. Jacobs expressed optimism about the partnership, indicating it reflects the potential of Matrix-M in new product development. However, the agreement comes with various risks and uncertainties regarding implementation and regulatory approval.
Read more →NVAX▲ +6.6%on this news· ran to +19% by day 1
xA9; 2026 NOVAVAX. All rights reserved. 1 Novavax Corporate Presentation John C. Jacobs, President and Chief Executive Officer J.P. Morgan Healthcare Conference © 2026 NOVAVAX. All rights reserved. 1 © 2026 NOV
Novavax has outlined several challenges it faces in its corporate presentation, particularly concerning obtaining necessary regulatory approvals for its COVID-19 vaccine. The company has emphasized potential risks including delays in manufacturing, supply chain issues, and the impact of external partnerships. Investors are warned against placing heavy reliance on forward-looking statements due to these uncertainties. Additionally, the presentation mentions challenges in securing funding for ongoing operations and further development of vaccine candidates.
Read more →NVAXNovavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Novavax, Inc. has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The event will feature a webcast of their presentation, available for 30 days post-event. The company aims to tackle global health challenges through its innovative vaccine technology and seeks to expand its partnerships and research efforts.
Read more →NVAXNovavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. has announced its participation in the Jefferies London Healthcare Conference scheduled for November 19, 2025. The event will feature a fireside chat at 4:30 p.m. GMT, which will also be available via webcast. This participation highlights Novavax's ongoing efforts to engage with investors and share insights into its vaccine development initiatives.
Read more →NVAXNovavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Novavax, Inc. has reported its financial results for Q3 2025, highlighting a strategic focus on R&D and partnerships aimed at long-term growth. Despite a significant drop in total revenue and Nuvaxovid sales, the company is prioritizing the optimization of its partnership with Sanofi and advancing its technology platform. The net loss for the quarter was $202.4 million.
Read more →NVAX▼ -5.1%on this newsshared move
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax has successfully transferred the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™, to Sanofi, which will now manage commercial and regulatory activities in the U.S. This transfer has triggered a $25 million milestone payment to Novavax, contributing to a total of $225 million in milestone revenue. Novavax remains eligible for additional future milestones and royalties under their collaboration agreement with Sanofi.
Read more →NVAX▼ -5.1%on this newsshared move
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid , Triggering a $25 Million Milestone Payment Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S
Novavax has completed the transfer of U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi, allowing Sanofi to manage commercialization in the U.S. This transfer triggered a $25 million milestone payment for Novavax, following a similar transfer to the European Union. With this, Novavax has secured $225 million in milestone revenue to date. Additionally, Novavax is eligible for future milestone payments under its collaboration with Sanofi, which may include royalties and new product opportunities.
Read more →NVAXNovavax to Report Third Quarter 2025 Financial Results on November 6, 2025
Novavax, Inc. has announced it will report its third quarter 2025 financial results and operational highlights on November 6, 2025. The announcement includes details about a conference call for stakeholders, emphasizing the importance of timely participation. The company continues to focus on expanding its technological capabilities and partnerships in the healthcare sector.
Read more →NVAXNovavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
Novavax has announced a site consolidation in Maryland as part of its strategy to become a leaner organization. This move is expected to generate $60 million in upfront payments and save $230 million over 11 years. The consolidation aligns with Novavax's focus on enhancing its research and development capabilities while minimizing costs.
Read more →NVAXNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
Novavax has successfully transferred the EU marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi, which has triggered a $25 million milestone payment. This transfer allows Sanofi to manage commercial and regulatory activities in the EU, furthering their collaboration. Novavax is also eligible for additional payments and royalties related to future products developed by Sanofi using its technology.
Read more →NVAXNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment GAITHERSBURG, Md.
Novavax, Inc. has successfully completed the transfer of marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi in the European Union. This transfer enables Sanofi to handle commercial and regulatory activities for the vaccine in the EU and triggers a milestone payment of $25 million to Novavax. The collaboration between Novavax and Sanofi continues to evolve, with opportunities for additional milestones and royalties from future products. This development is part of Novavax’s strategy to optimize its partnerships and expand its vaccine portfolio.
Read more →NVAXNovavax Announces Progress on Sanofi Agreement
Novavax has announced an amendment to its collaboration and license agreement with Sanofi, allowing the use of its Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. This partnership aims to enhance vaccine development and is supported by funding from the Biomedical Advanced Research and Development Authority. The agreement could lead to substantial financial benefits for Novavax as Sanofi progresses through clinical phases.
Read more →NVAX▲ +5.3%on this news
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
Novavax has received regulatory approval for its COVID-19 vaccine, Nuvaxovid, in Japan, triggering a milestone payment from Takeda. This approval allows for both initial and booster vaccinations for various age groups. The partnership with Takeda is expected to enhance Novavax's market presence and financial stability, despite potential regulatory and production challenges.
Read more →NVAXNovavax to Participate in the Cantor Global Healthcare Conference
Novavax, Inc. will participate in the Cantor Global Healthcare Conference on September 4, 2025. The event will feature a fireside chat at 10:20 a.m. ET in New York, NY. A webcast of the chat will be available on the company's website, with a replay accessible for 30 days. This participation highlights Novavax's ongoing efforts in the healthcare sector.
Read more →NVAXNovavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Novavax has received FDA approval for its Nuvaxovid 2025-2026 Formula COVID-19 vaccine, targeting adults aged 65 and older and younger individuals with high-risk conditions. The vaccine is designed to combat the JN.1 variant and is set to be commercialized in partnership with Sanofi. Clinical data supports its safety and efficacy, although there are ongoing risks related to regulatory approvals and manufacturing dependencies.
Read more →NVAXNovavax's Nuvaxovid 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERS
Novavax, Inc. has announced the U.S. FDA's approval of its Nuvaxovid 2025-2026 Formula COVID-19 vaccine, making it the only protein-based, non-mRNA option available. This vaccine is intended for individuals aged 65 and older, or those aged 12 to 64 with underlying health conditions. The company plans to partner with Sanofi for distribution ahead of the upcoming vaccination season. While the vaccine has shown safety and efficacy, there are concerns regarding adverse reactions and potential supply chain issues that may impact availability.
Read more →NVAX▼ -12.7%on this news
Novavax Announces Convertible Debt Refinancing
Novavax, Inc. has announced a refinancing of its debt by issuing $225 million in new convertible senior notes due in 2031, replacing a portion of existing notes due in 2027. The company will issue approximately $175 million in exchange for retiring some existing debt and raising an additional $50 million in new capital. This refinancing is aimed at improving the company's capital structure and extending the maturity of significant portions of its existing debt to 2031. The conversion price for the new notes is set at a premium over current stock prices, which could impact shareholder perspectives.
Read more →NVAX▼ -8.2%on this news· ran to -21% by day 3shared move
Novavax Announces Convertible Debt Refinancing Refinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange
Novavax, Inc. has announced a refinancing of its convertible debt, extending the maturity of a significant portion of its existing 5.00% Convertible Senior Notes from 2027 to new 4.625% Convertible Senior Notes due in 2031. The transaction includes issuing $225 million in notes, with a substantial part converted from existing notes and a cash subscription component. This refinancing is aimed at strengthening the company's capital structure, with a conversion price set at a premium over current stock prices. The completion of these transactions is anticipated to improve the company's financial flexibility ahead.
Read more →NVAX▲ +12.6%on this news· ran to +30% by day 1
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
Novavax reported its financial results for Q2 2025, highlighting total revenue of $239 million, down from $415 million in Q2 2024. Key achievements include FDA BLA approval for Nuvaxovid, generating a $175 million milestone payment from Sanofi. The company also noted promising immune responses from its COVID-19-Influenza-Combination and stand-alone influenza vaccines in Phase 3 trials. However, significant declines in product sales and overall revenue present challenges ahead as Novavax transitions commercial leadership to Sanofi for the upcoming vaccination season.
Read more →NVAXNovavax to Report Second Quarter 2025 Financial Results on August 6, 2025
Novavax, Inc. has announced that it will report its second quarter 2025 financial results and operational highlights on August 6, 2025. The conference call is scheduled for 8:30 a.m. ET and will be accessible via dial-in and webcast. Novavax emphasizes its commitment to addressing significant health issues through its vaccine technology and partnerships.
Read more →NVAXNovavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate,...
Novavax, Inc. announced promising preclinical results for its H5N1 avian influenza vaccine candidate, indicating robust immunogenicity against current variants. The vaccine demonstrated strong immune responses from both single and two-dose administrations, with results published in Nature Communications. The company emphasized the potential for single-dose delivery methods, either intranasally or intramuscularly, as part of its pandemic preparedness efforts. Novavax also plans to pursue partnerships and funding to advance the development of its vaccine candidate.
Read more →NVAXNovavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Both vaccine candidates indu
Novavax announced positive results from the initial cohort of its Phase 3 trial for both its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. The data revealed that both candidates elicited strong immune responses and were well tolerated by participants aged 65 and older. With no new safety concerns raised, the results are seen as supportive of further development and potential partnerships. However, the trial lacked sufficient power for statistical significance, and Novavax faces challenges in partnerships and regulatory pathways.
Read more →NVAXNovavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Novavax, Inc. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent...
Novavax, Inc. announced positive results from an initial cohort of its Phase 3 trial for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccines. Both candidates demonstrated robust immune responses and were well tolerated by participants, aligning with previous Phase 2 findings. The trial, designed for descriptive data, engaged around 2,000 adults aged 65 and older. These results will inform potential partnerships and future registrational programs, marking a positive step in vaccine development.
Read more →NVAX▲ +15%on this news
U.S. FDA Approves BLA for Novavax
The U.S. FDA has approved Novavax's Biologics License Application for its COVID-19 vaccine, Nuvaxovid™, aimed at adults aged 65 and older and younger individuals with underlying health conditions. This approval triggers a significant milestone payment from Sanofi and marks a pivotal point for vaccine options in the U.S. The FDA also requires a new postmarketing commitment for further trials to assess the vaccine in a broader population. Novavax intends to prepare for commercial delivery of this vaccine for the upcoming vaccination season, while also managing safety risks highlighted in the approval process.
Read more →NVAX▲ +11.9%on this news
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
Novavax, Inc. reported its first quarter 2025 financial results, showcasing a total revenue of $667 million, significantly up from $94 million a year earlier. The FDA has indicated a potential pathway to approval for Novavax's COVID-19 Biologics License Application, contingent on aligning on study parameters for a postmarket commitment. The company also experienced a strengthened partnership with Takeda in Japan, which bodes well for future revenue generation. Furthermore, Novavax raised its full-year 2025 revenue guidance, anticipating revenues between $975 million and $1,025 million.
Read more →NVAXNovavax to Participate in BofA Securities 2025 Health Care Conference
Novavax, Inc. has announced its participation in the BofA Securities 2025 Health Care Conference scheduled for May 14, 2025, in Las Vegas, NV. The company will hold a fireside chat and investor meetings, providing a platform to present its advancements in vaccine technology. A webcast of the fireside chat will be accessible on their website, with a replay available for 30 days. Novavax aims to expand its partnerships and diversify its growth strategy by leveraging its scientific expertise in vaccines.
Read more →NVAXNovavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
Novavax, Inc. has announced enhanced collaboration terms with Takeda for its COVID-19 vaccine, Nuvaxovid®, in Japan. The updated agreement includes improved financial arrangements such as upfront payments and royalties linked to sales. This strengthened partnership is expected to facilitate Novavax's operations in the significant Japanese market. However, the company acknowledges various risks including regulatory challenges and reliance on third-party manufacturers that could impact its success.
Read more →NVAXNovavax to Report First Quarter 2025 Financial Results on May 8, 2025
Novavax, Inc. has announced that it will report its financial results for the first quarter of 2025 on May 8, 2025. The conference call is scheduled for 8:30 a.m. Eastern Time. Interested participants can register online for the call or listen to the webcast on the company's investor relations website. Novavax is focusing on strategic collaborations and expanding its pipeline in infectious diseases and potentially other areas.
Read more →NVAXNovavax Appoints Charles Newton to Board of Directors
Novavax, Inc. has appointed Charles Newton as an independent director on its board. Newton, who has extensive experience in healthcare investment banking, is expected to contribute significantly to the company's growth strategy, particularly in securing partnerships for its R&D initiatives. The company aims to leverage its advanced technology platform, including its Matrix-M adjuvant, to enhance access to its products. With a strong background in finance and governance, Newton's addition to the board represents a strategic move for Novavax as it seeks to navigate challenges in the vaccine market.
Read more →NVAXSHIELD-Utah Study Shows Novavax
Preliminary results from the SHIELD-Utah study indicate that Novavax's non-mRNA COVID-19 vaccine has a better side effect profile compared to Pfizer-BioNTech's mRNA vaccine. The study, conducted by the University of Utah Health, revealed that recipients of the Novavax vaccine experienced fewer and less severe reactogenicity symptoms. Participants also reported a lower impact on daily activities due to vaccine-related symptoms. Full results are expected to be published later this year.
Read more →NVAXNovavax Announces Changes to Board of Directors
Novavax, Inc. announced the retirement of James Young, PhD, as Chair of the Board, with Margaret McGlynn, RPh, appointed as his successor. John Shiver, PhD, has also been appointed to the board as an independent director. Under Young's leadership, the company made several key acquisitions and launched its COVID-19 vaccine. With the new appointments, Novavax aims to advance its corporate growth strategy and expand its vaccine pipeline.
Read more →NVAXNovavax Announces Changes to Board of Directors James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointed John Shiver, PhD appointed to board of directors GAITHERSBURG, Md.
Novavax, Inc. announced changes to its Board of Directors, with Dr. James Young retiring as Chair and being succeeded by Margaret McGlynn, alongside the appointment of John Shiver as an independent director. Dr. Young, who held his position since 2011, is credited with significant contributions including Novavax's COVID-19 vaccine development and strategic partnerships. McGlynn and Shiver bring extensive experience in vaccine development, which positions the company well for future growth initiatives and collaborations.
Read more →NVAXNovavax Corporate Presentation March 2025 2025 NOVAVAX. All rights reserved. 2 Cautionary Note Regarding Forward - Looking Statements 2025 NOVAVAX. All rights reserved. This presentation includes forward - looking statem
Novavax is set to transition its Nuvaxovid commercial supply to Sanofi for the upcoming vaccination seasons in 2025 and 2026, with reimbursement recorded as product sales. The company is also eligible for up to $200 million in milestones and royalties from its vaccine collaborations, including potential phase 3 development payments associated with combination products. However, sales forecasts remain reliant on Sanofi's predictions, with initial projections indicating that sales could be immaterial. The financial outlook suggests a shift towards licensing and royalty revenue, alongside a decrease in operating expenses as Novavax focuses on key value-producing R&D programs.
Read more →NVAXNovavax to Participate in Upcoming March Investor Conferences
Novavax, Inc. (Nasdaq: NVAX) announced its participation in several upcoming investor conferences in March 2025. The events include the TD Cowen 45th Annual Health Care Conference and the Leerink Partners 2025 Global Healthcare Conference, where they will present and engage in investor meetings. Novavax aims to leverage its scientific expertise and technology to address significant health challenges, focusing on building partnerships and advancing its pipeline.
Read more →NVAXNovavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Novavax reported its financial results for Q4 and the full year 2024, transitioning commercial responsibility for its COVID-19 vaccine to Sanofi to focus on expanding its pipeline. The company achieved total revenue of $682 million in 2024, though down from the previous year, with significant cost reductions from selling its Czech manufacturing facility. Novavax expects to provide financial guidance for 2025, targeting adjusted revenues of $300 to $350 million. The company's financial strategy indicates a shift towards leveraging partnerships and advancing its technology platform.
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
Novavax, Inc. has announced a conference call scheduled for February 27, 2025, to discuss its financial results for the fourth quarter and full year of 2024. Participants can register for the call and it will also be available via webcast. The company is focused on developing innovative vaccines, including a COVID-19 vaccine and other pipeline candidates. This call represents an important opportunity for stakeholders to hear directly from the company regarding its operational highlights.
Read more →NVAX▼ -7.6%on this news
Novavax Corporate Presentation January 2025 2025 NOVAVAX. All rights reserved. 2 Cautionary note regarding forward - looking statements 2025 NOVAVAX. All rights reserved. This presentation includes forward - looking stat
Novavax provided guidance for its financial performance in 2024, highlighting an expectation of $100 million in product sales from APA dose deliveries in the first half. The company also anticipates $450 million in revenue from an upfront payment from Sanofi. However, Novavax faces risks, including supply chain challenges and uncertainties regarding the market acceptance of its vaccine products. Additionally, the company's forward-looking statements underscore the inherent risks and uncertainty associated with operational execution.
Read more →NVAXNovavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax has made significant progress in its partnership with Sanofi, achieving the first $50 million milestone related to its COVID-19 vaccine clinical trials. This partnership includes potential future milestones totaling up to $300 million and tiered royalties from combined vaccine products. With the Fast Track designation received for combination vaccine trials, Novavax is positioned for enhanced growth, although it faces certain operational risks and dependencies that could affect future outcomes. Overall, this advancement reflects Novavax's strategic efforts to strengthen its corporate growth through partnerships and vaccine development.
Read more →NVAXNovavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Novavax has initiated a Phase 3 trial for its COVID-19-Influenza Combination and stand-alone seasonal influenza vaccines, marking a key advancement in its late-stage pipeline. The trial, involving around 2,000 participants, aims to assess the safety and immunogenicity of the vaccine candidates compared to existing vaccines. The company is exploring an accelerated approval pathway with the U.S. FDA while addressing various risks, including challenges related to clinical trials and regulatory processes. Novavax expects to provide updates on the trial by Q2 2025.
Read more →NVAXNovavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
Novavax, Inc. has announced the sale of its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk for $200 million. The agreement includes a $190 million cash payment in 2024 and an additional $10 million in 2025, along with expected annual operating cost reductions of approximately $80 million. This transaction aims to support Novavax's corporate growth strategy by allowing the company to focus more on its pipeline assets utilizing its technology platform. The transfer is expected to be completed by December 30, 2024.
Read more →NVAXInvestor Presentation © 2024 NOVAVAX. All rights reserved. 1 NASDAQ: NVAX | NOVEMBER 2024 2 Cautionary note regarding forward-looking statements © 2024 NOVAVAX. All rights reserved. This presentation includes f
Novavax has outlined its financial guidance for 2024, projecting $100 million in APA dose deliveries and between $75 million to $125 million in commercial sales for the second half. The company highlights its competitive position in the COVID-19 vaccine market, achieving a 70% regional market share, primarily among the 65+ audience. However, it faces substantial risks including production delays, challenges in regulatory approvals, and dependence on partnerships. The company has also cautioned investors regarding the uncertainty of forward-looking statements.
Read more →NVAXNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
Novavax, Inc. has granted a non-qualified stock option and restricted stock units to Dr. Ruxandra Draghia-Akli following her appointment as Executive Vice President and Head of Research & Development. This grant, effective November 11, 2024, includes an option to purchase 64,150 shares at a price of $9.01 and applying to her continued employment. These actions were taken in compliance with Nasdaq Listing Rule 5635(c)(4) and underscore Novavax's commitment to its innovative vaccine development strategy.
Read more →NVAX▼ -6.1%on this news· ran to -19% by day 3shared move
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Novavax reported its financial results for Q3 2024, achieving $85 million in revenue despite a decline from $187 million in the previous year. The company recently received FDA authorization for its updated COVID-19 vaccine and has made progress in removing clinical holds on its vaccine candidates. Novavax is focusing on reducing operating expenses and enhancing its R&D strategy to drive future growth. The net loss for the quarter was $121 million, showing marginal improvement from a loss in the same period of 2023.
Read more →NVAXU.S. FDA Removes Clinical Hold on Novavax
Novavax, Inc. announced that the U.S. FDA has lifted the clinical hold on its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. The FDA's decision allows Novavax to proceed with enrolling participants in a Phase 3 trial after resolving issues surrounding a serious adverse event previously reported. The adverse event was reclassified and deemed unrelated to the vaccine. Novavax aims to resume trial activities quickly while navigating potential risks and uncertainties as outlined in its forward-looking statements.
Read more →NVAXU.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial GAITHERSBURG, Md.
Novavax, Inc. announced that the U.S. FDA has removed the clinical hold on its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates, permitting the commencement of Phase 3 trials. This decision follows satisfactory resolution of clinical hold issues, with the FDA confirming that a previously reported serious adverse event was not related to their investigational vaccine. Novavax plans to quickly resume trial activities in collaboration with clinical trial investigators and partners.
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
Novavax, Inc. has announced it will hold a conference call on November 12, 2024, to discuss its third quarter financial results and operational highlights. The call will take place at 8:30 a.m. ET, with details for participation provided. Novavax, known for its protein-based vaccine platform, continues to develop and commercialize innovative vaccines targeting serious infectious diseases, including COVID-19 and influenza.
Read more →NVAX▼ -19.4%on this news
Update on Novavax
Novavax, Inc. has announced that the FDA has placed a clinical hold on its Investigational New Drug application for its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates due to a reported serious adverse event involving motor neuropathy. The event occurred in a participant from a Phase 2 trial outside the U.S. who received the vaccine in January 2023. Novavax is working closely with the FDA to address these concerns and hopes to resolve the hold and proceed with the Phase 3 trial as soon as possible.
Read more →NVAX▼ -19.4%on this news
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial GAITHERSBURG, Md.
Novavax has announced that the FDA has issued a clinical hold on its Investigational New Drug application for the COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. This decision stems from a serious adverse event involving motor neuropathy reported by a trial participant who had received the vaccine. Novavax is working with the FDA to address concerns and hopes to resolve the hold to begin the Phase 3 trial. Notably, their existing COVID-19 vaccine candidate is not affected by this hold.
Read more →NVAXNovavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European...
Novavax has announced that its 2024-2025 Nuvaxovid™ COVID-19 vaccine has received Marketing Authorization from the European Commission for individuals aged 12 and older. This authorization follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use. Notably, the vaccine targets the JN.1 variant, showing non-clinical data indicating cross-reactivity against multiple lineage viruses. Although it has received authorization, the vaccine is under Emergency Use Authorization in the U.S. and carries potential safety risks, including myocarditis and limitations in its effectiveness.
Read more →NVAX▼ -9.4%on this news
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
Novavax has appointed Dr. Ruxandra Draghia-Akli as the new Executive Vice President and Head of Research & Development, effective November 2024. Dr. Draghia-Akli boasts over 20 years of experience in clinical and public health, having held senior roles at notable organizations including Johnson & Johnson and Merck. She is expected to play a crucial role in reshaping Novavax's R&D strategy and evaluating its pipeline of vaccines, particularly the Matrix-M™ adjuvant technology. Her predecessor retired in July 2024, and her appointment comes as Novavax aims to expand beyond COVID-19 vaccine efforts.
Read more →NVAX▲ +14.2%on this news
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
Novavax has announced that its 2024-2025 Formula COVID-19 vaccine is now available at thousands of U.S. pharmacies, making it the only protein-based option for individuals aged 12 and older this fall. The vaccine received Emergency Use Authorization from the FDA on August 30, 2024, and features a pre-filled syringe for easier administration. It targets the JN.1 variant and demonstrates cross-reactivity against other circulating strains. However, the vaccine is still under EUA and comes with warnings regarding potential adverse reactions including myocarditis.
Read more →NVAX▼ -6.3%on this news
Novavax to Participate in Upcoming September Conferences
Novavax, Inc. will participate in two upcoming investor conferences in New York City. The H.C. Wainwright Global Investment Conference will take place on September 9, 2024, featuring a fireside chat with company executives. The following day, Novavax will present at the Baird 2024 Global Healthcare Conference. These events aim to provide insights into the company's advancements in vaccine technology and corporate strategy.
Read more →NVAXNovavax 2024-2025 Formula COVID-19-Impfstoff jetzt für die Verwendung in den USA zugelassen und empfohlen.
Novavax has received Emergency Use Authorization for its 2024-2025 COVID-19 vaccine (NVX-CoV2705) from the FDA, making it the only protein-based option available for individuals 12 years and older in the USA. The vaccine, which targets the JN.1 variant, is now recommended by the CDC and will be distributed through various retail locations. Clinical studies highlighted side effects such as headaches and fatigue, and while the vaccine has shown effectiveness, it remains only authorized for emergency use, with certain safety warnings including a risk of myopericarditis.
Read more →NVAXLa vacuna contra la COVID-19 de fórmula 2024-2025 de Novavax ya está autorizada en EE. UU.
Novavax, Inc. ha anunciado que su vacuna contra la COVID-19 de fórmula 2024-2025 ha sido autorizada para uso de emergencia por la FDA en EE. UU., permitiendo su administración en personas a partir de 12 años. La vacuna, que se basa en proteínas y utiliza el adyuvante Matrix-M, está diseñada para proporcionar protección contra la cepa JN.1 y se espera que esté disponible en miles de farmacias y tiendas. A pesar de su autorización, las reacciones adversas y la posibilidad de eficacia limitada son consideraciones importantes a tener en cuenta.
Read more →NVAXL'utilisation du vaccin Novavax 2024-2025 Formula COVID-19 est désormais autorisée et recommandée aux États-Unis Novavax, Inc. (Nasdaq : NVAX), société mondiale qui fait progresser les vaccins à base de protéines avec son adjuvant Matrix-M™, annonce aujourd'hui...
Novavax, Inc. a annoncé l'autorisation d'utilisation d'urgence de son vaccin COVID-19 2024-2025 par la FDA pour les personnes âgées de 12 ans et plus. Le vaccin, qui cible la souche JN.1, sera disponible sous forme de seringues préremplies dans diverses pharmacies et points de vente aux États-Unis. Cette décision est soutenue par une recommandation du CDC, permettant d'adopter cette option pour prévenir la maladie. Cette mise à disposition vise à renforcer la lutte contre le COVID-19 dans le pays.
Read more →NVAX▲ +8.6%on this newsshared move
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), has received Emergency Use Authorization from the FDA for individuals aged 12 and older. This protein-based vaccine is the only option available of its kind in the U.S. and targets the JN.1 variant of COVID-19. Pre-filled syringes will be distributed across various locations nationwide. While authorization is a positive development, the vaccine still carries risks including potential adverse reactions.
Read more →NVAX▲ +9.1%on this news
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
Novavax reported financial results for the second quarter of 2024, achieving $415 million in revenue and securing a $570 million investment from Sanofi. The company anticipates initiating Phase 3 trials for a COVID-19-Influenza Combination vaccine in Q4 2024, with results expected by mid-2025. While operating cash was bolstered to $1.1 billion, total revenues and R&D expenses showed fluctuations compared to previous periods, reflecting ongoing adjustments as Novavax evolves its operational strategy.
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
Novavax, Inc. has announced a conference call scheduled for August 8, 2024, to discuss its second quarter financial results and operational highlights. The call will take place at 8:30 a.m. Eastern Time and will provide insights into the company's performance and strategic plans. Interested participants can join via phone or webcast, with details available on Novavax's investor relations page. Following the call, a replay will be accessible for a limited time.
Read more →NVAXNovavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax has submitted a type II application to the European Medicines Agency for its updated JN.1 COVID-19 vaccine, aimed at individuals aged 12 and older. The vaccine is targeted to current circulating strains, including KP.2 and KP.3. Nonclinical data suggest strong immune responses, and Novavax plans for immediate distribution upon approval in the EU. The company is also filing for FDA approval, but there are inherent risks including potential delays in regulatory processes and challenges with manufacturing resources.
Read more →NVAXNovavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax has submitted an amendment for its JN.1 COVID-19 vaccine to the U.S. FDA, targeting current variants including KP.2 and KP.3. This protein-based vaccine aims to be available in the U.S. for the upcoming vaccination season and is aligned with recommendations from major health authorities. The new formula is designed to meet emerging strains and enhance immunogenic response, although challenges regarding regulatory approval and supply chain logistics are noted. If authorized, Novavax plans to distribute the vaccine swiftly.
Read more →NVAX▼ -6.7%on this news· ran to -20% by day 3
Investor Presentation 1 2024 NOVAVAX. All rights reserved. NASDAQ: NVAX | JUNE 2024 2 Cautionary note regarding forward - looking statements 2024 NOVAVAX. All rights reserved. This presentation includes forward - looking
Novavax provided an investor presentation outlining key updates for 2024, including a significant shift of $250 million in contracted vaccine doses to future periods. The company has secured a $500 million upfront payment from Sanofi, which may enhance various operational capabilities. However, substantial risks remain, including regulatory challenges and high dependency on supply partners like Serum Life Sciences. Overall, Novavax is pursuing opportunities in key markets and is preparing for future vaccine approvals.
Read more →NVAXNovavax to Participate in 2024 Jefferies Global Healthcare Conference
Novavax, Inc. has announced its participation in the 2024 Jefferies Global Healthcare Conference, scheduled for June 6, 2024, in New York, NY. The event will feature a fireside chat with John C. Jacobs, President and CEO, and provide opportunities for investor meetings. Novavax is known for its protein-based vaccines, including COVID-19 and combination vaccine candidates. A replay of the session will be available on the company's website for 30 days post-conference.
Read more →NVAX▲ +47.6%on this news· ran to +62% by day 3
Novavax to Participate in BofA Securities 2024 Health Care Conference
Novavax, Inc. (Nasdaq: NVAX) will participate in the BofA Securities 2024 Health Care Conference on May 15, 2024, where CEO John C. Jacobs will engage in a fireside chat. This participation reflects Novavax's commitment to advancing its protein-based vaccine technologies and offers the company a platform to connect with investors. The event will also include investor meetings, reinforcing Novavax's efforts to enhance its visibility within the biopharmaceutical sector.
Read more →NVAX▲ +98.7%on this news· ran to +193% by day 1shared move
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. has reported its financial results and operational highlights for Q1 2024, announcing a co-exclusive licensing agreement with Sanofi aimed at co-commercializing COVID-19 vaccines and developing combination vaccines. This deal presents a potential revenue opportunity of approximately $1.3 billion for Novavax, which includes an upfront payment of $500 million. Additionally, the company has made significant progress in reducing liabilities and enhancing its financial health. Novavax is also on track to launch a Phase 3 trial for its COVID-19-Influenza combination vaccine in the latter half of 2024.
Read more →NVAX▲ +98.7%on this news· ran to +193% by day 1shared move
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza
Novavax, Inc. has reported its financial results for the first quarter of 2024 and highlighted an important partnership with Sanofi. The companies have signed a co-exclusive licensing agreement to commercialize Novavax's COVID-19 vaccine and collaborate on developing a COVID-19-Influenza combination vaccine. This partnership aims to bolster Novavax's market position and funding for R&D projects. However, the agreement also brings challenges in ensuring successful implementation and navigating regulatory approvals for new vaccines.
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024
Novavax, Inc. announced that it will report its first quarter 2024 financial results and operational highlights on May 10, 2024. The conference call is scheduled to commence at 8:30 a.m. ET and will provide participants with insights into the company's performance. Details regarding joining the call and accessing the replay have been outlined in the announcement.
Read more →NVAX▲ +12%on this news· ran to +26% by day 3
Novavax to Participate in TD Cowen
Novavax, Inc. announced its participation in TD Cowen's 44th Annual Health Care Conference, scheduled for March 6, 2024, in Boston. John Jacobs, the President and CEO of Novavax, will engage in a fireside chat during the event. This forum allows Novavax to showcase its advancements in protein-based vaccines and to discuss both current and future vaccine developments, including its COVID-19 and influenza vaccines. The event highlights Novavax's ongoing commitment to innovating in the vaccine sector.
Read more →NVAX▼ -26.7%on this newsshared move
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Novavax reported its fourth quarter and full year 2023 financial results, highlighting revenue of $291 million for Q4 and $984 million for the full year. The company is focused on expanding its pipeline, planning a Phase 3 trial for a COVID-19-Influenza Combination vaccine expected to launch in 2026. Operationally, Novavax has executed significant cost reductions, achieving a 41% decrease in expenses. Additionally, a settlement with Gavi has alleviated previous financial uncertainties, allowing Novavax to concentrate on its public health mission.
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
Novavax, Inc. announced a conference call to discuss its fourth quarter and full year 2023 financial results and operational highlights, scheduled for February 28, 2024. The call aims to provide insights into the company's advancements in protein-based vaccines and its pipeline developments. Participants can join via phone or webcast, with a replay available shortly after the event. This comes as Novavax continues to work on vaccines that target serious infectious diseases, including a combined COVID-19 and influenza vaccine.
Read more →NVAXJ.P. Morgan 42 nd Annual Healthcare Conference 1 2024 NOVAVAX. All rights reserved. NASDAQ: NVAX | JANUARY 2024 This presentation includes forward - looking statements . These forward - looking statements generally can b
Novavax presented an overview of its vaccine prospects at the J.P. Morgan 42nd Annual Healthcare Conference. The company highlighted the anticipated significant market opportunities for a combination Flu and COVID-19 vaccine, aiming to address high unmet needs. However, Novavax also emphasized the various challenges it faces, including restructuring efforts and pending legal disputes, which could impact its operational success and market access. The forward-looking statements provide an optimistic view tempered by caution regarding execution risks and market dynamics.
Read more →NVAXNovavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities New organizational structure for executive leadership team designed to facilitate a leaner and more fo
Novavax, Inc. has announced changes to its executive leadership team to enhance focus on its strategic priorities, particularly in delivering its COVID-19 vaccine. John Trizzino steps into the newly created role of President and COO, overseeing commercial, manufacturing, and regulatory operations. Current Chief Legal Officer John Herrmann will retire, and Mark Casey will take over, bringing over 30 years of experience in the life sciences sector. The organizational changes aim to streamline operations and position Novavax for future success.
Read more →NVAX▲ +8.2%on this news
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID va
Novavax has received Emergency Use Authorization (EUA) from the FDA for its COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) for individuals aged 12 and older. This vaccine, which offers a protein-based non-mRNA option, is now included in CDC recommendations for COVID-19 vaccination. Doses are expected to be available soon at various nationwide locations, enhancing access for the public amidst rising COVID-19 cases. Although the vaccine demonstrates a positive immune response to current virus variants, it has not yet received full FDA approval and carries potential safety risks.
Read more →NVAXLe vaccin XBB contre la COVID-19 de Novavax, à base de protéines, a été amélioré pour générer des réactions neutralisantes vis-à-vis des nouveaux sous-variants, notamment EG.5.1 et XBB.1.16.6
Novavax a annoncé que son vaccin XBB contre la COVID-19 a montré la capacité d'induire des réponses immunitaires face aux sous-variants EG.5.1 et XBB.1.16.6. Si approuvé, ce vaccin deviendrait le seul à base de protéines sur les marchés principaux pour l'automne 2023. Actuellement, il est autorisé pour une utilisation d'urgence mais n'a pas encore reçu d'approbation complète de la FDA. Novavax a l'intention de collaborer étroitement avec les autorités internationales de régulation pour assurer la disponibilité de son produit.
Read more →NVAX▲ +13.5%on this newsshared move
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated...
Novavax has announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing responses against the EG.5.1 and XBB.1.16.6 subvariants. This vaccine is expected to be the only protein-based non-mRNA option available in key markets for the upcoming fall season. The company is working diligently with regulatory bodies to ensure its availability. Previous non-clinical data also showed adequate immune responses to other XBB variants, suggesting broad applicability against evolving strains.
Read more →NVAX▲ +13.5%on this newsshared move
La vacuna XBB COVID de Novavax indujo respuestas neutralizantes contra subvariantes emergentes
Novavax ha anunciado que su vacuna candidata contra COVID-19, la XBB, ha inducido respuestas neutralizantes efectivas contra subvariantes emergentes como EG.5.1 y XBB.1.16.6. Este avance es significativo, ya que la vacuna se convierte en la única opción basada en proteínas en mercados clave para la próxima temporada de otoño. La compañía confía en su producto actual y está trabajando con reguladores para su disponibilidad, mientras que estudios previos indican que la vacuna podría responder efectivamente a más variantes del virus.
Read more →NVAX▲ +13.5%on this newsshared move
Aktualisierter XBB-COVID-Impfstoff auf Proteinbasis von Novavax induziert neutralisierende Reaktionen gegen aufkommende Subvarianten, einschließlich EG.5.1 und XBB.1.16.6 Novavax, Inc. (Nasdaq: NVAX), ein globales Unternehmen, das mit seinem neuartigen Matrix-M™-Adjuvans Impfstoffe auf Proteinbasis entwickelt, gab...
Novavax has announced that its updated protein-based COVID vaccine candidate induces neutralizing antibody responses against emerging subvariants, including EG.5.1 and XBB.1.16.6. This vaccine will be the only protein-based non-mRNA option available for the upcoming fall season after regulatory approval. The company is actively working with global regulatory authorities to ensure its availability.
Read more →NVAXNovavax Reports Second Quarter 2023 Financial Results and Operational Highlights
Novavax announced its second quarter financial results for 2023, reporting total revenues of $424 million and a net income of $58 million, a recovery from a net loss of $510 million in the same period last year. The company has executed a strategic partnership with SK bioscience and initiated submissions for its XBB COVID vaccine with plans for market entry by fall 2023. While current liabilities have been reduced significantly, Novavax continues to navigate challenges related to cash flow and operational expenses.
Read more →NVAX▼ -5.7%on this news
Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023
Novavax, Inc. has announced a conference call scheduled for August 8, 2023, to discuss its financial results for the second quarter of 2023 along with operational highlights. The call will begin at 8:30 a.m. EDT, and participants are encouraged to join early. Following the call, a replay will be available, providing further insights into the company's ongoing vaccine developments and financial performance.
Read more →NVAX▲ +29.5%on this news
Nuvaxovid™ de Novavax reçoit une autorisation de mise sur le marché complète dans l
Novavax has received full market authorization for its COVID-19 vaccine, Nuvaxovid, in the European Union, replacing the previously granted conditional authorization. The vaccine is approved for use as a primary series in adolescents aged 12 and older and as a booster in adults. This milestone enables Novavax to ensure rapid updates to the vaccine, particularly for future vaccination campaigns. The company is also preparing to file for full approval in the U.S. and aims to provide protein-based vaccine options globally.
Read more →NVAXNuvaxovid™ von Novavax erhält vollständige Marktzulassung in der EU zur Prävention von COVID
Novavax, Inc. has achieved full market authorization for its COVID-19 vaccine, Nuvaxovid™, in the European Union, transitioning from conditional approval. The vaccine is now authorized for use as a primary series for individuals aged 12 and older and as a booster for adults. This approval follows a positive recommendation from the European Medicines Agency and provides a basis for future regulatory approvals of updated vaccine versions. Novavax is also preparing for full licensing applications in the United States and other regions.
Read more →NVAXNuvaxovid™ de Novavax recibe plena autorización de comercialización en la UE para la prevención de COVID
Novavax has secured full marketing authorization in the European Union for its COVID-19 vaccine, Nuvaxovid™. This authorization transitions from a conditional approval and allows the vaccine's use as both a primary series for individuals aged 12 and above and as a booster for adults. The approval positions Novavax to update and introduce future vaccine versions more efficiently. While Nuvaxovid is authorized in over 40 markets worldwide, it has not yet received FDA approval in the U.S., and specific risks associated with the vaccine have been identified.
Read more →NVAXNovavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing...
Novavax, Inc. has been granted full Marketing Authorization for its COVID-19 vaccine, Nuvaxovid™, in the European Union. This authorization allows the vaccine to be used as both a primary series for individuals aged 12 and older and as a booster for adults. The decision follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. The company is also preparing to seek full approval in the U.S. and other markets while ensuring accessibility of protein-based vaccines globally.
Read more →NVAX▼ -7.1%on this news
Novavax est prêt à fournir un vaccin monovalent protéinique contre le virus XBB COVID conformément à la recommandation du VRBPAC de la FDA pour l
Novavax has developed a monovalent protein-based COVID vaccine targeting the XBB.1.5 variant, intending to launch it during the upcoming vaccination campaign this fall. Data presented to the FDA's VRBPAC indicates strong immune responses against several sub-variants. If authorized, this vaccine would offer a non-mRNA option for U.S. consumers. Novavax aims to distribute the vaccine globally per established health authority recommendations.
Read more →NVAXNovavax entregará la vacuna XBB COVID monovalente según la recomendación VRBPAC de la FDA para el otoño
Novavax is set to deliver its monovalent XBB COVID-19 vaccine this fall, as recommended by the FDA's VRBPAC. The company shared data showing that its candidate induces effective immune responses to various XBB subvariants. If authorized, it will offer a unique protein-based vaccination option in the U.S., complementing existing vaccines. Novavax aims not only to meet U.S. needs but also to supply the vaccine globally, adhering to public health guidelines.
Read more →NVAXNovavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023
Novavax, Inc. has announced the adjournment of its 2023 Annual Meeting of Stockholders to July 11, 2023, due to not achieving the required quorum. The meeting was initially set for June 15, 2023, but only 49.3% of shares were represented by proxy. No business was conducted during the initial meeting, and the proposals outlined in the Proxy Statement remain unchanged. The company will continue to solicit votes from stockholders during the adjournment period.
Read more →NVAXNovavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
Novavax is set to launch its protein-based monovalent XBB.1.5 COVID vaccine following a positive recommendation from the FDA's VRBPAC. Clinical data indicates that the vaccine effectively stimulates immune responses against several subvariants of the virus. If authorized, it will be the only non-mRNA vaccine available for this particular variant in the U.S. Novavax aims to supply this vaccine globally and prepare for an extensive fall vaccination campaign.
Read more →NVAXNovavax annonce la signature d
Novavax has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its Matrix-M™ adjuvant for preclinical vaccine research. The partnership aims to enhance vaccine development efforts focused on public health. Novavax's Matrix-M™ adjuvant is already a key component in existing COVID-19 and malaria vaccines, underlining its significance in current medical applications. The company expresses a commitment to collaborating with various organizations to further develop vaccines across multiple health challenges.
Read more →NVAXNovavax gibt eine Vereinbarung mit dem Bill & Melinda Gates Medical Research Institute über die Aufnahme des Matrix-M™ Adjuvanten als potenzielle Komponente in der Impfstoffforschung bekannt
Novavax has announced a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its Matrix-M™ Adjuvant for preclinical vaccine research. This collaboration aims to leverage Novavax's proprietary technology to improve vaccine efficacy in developing vaccines for various diseases, including COVID and influenza. Novavax’s Matrix-M™ Adjuvant is known to enhance immune responses when included in vaccines, thus playing a crucial role in the development of public health vaccines.
Read more →NVAXNovavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
Novavax has entered a three-year agreement with the Bill & Melinda Gates Medical Research Institute to utilize its Matrix-M adjuvant in preclinical vaccine research. This partnership aims to advance public health-focused vaccine development, leveraging the adjuvant's ability to broaden the immune response. Novavax's Matrix-M is already an integral component of various vaccines, including those for COVID-19 and malaria. However, the company faces several risks linked to regulatory compliance and clinical trial challenges.
Read more →NVAXNovavax y el Instituto de Investigación Médica Bill & Melinda Gates: acuerdo sobre el adyuvante Matrix-M™
Novavax announced a three-year agreement with the Bill & Melinda Gates Medical Research Institute to integrate its Matrix-M adjuvant into vaccine research. This collaboration aims to enhance public health initiatives by improving immune responses through the patented Matrix-M technology, which is currently used in vaccines against COVID and malaria. The partnership indicates Novavax's commitment to expand its collaborations to address urgent health challenges worldwide.
Read more →NVAXNovavax to Participate in the Jefferies Global Healthcare Conference
Novavax, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 8, 2023. The conference will include a fireside chat featuring CEO John C. Jacobs and MD Filip Dubovsky, President of Research and Development. The session will provide insights into Novavax's advancements in vaccine technology and their efforts to address serious infectious diseases. A replay will be available on the company's website for 30 days post-conference.
Read more →NVAXNuvaxovid™ de Novavax recibe la opinión positiva del CHMP para la autorización de comercialización completa
Novavax has received a positive opinion from the CHMP for its COVID-19 vaccine Nuvaxovid™, paving the way for full marketing authorization in the European Union. This recommendation allows for the vaccine's use as a primary series for individuals over 12 years and as a booster for those over 18. The company has previously demonstrated the vaccine's efficacy and safety through multiple clinical trials. A final decision from the European Commission regarding the marketing approval is pending.
Read more →NVAXNuvaxovid™ de Novavax reçoit un avis positif du CHMP pour l
Novavax, Inc. announced that its COVID-19 vaccine, Nuvaxovid™ (NVX-CoV2373), has received a positive recommendation for full marketing authorization from the CHMP in the European Union. This recommendation is significant as it moves Novavax closer to ultimately obtaining complete approval and possibly allows for the availability of an updated vaccine by fall. Novavax demonstrated efficacy and safety in various trials, although Nuvaxovid has yet to gain FDA approval in the U.S. and is currently only granted emergency use authorization.
Read more →NVAXNuvaxovid™ von Novavax erhält positive CHMP-Stellungnahme für vollständige Marktzulassung zur Prävention von COVID in der EU
Novavax has announced that its COVID-19 vaccine, Nuvaxovid, received a positive recommendation from the CHMP for full market authorization in the European Union. This recommendation allows for Nuvaxovid to be used as a primary vaccination for individuals aged 12 and older and as a booster for those aged 18 and older. The European Commission is expected to review and make a final decision soon. Novavax's studies demonstrate the vaccine's effectiveness and safety, marking a significant step toward full approval.
Read more →NVAXNovavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™...
Novavax, Inc. reported that its COVID-19 vaccine, Nuvaxovid, has received a positive opinion from the European Medicines Agency's CHMP for full marketing authorization. This approval is for use as a primary series in individuals aged 12 and older, and as a booster for those aged 18 and older. Novavax noted the vaccine's safety and efficacy demonstrated in clinical trials, while the final decision on authorization will be made by the European Commission. However, the trade name has not yet received FDA approval in the U.S.
Read more →NVAXAccess to Novavax
Novavax, Inc. announced that the Singapore Health Sciences Authority has granted extended interim authorization for its protein-based COVID-19 vaccine, Nuvaxovid, for adolescents aged 12 to 17 and included it in the National Vaccination Programme. This decision enhances public health options amid the ongoing pandemic. The authorization was based on positive trial data from the pediatric phase of the PREVENT-19 study. However, the vaccine still lacks full FDA approval and has known adverse reaction risks, including myocarditis.
Read more →NVAX▼ -5.6%on this newsshared move
Les résultats positifs de premier ordre de l
Novavax, Inc. announced positive results from its Phase 2 clinical trial evaluating three vaccine candidates, including a combined COVID-Influenza vaccine. The trial demonstrated robust immune responses and a reassuring safety profile for each candidate, comparable to approved flu vaccines. These encouraging results support the continued development of the candidates, which are aimed at enhancing public health efforts against infectious diseases.
Read more →NVAX▲ +27.8%on this newsshared move
Resultados positivos de COVID-influenza de Novavax, influenza independiente y dosis alta de COVID
Novavax announced positive Phase 2 results for its COVID-influenza combination and high-dose COVID vaccine candidates. The trials showed solid immune responses and a reassuring safety profile, comparable to authorized vaccines. Preliminary findings suggest a significant enhancement in antibody levels compared to existing flu vaccines, supporting further development of these candidates. The data contributes to Novavax's strategy for diversifying its vaccine portfolio.
Read more →NVAX▲ +27.8%on this newsshared move
Los resultados positivos de la fase 2 muestran que las vacunas candidatas de combinación COVID-Influenza, Influenza independiente y de alta dosis contra la COVID de Novavax demuestran respuestas inmunes sólidas
Novavax announced positive results from a phase 2 trial evaluating three vaccine candidates: a combination COVID-Influenza vaccine, an independent influenza vaccine, and a high-dose COVID vaccine. Preliminary immune responses were solid, showing significant improvements compared to authorized comparators, and were well-tolerated among participants. The study supports continued development for these candidates, with increased confidence for future phase 3 trials based on these encouraging data. The results not only validate the vaccine platform but also its potential impact on global public health.
Read more →NVAX▲ +27.8%on this newsshared move
Resultados positivos da Fase 2 mostram que as candidatas à vacina contra a combinação COVID-Influenza da Novavax, e a dose alta da vacina contra COVID demonstraram respostas imunológicas robustas
Novavax announced positive Phase 2 results for its COVID-Influenza combination vaccine, an isolated influenza vaccine, and a high-dose COVID vaccine. All candidates showed robust immune responses compared to authorized alternatives and a promising safety profile. The study indicates that the combination vaccine achieved neutralizing antibody responses comparable to the prototype NVX-CoV2373. These findings support further development and enhance the likelihood of success in Phase 3 trials.
Read more →NVAX▲ +27.8%on this newsshared move
Novavax Reports First Quarter 2023 Financial Results and Operational Highlights
Novavax reported its financial results for the first quarter of 2023, highlighting a significant reduction in total revenue, which fell from $704 million in Q1 2022 to $81 million primarily due to shifts in COVID vaccine demand. Despite this, the company is on track to deliver an updated COVID vaccine for the upcoming Fall season and announced positive Phase 2 results for several vaccine candidates. However, Novavax's net loss widened to $294 million, reflecting ongoing challenges, while the company has initiated a restructuring plan aimed at cutting R&D and SG&A costs by about 40% to 50% in 2024.
Read more →NVAX▲ +27.8%on this newsshared move
Positive Phase-2-Topline-Ergebnisse zeigen, dass die COVID-Influenza-Kombination, eigenständige Influenza- und hochdosierte COVID-Impfstoffkandidaten von Novavax robuste Immunreaktionen auslösen
Novavax announced positive Phase 2 results for its COVID-Influenza Combination vaccine and standalone flu and high-dose COVID vaccine candidates. The study demonstrated robust immunogenic responses and a reassuring safety profile, comparable to licensed comparators. Preliminary findings indicated significant antibody responses for the flu vaccine candidate and promising safety data, supporting further development as they prepare for upcoming Phase 3 trials.
Read more →NVAX▲ +27.8%on this newsshared move
Positive Phase 2 Topline Results Show Novavax
Novavax, Inc. reported promising results from a Phase 2 trial evaluating three vaccine candidates, including a COVID-Influenza combination vaccine. Each candidate demonstrated robust immune responses compared to authorized comparators and showed a reassuring safety profile, consistent with other Novavax vaccines. Notably, the stand-alone influenza vaccine candidate achieved significantly higher antibody responses to influenza strains. These encouraging topline results support the continued development of all three vaccine candidates.
Read more →NVAX▲ +5.9%on this news· ran to +33% by day 3shared move
Novavax to Participate in the BofA Securities 2023 Health Care Conference
Novavax, Inc. announced its participation in the BofA Securities 2023 Health Care Conference, scheduled for May 10-11, 2023, in Las Vegas, Nevada. Key company representatives, including the CEO and the President of Research & Development, will be involved in discussions. The conference serves as a platform for investor meetings and includes a fireside chat, which will be made available for replay on their website. Novavax continues to focus on developing vaccines for COVID-19, influenza, and combined strains.
Read more →NVAX▼ -8.8%on this newsshared move
Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023
Novavax, Inc. announced a conference call scheduled for May 9, 2023, to discuss its first quarter financial results and operational highlights. The call will begin at 8:30 a.m. EDT, with details provided for domestic and international participants. The company emphasizes its role in advancing protein-based vaccines and addressing significant health challenges.
Read more →NVAXNovavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
Novavax, Inc. will present data on its COVID-19 vaccine and COVID-Influenza Combination vaccine at two significant conferences: the World Vaccine Congress 2023 and the 33rd European Congress of Clinical Microbiology & Infectious Diseases. The company has been named a finalist for two awards at the WVC, highlighting its innovative efforts in vaccine development. Additionally, Novavax is hosting discussions on countering vaccine hesitancy and understanding vaccine safety. These events showcase Novavax's commitment to addressing urgent health challenges through its advanced vaccine technologies.
Read more →NVAX▲ +6.8%on this news· ran to -21% by day 1shared move
Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as Presi
Novavax, Inc. reported strong financial results for Q4 and full year 2022, achieving $2 billion in revenue. The company appointed John C. Jacobs as its new CEO and secured an updated government agreement for additional COVID-19 vaccine doses in 2023. However, there are concerns about its future viability as a going concern due to uncertainties regarding revenue and funding. Strategies for 2023 include focusing on product development for the upcoming vaccination season and managing cash flow effectively.
Read more →NVAX▼ -6.3%on this news
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
Novavax, Inc. will host a conference call on February 28, 2023, to discuss its financial results for the fourth quarter and the full year of 2022. The call will take place at 4:30 p.m. EST, following the closure of U.S. markets. Participants can join by dialing the provided numbers or through a webcast. This event is intended to provide insights into Novavax's operational highlights and investment outlook amidst its development of various vaccines.
Read more →NVAXEl gobierno de Estados Unidos y Novavax aseguran hasta 1,5 millones de dosis más de la vacuna de la COVID-19
The U.S. government has expanded its partnership with Novavax, securing up to 1.5 million additional doses of their COVID-19 vaccine. The modified agreement will also support the development of an updated vaccine expected in the fall of 2023. This contract aims to maintain public access to Novavax's protein-based vaccine and facilitate a smooth transition to commercial distribution, addressing the ongoing needs of vaccination in the United States.
Read more →NVAXVerlängerung der Partnerschaft zwischen der US-Regierung und Novavax zur Bereitstellung von bis zu 1,5 Millionen zusätzlichen Dosen des COVID-19-Impfstoffs von Novavax
Novavax has announced an extension of its partnership with the U.S. government to supply up to 1.5 million additional doses of its COVID-19 vaccine, NVX-CoV2373. This agreement includes the development of an updated vaccine version by Fall 2023, ensuring continued access for the U.S. population. Novavax's efforts support the government's initiative to provide a varied vaccine portfolio, emphasizing the significance of this collaboration for public health readiness in future vaccination campaigns.
Read more →NVAXU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax
Novavax has announced a modification to its agreement with the U.S. Department of Health and Human Services to provide up to 1.5 million additional doses of its COVID-19 vaccine, NVX-CoV2373. This collaboration aims to ensure ongoing public access to a protein-based vaccine option as part of national health measures. The modified contract also supports the development of updated vaccine formulations for the upcoming 2023/2024 vaccination campaign. Overall, this partnership underscores Novavax's commitment to public health in addressing COVID-19.
Read more →NVAXEl gobierno de los Estados Unidos y Novavax extienden su alianza y aseguran hasta 1,5 millones de dosis adicionales de la vacuna de Novavax contra la COVID-19
Novavax has modified its existing agreement with the U.S. government to deliver up to 1.5 million additional doses of its COVID-19 vaccine, NVX-CoV2373. The agreement also focuses on developing an updated version of the vaccine for the fall of 2023, ensuring continued public access. While the vaccine has Emergency Use Authorization from the FDA, concerns about serious side effects and limited effectiveness in certain groups remain. The partnership underlines the significance of a diverse vaccine portfolio in combating the pandemic.
Read more →NVAXGoverno dos EUA e Novavax ampliam parceria, garantindo até 1,5 milhões de doses adicionais da vacina contra a COVID-19 da Novavax
Novavax, Inc. has announced an expansion of its agreement with the U.S. Department of Health and Human Services to provide up to 1.5 million additional doses of its COVID-19 vaccine. This agreement also supports the development of a new vaccine formulation, scheduled for fall 2023. The initiative aims to ensure the continued availability of Novavax's vaccine while emphasizing a diversified approach to public health vaccination strategies in the United States.
Read more →NVAXLe gouvernement des États-Unis et Novavax étendent leur partenariat et garantissent jusqu
Novavax, Inc. announced the modification of its existing agreement with the U.S. Department of Health and Human Services and Department of Defense. This partnership aims to deliver up to 1.5 million doses of its COVID-19 vaccine, including the development of a revised version for fall 2023. The contract emphasizes the need for a diverse vaccine portfolio and ensures the vaccine remains available at no cost to Americans through federal and state health channels. However, the Novavax vaccine still holds an emergency use authorization and not full FDA approval.
Read more →NVAXNovavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
Novavax announced that its COVID-19 vaccine, Nuvaxovid, has been approved by the Korean Ministry of Food and Drug Safety for use as a booster in adults aged 18 and older. This decision follows earlier recommendations from the Korean Centers for Disease Control and Prevention. The approval is supported by clinical trial data demonstrating the vaccine's efficacy and safety as a booster dose, leading to enhanced immune responses. Novavax continues to collaborate with SK bioscience to ensure widespread distribution and access in South Korea and beyond.
Read more →NVAX▲ +11.3%on this news
Novavax Names John C. Jacobs as New President & Chief Executive Officer
Novavax, Inc. has announced a leadership transition, with John C. Jacobs set to succeed Stanley C. Erck as President and CEO on January 23, 2023. Erck will remain as an advisor for 15 months to ensure a smooth transition. Jacobs brings over 25 years of experience in the biopharma sector, having previously led Harmony Biosciences through an IPO. Under Erck's leadership, Novavax made significant strides in vaccine development, particularly its COVID-19 vaccine, which has been authorized in over 40 countries globally.
Read more →NVAX▲ +11.3%on this news
Novavax Names John C. Jacobs as New President & Chief Executive Officer Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisor
Novavax, Inc. announced the appointment of John C. Jacobs as the new President and Chief Executive Officer, effective January 23, 2023, succeeding Stanley C. Erck who will retire. Erck will remain with the company for 15 months as an advisor to ensure a smooth transition. Jacobs, who has over 25 years of industry experience, is expected to bring fresh perspectives and leadership to Novavax as it continues to advance its vaccine development initiatives, including COVID-19 and influenza candidates.
Read more →NVAX▲ +5.8%on this news· ran to +20% by day 3
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
GAITHERSBURG, Md., Dec. 30, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenz
Read more →NVAXNovavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of
Read more →NVAX▼ -6.4%on this news
Novavax kündigt Preis für öffentliches Stammaktienangebot in Höhe von 65 Millionen Dollar an
GAITHERSBURG, Maryland, 18. Dezember 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute die Preisge
Read more →NVAX▼ -6.4%on this news
Novavax gibt die Preisgestaltung seines 150-Millionen-Dollar-Angebots von Wandelschuldverschreibungen bekannt
GAITHERSBURG, Maryland, 18. Dezember 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute die Preisge
Read more →NVAX▼ -6.4%on this newsshared move
Novavax annonce la fixation du prix de l
GAITHERSBURG, Md., 17 décembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération pour les maladies infectieuses graves, a annoncé aujourd'hui la fixation d
Read more →NVAX▼ -6.4%on this newsshared move
Novavax annonce une offre proposée de 150 millions de dollars d
GAITHERSBURG, Md., 17 décembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération pour les maladies infectieuses graves, a annoncé aujourd'hui une offre pro
Read more →NVAXNovavax annonce une offre proposée de 125 millions de dollars d
GAITHERSBURG, Md., 16 décembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération pour les maladies infectieuses graves, a annoncé aujourd'hui une offre pro
Read more →NVAXNovavax anuncia valor de $65 milhões para oferta pública de ações ordinárias
GAITHERSBURG, Maryland, 16 de dezembro de 2022 /PRNewswire/ -- ANovavax, Inc. (Nasdaq: NVAX), empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje o preço de uma oferta pública para vend
Read more →NVAXNovavax anuncia el precio de la oferta de 150 millones de dólares de bonos preferentes convertibles
GAITHERSBURG, Md., 16 de diciembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), empresa biotecnológica dedicada al desarrollo y comercialización de vacunas de nueva generación contra enfermedades infecciosas graves, ha anunciado hoy el precio de una oferta de 150 millone
Read more →NVAXNovavax anuncia preço de $150 milhões de ofertas de títulos seniores conversíveis
GAITHERSBURG, Maryland, 16 de dezembro de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje o preço de uma oferta de $150 milhõe
Read more →NVAXNovavax anuncia el precio de una oferta pública de 65 millones de dólares en acciones ordinarias
GAITHERSBURG, Maryland, 16 de diciembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comercialización de vacunas de última generación contra enfermedades infecciosas graves, anunció hoy el precio de una oferta pública
Read more →NVAXNovavax anuncia el precio de una oferta de $150 millones de bonos sénior convertibles
GAITHERSBURG, Maryland, 16 de diciembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología que desarrolla y comercializa vacunas de última generación para enfermedades infecciosas graves, anunció el precio de una oferta de $150 millones de la canti
Read more →NVAXNovavax annonce une proposition d
GAITHERSBURG, Maryland, 16 décembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une entreprise de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération contre les maladies infectieuses graves, a annoncé aujourd'hui une
Read more →NVAXNovavax kündigt geplantes öffentliches Stammaktienangebot in Höhe von 125 Millionen Dollar an
GAITHERSBURG, Maryland, 16. Dezember 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute ein geplant
Read more →NVAX▼ -34.3%on this newsshared move
Novavax anuncia oferta propuesta de 125 millones de dólares de notas sénior convertibles
GAITHERSBURG, Md., 15 de diciembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comercialización de vacunas de próxima generación para enfermedades infecciosas graves, anunció hoy una propuesta de oferta de 125 millon
Read more →NVAX▼ -34.3%on this newsshared move
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate princi
Read more →NVAX▼ -34.3%on this newsshared move
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,50
Read more →NVAX▼ -34.3%on this newsshared move
Novavax kündigt geplante Emission von 125 Mio. USD an wandelbaren vorrangigen Anleihen an
GAITHERSBURG, Maryland, 15. Dezember 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute ein geplant
Read more →NVAX▼ -34.3%on this newsshared move
Novavax anuncia oferta proposta de US$ 125 milhões em notas seniores conversíveis
GAITHERSBURG, Maryland, 15 de dezembro de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje uma oferta proposta de US$ 125 milhõ
Read more →NVAX▼ -34.3%on this newsshared move
Novavax anuncia una propuesta de oferta de 125 millones de dólares en bonos sénior convertibles
GAITHERSBURG, Maryland, 15 de diciembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a al desarrollo y comercialización de vacunas de última generación para combatir enfermedades infecciosas graves, anunció hoy una propuesta de ofert
Read more →NVAX▼ -34.3%on this newsshared move
Novavax anuncia proposta de oferta pública de $125 milhões em ações ordinárias
GAITHERSBURG, Md., 15 de dezembro de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje uma proposta oferta pública subscrita par
Read more →NVAX▼ -34.3%on this newsshared move
Novavax anuncia propuesta de oferta pública de acciones ordinarias por valor de 125 millones de dólares
GAITHERSBURG, Md., 15 de diciembre, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comercialización de vacunas de última generación para enfermedades infecciosas graves, anunció hoy una propuesta de oferta pública suscrita
Read more →NVAX▼ -34.3%on this newsshared move
Novavax anuncia propuesta de oferta pública de $125 millones en acciones ordinarias
GAITHERSBURG, Maryland, 15 de diciembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy una propuesta de oferta pública suscrit
Read more →NVAXNovavax Announces Proposed $125 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125
Read more →NVAXNovavax Announces Proposed Offering of $125 Million of Convertible Senior Notes
GAITHERSBURG, Md., Dec. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amo
Read more →NVAXNovavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents
GAITHERSBURG, Md., Dec. 7, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has approved a supplement to a New Drug S
Read more →NVAXNovavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference
GAITHERSBURG, Md., Dec. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual
Read more →NVAXWeltgesundheitsorganisation aktualisiert die Notfallliste für COVID-19-Impfstoff Nuvaxovid von Novavax als Primärserie bei Jugendlichen und als Booster bei Erwachsenen
GAITHERSBURG, Maryland, 1. Dezember 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute bekannt, das
Read more →NVAXL'Organisation mondiale de la santé met à jour la liste des utilisations d'urgence du vaccin Novavax Nuvaxovid COVID-19 en tant que série primaire chez les adolescents et en tant que rappel chez les adultes Novavax, Inc. (NASDAQ: NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle...
GAITHERSBURG, Maryland, 1er décembre 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération pour les maladies infectieuses graves, annonce aujourd'hui que l'Orga
Read more →NVAXLa OMS actualiza la lista de uso de emergencia para la vacuna Novavax Nuvaxovid COVID-19
- La Organización Mundial de la Salud actualiza la lista de uso de emergencia para la vacuna Novavax Nuvaxovid COVID-19 como serie primaria en adolescentes y como refuerzo en adultos GAITHERSBURG, Md., 30 de noviembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una emp
Read more →NVAXWorld Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
GAITHERSBURG, Md., Nov. 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an upda
Read more →NVAX▼ -5.4%on this news· ran to -18% by day 3
Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
GAITHERSBURG, Md., Nov. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted expanded authorization for N
Read more →NVAX▲ +18.8%on this news· ran to +34% by day 1shared move
L'essai de phase 3 COVID-19 Omicron de Novavax soutient l'utilisation continue et future du prototype de vaccin de Novavax comme vaccin de rappel Novavax, Inc. (NASDAQ: NVAX), société de biotechnologie spécialisée dans le développement et la commercialisation de vaccins de nouvelle génération...
Le vaccin candidat Novavax BA.1 a rempli son critère principal de changement de souche, ce qui permet de développer des vaccins variantes, si nécessaire Le prototype de vaccin de Novavax a induit une large réponse immunitaire contre les souches originales Wuhan, BA.1 et BA.5 L'
Read more →NVAX▼ -5.2%on this news· ran to +17% by day 3shared move
El ensayo ómicron COVID-19 de fase 3 de Novavax respalda el uso continuo y futuro de la vacuna prototipo de Novavax como refuerzo
La candidata a vacuna BA.1 de Novavax cumplió con su criterio de valoración primario de cambio de cepa, lo que permite el desarrollo de vacunas variantes de ser necesario La vacuna prototipo de Novavax indujo una amplia respuesta inmune contra las cepas originales de Wuhan, BA.1
Read more →NVAX▼ -5.2%on this news· ran to +17% by day 3shared move
Novavax Phase-3-Studie COVID-19 Omikron unterstützt den weiteren und zukünftigen Einsatz des Novavax Prototyp-Impfstoffs als Booster
Der Novavax BA.1 Impfstoffkandidat hat den primären Endpunkt der Stammänderung erreicht, was ggf. die Entwicklung von Impfstoffvarianten ermöglicht Der Prototyp-Impfstoff von Novavax induziert eine breite Immunreaktion gegen den ursprünglichen Wuhan-Stamm, BA.1 und BA.5 Die Stu
Read more →NVAX▼ -5.2%on this news· ran to +17% by day 3shared move
Estudo Omicron de Fase 3 da COVID-19 da Novavax apoia o uso contínuo e futuro do protótipo de vacina da Novavax como reforço
A candidata a vacina contra BA.1 da Novavax atingiu seu desfecho primário de mudança de cepa permitindo o desenvolvimento de vacinas contra a variante, se necessário O protótipo de vacina da Novavax induziu ampla resposta imunológica contra as cepas originais BA.1 e BA.5 de Wuha
Read more →NVAX▼ -5.2%on this news· ran to +17% by day 3shared move
Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
GAITHERSBURG, Md., Nov. 9, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency
Read more →NVAXNovavax Reports Third Quarter 2022 Financial Results and Operational Highlights Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to date Authorized as a
Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights GAITHERSBURG, Md., November 8, 2022 - Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, to
Read more →NVAXEl ensayo de fase 3 COVID-19 Omicron de Novavax apoya el uso de la vacuna prototipo de Novavax como refuerzo
-El ensayo de fase 3 COVID-19 Omicron de Novavax apoya el uso continuo y futuro de la vacuna prototipo de Novavax como refuerzo La vacuna candidata BA.1 de Novavax cumplió su criterio de valoración primario de cambio de cepa, lo que permite el desarrollo de vacunas variantes, si
Read more →NVAXNovavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains The trial showed no benefit for a bivalen
Read more →NVAX▼ -6.8%on this news
Novavax nomme Rick Rodgers à son conseil d
GAITHERSBURG, Maryland, 2 novembre 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), une société de biotechnologie spécialisée dans le développement et la commercialisation de vaccins de nouvelle génération contre les maladies infectieuses graves, a annoncé aujourd'hui la nomina
Read more →NVAX▼ -6.8%on this news
Novavax beruft Rick Rodgers in den Vorstand
GAITHERSBURG, Maryland, 2. November 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich der Entwicklung und Vermarktung innovativer Impfstoffe gegen schwere Infektionskrankheiten verschrieben hat, hat heute die Ernennung von Richard Rodgers,
Read more →NVAX▼ -6.8%on this news
Novavax nombra a Rick Rodgers miembro de la junta directiva
GAITHERSBURG, Md., 2 de noviembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comercialización de vacunas de última generación para enfermedades infecciosas graves, anunció hoy el nombramiento de Richard Rodgers, MBA
Read more →NVAXNovavax Appoints Rick Rodgers to Board of Directors GAITHERSBURG, Md.
Novavax Appoints Rick Rodgers to Board of Directors GAITHERSBURG, Md., November 1, 2022 - Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment
Read more →NVAXNovavax Appoints Rick Rodgers to Board of Directors
GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an i
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022
GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and
Read more →NVAX▲ +7.6%on this news
La FDA de los EE. UU. autoriza el uso de emergencia de la vacuna adyuvada contra la COVID-19 de Novavax como refuerzo para adultos
GAITHERSBURG, Maryland, 22 de octubre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy que la vacuna contra la COVID-19 de Novav
Read more →NVAX▲ +7.6%on this news
FDA dos EUA autoriza uso emergencial para vacina com adjuvante contra COVID-19 da Novavax como reforço para adultos
GAITHERSBURG, Maryland, 22 de outubro de 2022 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje que a vacina com adjuvante da Novav
Read more →NVAX▲ +7.6%on this news
La FDA américaine accorde une autorisation d
GAITHERSBURG, Md. , 22 octobre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), entreprise de biotechnologie vouée à la mise au point et à la commercialisation de vaccins de prochaine génération pour les maladies infectieuses graves, a annoncé aujourd'hui que le vaccin Novavax
Read more →NVAX▲ +7.6%on this news
Die US-amerikanische Arzneimittelbehörde FDA erteilt eine Notfallzulassung für den Novavax COVID-19-Impfstoff, adjuvantiert als Booster für Erwachsene
GAITHERSBURG, Maryland, 22. Oktober 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von neuartigen Impfstoffen gegen schwere Infektionskrankheiten spezialisiert hat, gab heute bekannt, dass der Novavax
Read more →NVAX▲ +12.6%on this news· ran to +33% by day 3shared move
La FDA de EE. UU. otorga autorización de uso de emergencia para la vacuna Novavax COVID-19
- La FDA de EE. UU. otorga autorización de uso de emergencia para la vacuna Novavax COVID-19, con adyuvante como refuerzo para adultos GAITHERSBURG, Md., 21 de octubre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y com
Read more →NVAXNovavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022
New Phase 3 PREVENT-19 data reinforce the Novavax COVID-19 vaccine's benefits as an adult booster in both younger and older adults, and with varying time intervals for the booster dose Phase 1/2 trial data show COVID-19-Influenza Combination vaccine candidate induced antibody an
Read more →NVAXU.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults
GAITHERSBURG, Md., Oct. 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Read more →NVAXLe candidat vaccin combiné Novavax COVID-19-Influenza a induit des réponses en anticorps et en cellules T contre le SRAS-CoV-2 et les souches de grippe homologues et hétérologues
Cet essai est le premier de son genre à évaluer un vaccin combiné COVID-19-Influenza Les connaissances sur les doses obtenues lors de l'essai de phase 1/2 serviront de base à l'essai de confirmation de phase 2 qui débutera fin 2022 GAITHERSBURG, Maryland, 16 octobre 2022 /PRNew
Read more →NVAXNovavax Covid-19-Influenza-Kombinationsimpfstoffkandidat induziert Antikörper- und T-Zell-Reaktionen gegen SARS-CoV-2 und homologe und heterologe Influenza-Stämme
Die Studie ist die erste ihrer Art, die einen kombinierten Covid-19- und Grippeimpfstoff untersucht Erkenntnisse über die Dosis aus der Phase-I/II-Studie werden in die Phase-II-Bestätigungsstudie einfließen, die Ende 2022 beginnen soll GAITHERSBURG, Maryland, 16. Oktober 2022 /
Read more →NVAX▼ -7.6%on this newsshared move
La vacuna combinada Novavax COVID-19-gripe induce respuestas de anticuerpos y células T
-La vacuna combinada Novavax COVID-19-gripe induce respuestas de anticuerpos y células T contra el SARS-CoV-2 y cepas de gripe homólogas y heterólogas El ensayo es el primero de este tipo que evalúa una vacuna combinada de COVID-19 y gripe Los conocimientos sobre la dosis del e
Read more →NVAX▼ -7.6%on this newsshared move
Dados do protótipo da vacina contra a COVID-19 da Novavax suportam reforço homólogo e heterólogo e sugerem benefício contra variantes
Reforço homólogo com o protótipo de vacina contra a COVID-19 da Novavax induziu excelente resposta de títulos de anticorpos para as variantes Ômicron BA.1, BA.2 e BA.5 Estudo 307 (consistência de lote) chegou ao primeiro resultado clínico, mostrando que três lotes de vacinas ind
Read more →NVAX▼ -7.6%on this newsshared move
Daten zum Novavax Prototyp-Impfstoff gegen COVID-19 unterstützen homologe und heterologe Auffrischung und weisen auf Nutzen gegen Varianten hin
Homologe Auffrischung mit dem Novavax Prototyp-Impfstoff gegen COVID-19 führte zu robusten Antikörperwerten gegen Omikron BA.1, BA.2 und BA.5 Studie 307 (Chargen-Konsistenz) hat ihren primären Endpunkt erreicht und gezeigt, dass drei Impfstoffchargen eine vergleichbare Immunantw
Read more →NVAX▼ -7.6%on this newsshared move
Les données sur le prototype du vaccin COVID-19 de Novavax confirment le rappel homologue et hétérologue et suggèrent un avantage par rapport aux variants
Le rappel homologue avec le prototype du vaccin Novavax COVID-19 a induit des titres d'anticorps robustes pour Omicron BA.1, BA.2 et BA.5 L'étude 307 (uniformité des lots) a atteint son objectif principal : trois lots de vaccins ont induit une réponse immunitaire comparable, dém
Read more →NVAX▲ +5.1%on this newsshared move
Los datos del prototipo de la vacuna de Novavax contra la COVID-19 apoyan el refuerzo homólogo y heterólogo y sugieren un beneficio contra las variantes
El refuerzo homólogo con el prototipo de vacuna de Novavax contra la COVID-19 indujo sólidos títulos de anticuerpos para la variante ómicron BA.1, BA.2 y BA.5 El Estudio 307 (Consistencia del lote) logró su criterio de valoración principal y demostró que tres lotes de vacunas in
Read more →NVAX▲ +5.1%on this newsshared move
Los datos del prototipo de la vacuna COVID-19 de Novavax apoyan el refuerzo homólogo y heterólogo
-Los datos del prototipo de la vacuna COVID-19 de Novavax apoyan el refuerzo homólogo y heterólogo y sugieren un beneficio contra las variantes El refuerzo homólogo con el prototipo de vacuna COVID-19 de Novavax indujo títulos de anticuerpos robustos para Omicron BA.1, BA.2 y BA
Read more →NVAX▲ +5.1%on this newsshared move
Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains
Trial is the first of its kind to evaluate a combined COVID-19 and influenza vaccine Dose insights from Phase 1/2 trial will inform Phase 2 confirmation trial to begin in late 2022 GAITHERSBURG, Md., Oct. 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology co
Read more →NVAX▲ +6.7%on this newsshared move
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating t
Read more →NVAX▲ +9.1%on this news· ran to +31% by day 3shared move
Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022
New safety and immunogenicity data for the COVID-19-Influenza Combination vaccine candidate Phase 1/2 trial will be presented New data will be presented for Novavax' COVID-19 vaccine supporting its use as a homologous and heterologous booster in adults aged 18 and older and adol
Read more →NVAX▲ +9.1%on this news· ran to +31% by day 3shared move
Novavax präsentiert neue Daten aus dem wachsenden Impfstoffportfolio auf dem World Vaccine Congress Europe 2022
Neue Daten zur Sicherheit und Immunogenität des COVID-19-Influenza-Kombinationsimpfstoffkandidaten aus der Phase 1/2-Studie werden vorgestellt Neue Daten für den Impfstoff COVID-19 von Novavax werden vorgestellt, die den Einsatz als homologe und heterologe Auffrischungsimpfung b
Read more →NVAX▲ +9.1%on this news· ran to +31% by day 3shared move
Novavax compartirá nuevos datos de la creciente cartera de vacunas
- Novavax compartirá nuevos datos de la creciente cartera de vacunas en el Congreso Mundial de Vacunas Europa 2022 Se presentarán nuevos datos de seguridad e inmunogenicidad para el ensayo de fase 1/2 del candidato a vacuna combinada de la COVID-19-Gripe Se presentarán nuevos d
Read more →NVAX▲ +9.1%on this news· ran to +31% by day 3shared move
Novavax partagera de nouvelles données sur son portefeuille croissant de vaccins au Congrès mondial des vaccins Europe 2022
De nouvelles données sur l'innocuité et l'immunogénicité de l'essai de phase 1/2 du vaccin combiné contre la COVID-19 et la grippe seront présentées De nouvelles données seront présentées sur le vaccin contre la COVID-19 de Novavax, appuyant son utilisation comme rappel homologu
Read more →NVAX▲ +6.2%on this news
Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom
GAITHERSBURG, Md., Sept. 27, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV23
Read more →NVAX▼ -6.6%on this news· ran to -21% by day 3
Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17
GAITHERSBURG, Md., Sept. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has gr
Read more →NVAX▼ -6.6%on this news· ran to -21% by day 3
Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
The Israeli Advisory Committee on Epidemics has recommended that Nuvaxovid™ be approved for ages 12 and older as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines GAITHERSBURG, Md., Sept. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nas
Read more →NVAX▲ +5.8%on this newsshared move
Le vaccin Nuvaxovid™ de Novavax contre la COVID-19 obtient une autorisation de mise sur le marché conditionnelle étendue dans l
Nuvaxovid™ est désormais autorisé dans l'UE pour une utilisation chez les adultes âgés de 18 ans et plus en tant que rappel, indépendamment des antécédents vaccinaux GAITHERSBURG, Maryland, 14 septembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), société de biotechnologie
Read more →NVAX▲ +5.8%on this newsshared move
Novavax Nuvaxovid™ Covid-19-Impfstoff erhält erweiterte bedingte Marktzulassung in der Europäischen Union zur Verwendung als Auffrischungsimpfung für Erwachsene ab 18 Jahren
Nuvaxovid™ ist jetzt in der EU für Erwachsene ab 18 Jahren als Auffrischungsimpfung zugelassen, unabhängig von früheren Impfungen GAITHERSBURG, Maryland, 14. September 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung
Read more →NVAX▼ -6.7%on this newsshared move
Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older
GAITHERSBURG, Md., Sept. 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine m
Read more →NVAXLa vacuna Novavax Nuvaxovid™ COVID-19 recibe autorización de comercialización condicional ampliada en la UE
-La vacuna Novavax Nuvaxovid™ COVID-19 recibe autorización de comercialización condicional ampliada en la Unión Europea para su uso como refuerzo en adultos mayores de 18 años Nuvaxovid™ está ahora autorizada en la UE para su uso en adultos mayores de 18 años como refuerzo, inde
Read more →NVAXNovavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older
Nuvaxovid™ is now authorized in the EU for use in adults aged 18 and older as a booster regardless of previous vaccine history GAITHERSBURG, Md., Sept. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next
Read more →NVAX▼ -6.1%on this newsshared move
Swissmedic autorise le vaccin Novavax Nuvaxovid™ COVID-19 pour les adolescents âgés de 12 à 17 ans et comme vaccin de rappel pour les adultes âgés de 18 ans et plus
GAITHERSBURG, Maryland, 6 Septembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une société de biotechnologie spécialisée dans le développement et la commercialisation de vaccins de nouvelle génération contre les maladies infectieuses graves, annonce aujourd'hui que Swissm
Read more →NVAX▼ -6.1%on this newsshared move
Zulassung der Swissmedic für Novavax Nuvaxovid™, den COVID-19-Impfstoff, für Jugendliche im Alter von 12 bis 17 Jahren und als Auffrischungsimpfung für Erwachsene ab 18 Jahren
GAITHERSBURG, Maryland, 6. September 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute bekannt, da
Read more →NVAX▼ -6.1%on this newsshared move
Swissmedic autoriza la vacuna Novavax Nuvaxovid™ COVID-19 Vaccine para adolescentes de 12 a 17 años
- Swissmedic autoriza la vacuna Novavax Nuvaxovid™ COVID-19 Vaccine para adolescentes de 12 a 17 años y como refuerzo en adultos mayores de 18 años GAITHERSBURG, Md., 5 de septiembre de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a de
Read more →NVAX▼ -6.1%on this newsshared move
Novavax Nuvaxovid™ COVID-19-Impfstoff vom CHMP zur erweiterten bedingten Zulassung als Auffrischungsimpfung für Erwachsene ab 18 Jahren in der EU empfohlen
Die Zulassung könnte es ermöglichen, Nuvaxovid™ als Auffrischungsimpfung unabhängig von früheren Impfungen zu verwenden GAITHERSBURG, Maryland, 5. September 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich der Entwicklung und Vermarktung
Read more →NVAX▼ -6.1%on this newsshared move
Le CHMP recommande le vaccin Nuvaxovid™ de Novavax contre la COVID-19 pour une autorisation de mise sur le marché conditionnelle étendue comme vaccin de rappel dans l
Cette autorisation permettrait l'utilisation du Nuvaxovid™ comme vaccin de rappel, quels que soient les antécédents vaccinaux GAITHERSBURG, Maryland, 5 septembre 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), société de biotechnologie spécialisée dans le développement et la
Read more →NVAXLa vacuna Nuvaxovid™ COVID-19 de Novavax recomendada como refuerzo para mayores de 18 años
- La vacuna Nuvaxovid™ COVID-19 de Novavax es recomendada por el CHMP para su autorización de comercialización condicional ampliada en la Unión Europea como refuerzo para adultos mayores de 18 años · La autorización podría permitir el uso de Nuvaxovid™ como refuerzo independient
Read more →NVAXSwissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older
GAITHERSBURG, Md., Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Swissmedic, the Swiss Agency for Therapeutic Products,
Read more →NVAXNovavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older
Authorization could allow Nuvaxovid™ to be used as a booster regardless of previous vaccine history GAITHERSBURG, Md., Sept. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser
Read more →NVAX▼ -5.5%on this news
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17
Nuvaxovid™ will be the first protein-based vaccine available for adolescents aged 12 through 17 in the United Kingdom GAITHERSBURG, Md., Aug. 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generatio
Read more →NVAXFDA dos EUA autoriza uso emergencial para vacina com adjuvante contra COVID-19 da Novavax para adolescentes de 12 a 17 anos
A vacina da Novavax é a primeira vacina contra COVID-19 à base de proteína autorizada nos EUA Doses da vacina com adjuvante contra COVID-19 da Novavax já estão disponíveis e as imunizações da série inicial para adolescentes podem começar assim que for recebida uma recomendação p
Read more →NVAXU.S. FDA erteilt Notfallzulassung für Novavax COVID-19 Impfstoff, adjuvantiert für Jugendliche im Alter von 12 bis 17 Jahren
Der Impfstoff von Novavax ist der erste proteinbasierte COVID-19-Impfstoff, der in den USA zugelassen ist. Dosen des Novavax COVID-19-Impfstoffs mit Adjuvans sind jetzt verfügbar und die erste Impfserie für Jugendliche kann beginnen, sobald eine Empfehlung der CDC vorliegt GAIT
Read more →NVAXLa FDA de los Estados Unidos autoriza el uso de emergencia de la vacuna adyuvada contra la COVID-19 de Novavax para adolescentes de edades entre 12 y 17 años
La vacuna contra la COVID-19 basada en proteínas de Novavax es la primera autorizada en los Estados Unidos Las dosis de la vacuna adyuvada contra la COVID-19 de Novavax ya están disponibles y la inmunización de la serie primaria para adolescentes pueden comenzar una vez que se r
Read more →NVAXLa FDA concede la autorización de uso de emergencia de la vacuna Novavax COVID-19 para adolescentes
- La FDA de EE.UU. concede la autorización de uso de emergencia de la vacuna Novavax COVID-19 adyuvada para adolescentes de 12 a 17 años La vacuna de Novavax es la primera vacuna COVID-19 basada en proteínas autorizada en Estados Unidos Las dosis de la vacuna COVID-19 de Novava
Read more →NVAXU.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can begin once a policy recommendation from the CDC is received GAITHERSBURG,
Read more →NVAX▼ -5.6%on this newsshared move
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17
Nuvaxovid™ is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today anno
Read more →NVAXNovavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
If authorized, Novavax' vaccine would be the first protein-based COVID-19 booster for adults If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine GAITH
Read more →NVAXNovavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to dev
Read more →NVAXNovavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
GAITHERSBURG, Md., Aug. 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the SVB
Read more →NVAX▼ -5%on this news· ran to -33% by day 1shared move
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights Received FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights GAITHERSBURG, Md., August 8, 2022 - Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, tod
Read more →NVAXNovavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
GAITHERSBURG, Md., Aug. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of its Phase 2b/3 Hummingbird™ global clinica
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022
GAITHERSBURG, Md., Aug. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and
Read more →NVAXNovavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious
Read more →NVAXNovavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generat
Read more →NVAX▼ -7%on this newsshared move
Comitê Consultivo do CDC dos EUA recomenda por unanimidade a vacina com adjuvante da Novavax contra a COVID-19 como série inicial para pessoas com idade igual ou superior a 18 anos
A recomendação segue-se à Autorização de Uso Emergencial da FDA dos EUA para a vacina com adjuvante da Novavax contra a COVID-19 como uma série inicial de duas doses A FDA determinou que o primeiro lote de vacinas atendeu a todas as especificações de liberação e é aceitável para
Read more →NVAX▼ -7%on this newsshared move
El Comité Asesor de los CDC de los Estados Unidos recomienda por unanimidad la vacuna adyuvada contra la COVID-19 de Novavax como serie primaria para personas mayores de 18 años
La recomendación se da tras la autorización de uso de emergencia de la FDA en los Estados Unidos para la vacuna adyuvada contra la COVID-19 de Novavax como serie primaria de dos dosis La FDA determinó que el primer lote de vacunas cumplió con todas las especificaciones de emisió
Read more →NVAXLe comité consultatif des CDC américains recommande à l
Cette recommandation fait suite à l'autorisation d'utilisation d'urgence par la FDA américaine du vaccin Novavax COVID-19 avec adjuvant, en série de deux doses La FDA a déterminé que le premier lot de vaccin a satisfait à toutes les spécifications de mise en circulation et qu'il
Read more →NVAXCDC-Beratungsausschuss empfiehlt einstimmig Novavax Covid-19-Impfstoff, adjuvantiert, als primäre Impfserie für Personen ab 18 Jahren
Die Empfehlung folgt der FDA-Notfallzulassung für den Novavax Covid-19-Impfstoff, adjuvantiert, als Primärserie mit zwei Dosen. Die FDA hat festgestellt, dass die erste Impfstoffcharge alle Freigabespezifikationen erfüllt hat und für die Verwendung im Rahmen der Notfallzulassung
Read more →NVAXEl Comité Asesor de CDC de EE.UU. recomienda la vacuna COVID-19 de Novavax para mayores de 18 años
-El Comité Asesor de CDC de EE.UU. recomienda por unanimidad la vacuna COVID-19 de Novavax, adyuvante, como serie primaria para personas mayores de 18 años La recomendación sigue a la Autorización de Uso de Emergencia de la FDA de EE.UU. para la vacuna Novavax COVID-19, adyuvada
Read more →NVAX▲ +11.6%on this newsshared move
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series FDA has determined that first vaccine lot has met all release specifications and is acceptable for use under Emergency Use Authorization Novavax
Read more →NVAX▲ +11.6%on this newsshared move
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
GAITHERSBURG, Md., July 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has signed agreements with its partner, SK bioscience, for the manufacturin
Read more →NVAXU.S. FDA erteilt Notfallzulassung für Novavax COVID-19 Impfstoff, adjuvantiert für Personen ab 18 Jahren
Der Impfstoff von Novavax ist der erste proteinbasierte COVID-19-Impfstoff, der in den USA zugelassen ist. Impfungen mit dem Novavax COVID-19 Impfstoff, adjuvantiert als Primärserie beginnen nach der Produktfreigabe und sobald eine Empfehlung der CDC vorliegt. GAITHERSBURG, Mar
Read more →NVAXUne autorisation d
Le vaccin de Novavax est le premier vaccin protéique contre la COVID-19 autorisé aux États-Unis Les vaccinations avec le vaccin Novavax COVID-19, avec adjuvant en tant que série primaire, commenceront dès la sortie du produit et après réception d'une recommandation politique de
Read more →NVAX▲ +5.4%on this newsshared move
FDA dos EUA autoriza uso emergencial para vacina com adjuvante contra a COVID-19 da Novavax para indivíduos com 18 anos ou mais
A vacina da Novavax é a primeira vacina contra a COVID-19 à base de proteína autorizada nos EUA Imunizações com a vacina com adjuvante da Novavax contra a COVID-19, como série primária começarão após o lançamento do produto e recebimento de uma recomendação de política do CDC G
Read more →NVAX▲ +5.4%on this newsshared move
La FDA de EE. UU. autoriza el uso de emergencia de la vacuna adyuvada contra la COVID-19 de Novavax para personas mayores de 18 años
La vacuna de Novavax es la primera vacuna contra la COVID-19 basada en proteínas autorizada en los EE. UU. Las inmunizaciones con la vacuna adyuvada contra la COVID-19 de Novavax como serie primaria comenzarán después del lanzamiento del producto y una vez que se reciba una reco
Read more →NVAX▼ -26.2%on this newsshared move
La FDA concede una autorización de uso de emergencia para la vacuna Novavax COVID-19
- La FDA de Estados Unidos concede una autorización de uso de emergencia para la vacuna Novavax COVID-19, con adyuvante para personas mayores de 18 años La vacuna de Novavax es la primera vacuna de la COVID-19 basada en proteínas autorizada en Estados Unidos Las inmunizaciones
Read more →NVAXU.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July
Read more →NVAXGoverno dos EUA garante 3,2 milhões de doses da vacina da Novavax contra a COVID-19
O acordo oferecerá a primeira opção de vacina à base de proteína nos EUA, aguardando Autorização de Uso Emergencial da FDA e recomendação do CDC GAITHERSBURG, Maryland, 13 de julho de 2022 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), empresa de biotecnologia dedicada ao desen
Read more →NVAXLe gouvernement américain obtient 3,2 millions de doses du vaccin Novavax contre la COVID-19
L'accord fournira la première option de vaccin à base de protéines aux États-Unis, sous réserve de l'autorisation d'utilisation en urgence de la FDA et de la recommandation des CDC GAITHERSBURG, Md., 12 juillet 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une société de b
Read more →NVAX▼ -11.8%on this news· ran to -32% by day 3shared move
El gobierno de los Estados Unidos asegura 3,2 millones de dosis de la vacuna contra la COVID-19 de Novavax
El acuerdo proporcionará la primera opción de vacuna a base de proteínas en los Estados Unidos, en espera de la autorización de uso de emergencia de la FDA y la recomendación de los CDC GAITHERSBURG, Maryland, 11 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una
Read more →NVAX▼ -11.8%on this news· ran to -32% by day 3shared move
US-Regierung sichert sich 3,2 Millionen Dosen des Novavax Covid-19 Impfstoffs
Die Vereinbarung bietet die erste Impfstoffoption auf Proteinbasis in den USA, vorbehaltlich der FDA-Notfallzulassung und der CDC-Empfehlung GAITHERSBURG, Maryland, 12. Juli 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwic
Read more →NVAX▼ -11.8%on this news· ran to -32% by day 3shared move
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md., July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercial
Read more →NVAX▼ -11.8%on this news· ran to -32% by day 3shared move
El gobierno de Estados Unidos obtiene 3,2 millones de dosis de la vacuna contra la COVID-19 de Novavax
El acuerdo proporcionará la primera opción de vacuna basada en proteínas en Estados Unidos, en espera de la autorización de uso de emergencia de la FDA y la recomendación de los CDC GAITHERSBURG, Md., 11 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa
Read more →NVAXL'utilisation du vaccin contre la COVID-19 Nuvaxovid™ de Novavax est autorisée sous condition au sein de l'Union européenne pour les adolescents âgés de 12 à 17 ans Novavax, Inc. (Nasdaq : NVAX), une entreprise de biotechnologie spécialisée dans la mise au point et la commercialisation de vaccins de nouvelle...
Le vaccin contre la COVID-19 Nuvaxovid™ est la première option de vaccin à base de protéines pour les adolescents âgés de 12 à 17 ans en Europe GAITHERSBURG, Md., 6 juillet 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une entreprise de biotechnologie spécialisée dans la m
Read more →NVAXNovavax Nuvaxovid™ COVID-19-Impfstoff in der Europäischen Union für Jugendliche im Alter von 12 bis 17 Jahren unter Vorbehalt zugelassen
Nuvaxovid™ COVID-19-Impfstoff ist die erste proteinbasierte Option für Jugendliche zwischen 12 und 17 Jahren in Europa GAITHERSBURG, Md., 6. Juli 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Im
Read more →NVAXNuvaxovid™, vacina contra a COVID-19 da Novavax autorizada condicionalmente na União Europeia para adolescentes de 12 a 17 anos de idade 17
Nuvaxovid™, vacina contra a COVID-19, é a primeira opção à base de proteína para adolescentes com idade entre 12 e 17 anos na Europa GAITHERSBURG, Md., 6 de julho de 2022 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e à
Read more →NVAXLa vacuna Nuvaxovid™ de Novavax contra la COVID-19 se autoriza de forma condicional en la Unión Europea para adolescentes de 12 a 17 años
La vacuna Nuvaxovid™ contra la COVID-19 es la primera opción basada en proteínas para adolescentes de 12 a 17 años en Europa GAITHERSBURG, Md., 6 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar va
Read more →NVAX▲ +12.5%on this news· ran to +33% by day 3shared move
La vacuna de Novavax, Nuvaxovid™ COVID-19, autorizada en la Unión Europea para adolescentes de 12 a 17 años
La vacuna Nuvaxovid™ COVID-19 es la primera opción basada en proteinas para adolescentes de 12 a 17 años en Europa GAITHERSBURG, Md., 5 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y la comercialización de vac
Read more →NVAX▲ +12.5%on this news· ran to +33% by day 3shared move
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines f
Read more →NVAX▼ -5.1%on this news
Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants
Novavax prototype vaccine (NVX-CoV2373) demonstrates broad immune responses including against Omicron and other circulating variants Pre-clinical data demonstrated that boosting with Novavax' Omicron or prototype vaccine induces immune response against Omicron variants, includin
Read more →NVAXNovavax COVID-19-Impfstoff Nuvaxovid™ vom CHMP zur erweiterten bedingten Zulassung in der Europäischen Union für Jugendliche im Alter von 12 bis 17 Jahren empfohlen
Nach der Zulassung wäre Nuvaxovid™ die erste proteinbasierte Option für Jugendliche zwischen 12 und 17 Jahren in Europa Nuvaxovid™ zeigte bei Jugendlichen eine Wirksamkeit von 80 % und war im Allgemeinen gut verträglich GAITHERSBURG, Maryland, 27. Juni 2022 /PRNewswire/ -- Nova
Read more →NVAXLe CHMP recommande le vaccin Nuvaxovid™ de Novavax contre la COVID-19 pour une autorisation de mise sur le marché conditionnelle étendue dans l
En cas d'autorisation, Nuvaxovid™ serait la première option à base de protéines pour les adolescents âgés de 12 à 17 ans en Europe Nuvaxovid™ a démontré une efficacité de 80 % et a été généralement bien toléré par les adolescents GAITHERSBURG, Maryland, 27 juin 2022 /PRNewswire
Read more →NVAXNuvaxovid™, vacina contra a COVID-19 da Novavax recomendada para autorização de comercialização condicional expandida na União Europeia pelo CHMP para adolescentes de 12 a 17 anos de idade
Após a autorização, a Nuvaxovid™ seria a primeira opção baseada em proteína para adolescentes com idade entre 12 e 17 anos na Europa Nuvaxovid™ demonstrou 80% de eficácia e, em geral, foi bem tolerada em adolescentes GAITHERSBURG, Maryland, 24 de junho de 2022 /PRNewswire/ -- A
Read more →NVAXEl CHMP recomienda la ampliación de la autorización de comercialización condicional de la vacuna Nuvaxovid™ de Novavax contra la COVID-19 para adolescentes de 12 a 17 años en la Unión Europea
Una vez autorizada, Nuvaxovid™ será la primera opción basada en proteínas disponible en Europa para adolescentes de 12 a 17 años Nuvaxovid™ demostró una eficacia del 80 % y en general fue bien tolerada por los adolescentes GAITHERSBURG, Maryland, 24 de junio de 2022 /PRNewswire
Read more →NVAXNovavax COVID-19 Vaccine Nuvaxovid™ recomendada para adolescentes
- Novavax COVID-19 Vaccine Nuvaxovid™ recomendada para la autorización de comercialización condicional ampliada en la Unión Europea por CHMP para adolescentes de 12 a 17 años Tras la autorización, Nuvaxovid™ sería la primera opción basada en proteínas para adolescentes de 12 a 1
Read more →NVAX▲ +13.9%on this newsshared move
Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...
The EUA in Taiwan allows Novavax to begin fulfilling its commitment to the COVAX Facility GAITHERSBURG, Md., June 23, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infec
Read more →NVAX▲ +13.9%on this newsshared move
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 23, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX)
Read more →NVAX▼ -10.7%on this news
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commerci
Read more →NVAX▼ -17.2%on this newsshared move
El Comité Asesor de la FDA recomienda la autorización de uso de emergencia de la vacuna Novavax COVID-19 para personas de 18 años o más
La vacuna contra la COVID-19 de Novavax recibe el voto positivo del Comité Asesor de Vacunas y Productos Biológicos Relacionados de la Administración de Alimentos y Medicamentos de EE. UU. Si la FDA concede la autorización de uso de emergencia, la vacuna contra la COVID-19 de No
Read more →NVAX▼ -17.2%on this newsshared move
Comitê Consultivo da FDA recomenda autorização de uso emergencial da vacina contra a COVID-19 da Novavax para pessoas com idade igual ou superior a 18 anos
Vacina contra a COVID-19 da Novavax recebe voto positivo do Comitê Consultivo das Vacinas e Produtos Biológicos Concernentes da Agência de Administração de Alimentos e Medicamentos dos EUA Se concedida pela FDA a Autorização de Uso Emergencial, a vacina da Novavax contra a COVID
Read more →NVAX▼ -17.2%on this newsshared move
Beratender Ausschuss der FDA empfiehlt Notfallzulassung des Novavax Covid-19 Impfstoffs für Personen ab 18 Jahren
Novavax Covid-19-Impfstoff erhält positives Votum des Beratungsausschusses für Impfstoffe und verwandte biologische Produkte der US-Arzneimittelbehörde FDA Sollte die FDA eine Notfallzulassung erteilen, wäre der Novavax Covid-19 Impfstoff der erste in den USA erhältliche Impfsto
Read more →NVAX▼ -17.2%on this newsshared move
Le Comité consultatif de la FDA recommande l
Le vaccin Novavax contre la COVID-19 reçoit un vote positif du Comité consultatif sur les vaccins et les produits biologiques connexes de la Food and Drug Administration des États-Unis Si l'autorisation d'utilisation d'urgence est accordée par la FDA, le vaccin Novavax contre la
Read more →NVAX▲ +5.4%on this news· ran to -24% by day 3shared move
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vac
Read more →NVAX▼ -7.1%on this news
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company Reit
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights GAITHERSBURG, Md., May 9, 2022 - Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today a
Read more →NVAX▲ +6.5%on this newsshared move
Novavax to Participate in BofA Securities 2022 Healthcare Conference
GAITHERSBURG, Md., May 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in BofA Securities 2022 Healthcare C
Read more →NVAX▲ +19.3%on this news· ran to +31% by day 1shared move
Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
GAITHERSBURG, Md., May 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and o
Read more →NVAXFDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax
NVX-CoV2373 would be the first protein-based COVID-19 vaccine to be reviewed by VRBPAC in the U.S. GAITHERSBURG, Md., April 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser
Read more →NVAXLes premiers résultats de l
L'essai clinique de phase 1/2 du candidat vaccin combiné COVID-19 et grippe indique que le vaccin est bien toléré et immunogène Les données de cet essai combiné serviront de base à l'essai de confirmation de dose de phase 2, qui devrait débuter d'ici fin 2022 La réponse immunit
Read more →NVAXErste Ergebnisse der Studie mit dem COVID-19-Grippeimpfstoff von Novavax zeigen erstmals die Machbarkeit eines Kombinationsimpfstoffs
Klinische Phase 1/2-Studie mit dem Kombinationsimpfstoff COVID-19-Grippe hat ergeben, dass der Impfstoff gut verträglich und immunogen ist Daten aus dieser Kombinationsstudie werden in die geplante Phase-2-Studie zur Dosisbestätigung einfließen, die vor Ende 2022 beginnen soll
Read more →NVAXNovavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
PREVENT-19 trial participants aged 12 through 17 receive third dose of NVX-CoV2373 Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose GAITHERSBURG, Md., April 22, 2022 /PRNewswire/ -- Novavax,
Read more →NVAX▼ -9.1%on this newsshared move
Novavax annonce l
Nuvaxovid est le premier vaccin contre la COVID-19 à base de protéines approuvé pour les adultes de 18 ans ou plus au Japon Il s'agit de la première approbation au monde de NVX-CoV2373 qui inclut aussi bien la vaccination primaire que la vaccination de rappel GAITHERSBURG, Mary
Read more →NVAX▼ -9.1%on this newsshared move
Novavax gibt die Zulassung des Impfstoffs Nuvaxovid™ COVID-19 für die Grund- und Auffrischungsimpfung in Japan bekannt
Nuvaxovid ist der erste proteinbasierte COVID-19-Impfstoff, der in Japan für Erwachsene ab 18 Jahren zugelassen ist Weltweit erste Zulassung für NVX-CoV2373, die sowohl die Erst- als auch die Auffrischungsimpfung umfasst GAITHERSBURG, Maryland, 21. April 2022 /PRNewswire/ -- No
Read more →NVAX▼ -9.1%on this newsshared move
Resultados positivos de la vacuna combinada contra la COVID-19 y la gripe de Novavax
- Los resultados iniciales del ensayo de la vacuna contra la COVID-19 y la gripe de Novavax son los primeros en mostrar la viabilidad de la vacuna combinada El ensayo clínico de fase 1/2 de la vacuna candidata combinada contra la COVID-19 y la gripe indica que la vacuna es bien
Read more →NVAX▼ -9.1%on this newsshared move
Resultados iniciais do estudo da vacina contra a COVID-19 e a gripe da Novavax são os primeiros a mostrar viabilidade da vacina combinada
Estudo clínico de Fase 1/2 da candidata a vacina combinada contra a COVID-19 e a gripe indica que a vacina é bem tolerada e imunogênica Os dados desse estudo combinado fornecerão informações para o estudo de confirmação de dose de Fase 2 planejado, programado para começar até o
Read more →NVAX▼ -9.1%on this newsshared move
Los resultados iniciales del ensayo de la vacuna contra COVID-19-influenza de Novavax son los primeros en demostrar la viabilidad de la vacuna combinada
El ensayo clínico de fase 1/2 de la candidata a vacuna combinada contra COVID-19-influenza indica que la vacuna es bien tolerada e inmunogénica Los datos de este ensayo combinado respaldarán el ensayo de confirmación de dosis de fase 2 planificado, que se espera inicie a finales
Read more →NVAXNOVAVAX. All rights reserved. UPDATE ON NOVAVAX INVESTIGATIONAL N anoFlu VACCINE AND COVID - 19 - INFLUENZA COMBINATION VACCINE DEVELOPMENT VIVEK SHINDE, MD APRIL 20, 2022 | NOVAVAX SAFE HARBOR STATEMENT 2 2022 NOVAVAX.
Ratio of Day 21 GMTs 61% p=0.0002 3.8 3.9 3.5 2.1 0.0 1.0 2.0 3.0 4.0 5.0 180 g NanoFlu IIV3-HD 180 g NanoFlu IIV3-HD A/Singapore H3N2 (egg-adapted) A/Singapore H3N2 (wild-type) Geometric Mean Fold Titer Rise (95% CI) Ratio of Day 21 GMTs 61% p=0.0002 NanoFlu induced improved neu
Read more →NVAXNovavax anuncia la aprobación de la vacuna Nuvaxovid™ contra la COVID-19 para la inmunización primaria y de refuerzo en Japón
Nuvaxovid es la primera vacuna contra la COVID-19 basada en proteínas aprobada para su uso en adultos mayores de 18 años en Japón Esta aprobación es la primera en el mundo para NVX-CoV2373 que incluye tanto la vacunación primaria como el refuerzo GAITHERSBURG, Maryland, 20 de a
Read more →NVAXNovavax anuncia aprovação da vacina Nuvaxovid™ contra a COVID-19 para imunização primária e de reforço no Japão
A Nuvaxovid é a primeira vacina à base de proteína contra a COVID-19 aprovada para uso em adultos com idade igual ou superior a 18 anos no Japão Trata-se da primeira aprovação no mundo da NVX-CoV2373 que inclui a vacinação primária e de reforço GAITHERSBURG, Maryland, 20 de abr
Read more →NVAXInitial Results from Novavax
Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenic Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 Immune response confirmed
Read more →NVAXNovavax verstärkt seine Präsenz auf dem Weltimpfstoffkongress und dem 32. Europäischen Kongress für Klinische Mikrobiologie und Infektionskrankheiten
Neue Daten zum Covid-19/Grippe-Kombinationsimpfstoff und zum saisonalen Grippeimpfstoff werden auf dem Weltimpfstoffkongress vorgestellt Mehrere Abstracts und Präsentationen zu NVX-CoV2373, dem COVID-19-Impfstoff von Novavax, sind geplant GAITHERSBURG, Maryland, 19. April 2022
Read more →NVAXNovavax consolide sa présence au Congrès mondial sur les vaccins et au 32e Congrès européen de microbiologie clinique et des maladies infectieuses
Le Congrès mondial des vaccins présentera de nouvelles données sur le vaccin combiné contre la grippe COVID-19 et la grippe saisonnière Plusieurs exposés et présentations sont prévus pour faire le point sur le NVX-CoV2373, le vaccin COVID-19 de Novavax. GAITHERSBURG, Maryland,
Read more →NVAXNovavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination GAITHERSBURG, Md., April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq:
Read more →NVAX▼ -5.8%on this news· ran to -17% by day 3shared move
Novavax aumenta la presencia en dos Congresos
- Novavax aumenta la presencia en el World Vaccine Congress y en el 32º European Congress of Clinical Microbiology & Infectious Diseases En el World Vaccine Congress se presentarán nuevos datos sobre la vacuna combinada contra la gripe y la COVID-19 y la vacuna contra la gripe e
Read more →NVAX▼ -5.8%on this news· ran to -17% by day 3shared move
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 /PRNewswire/ -
Read more →NVAX▼ -5.8%on this news· ran to -17% by day 3shared move
Novavax aumenta su presencia en el Congreso Mundial de Vacunas y el 32.° Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas
En el Congreso Mundial de Vacunas se presentarán nuevos datos sobre la vacuna combinada contra la COVID-19 y la influenza, así como la vacuna contra la influenza estacional Novavax tiene previstos diferentes resúmenes y presentaciones para destacar actualizaciones sobre su vacun
Read more →NVAX▼ -5.8%on this news· ran to -17% by day 3shared move
Novavax aumenta sua presença no Congresso Mundial de Vacinas e no 32º Congresso Europeu de Microbiologia Clínica e Doenças Infecciosas
Novos dados sobre a vacina combinada contra a gripe e a COVID-19 e a vacina contra a gripe sazonal serão apresentados no Congresso Mundial de Vacinas Vários resumos e apresentações programados para destacar atualizações sobre a vacina NVX-CoV2373 da Novavax contra a COVID-19 GA
Read more →NVAX▼ -5.8%on this newsshared move
Swissmedic erteilt bedingte Marktzulassung für Novavax COVID-19-Impfstoff
Nuvaxovid™ ist der erste proteinbasierte COVID-19-Impfstoff, der in der Schweiz zugelassen ist GAITHERSBURG, Md., April 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten
Read more →NVAX▼ -5.8%on this newsshared move
Swissmedic accorde une autorisation de mise sur le marché conditionnelle pour le vaccin contre la COVID-19 de Novavax
- Nuvaxovid™ est le premier vaccin contre la COVID-19 à base de protéines autorisé en Suisse GAITHERSBURG, Maryland, 15 avril 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une société de biotechnologie qui se consacre au développement et la commercialisation de vaccins de n
Read more →NVAX▲ +7%on this newsshared move
Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
- Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Switzerland GAITHERSBURG, Md., April 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf
Read more →NVAXNovavax and Serum Institute of India Receive Emergency Use Authorization for Novavax
GAITHERSBURG, Md., and PUNE, India, April 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's
Read more →NVAXNovavax présente une demande d
Si elle est accordée, le vaccin contre la COVID-19, le Nuvaxovid™ (recombinant, avec adjuvant), serait la première option à base de protéines pour les adolescents âgés de 12 à 17 ans en Europe. GAITHERSBURG, Maryland, 2 avril 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), un
Read more →NVAXNovavax envia solicitação para expandir a autorização de comercialização condicional da vacina contra a COVID-19 na União Europeia para adolescentes (de 12 a 17 anos)
Se concedida, a vacina contra a COVID-19 Nuvaxovid™ (recombinante, com adjuvante) seria a primeira opção baseada em proteína para adolescentes com idade entre 12 e 17 anos na Europa GAITHERSBURG, Maryland, 1 de abril de 2022 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma em
Read more →NVAXNovavax stellt Antrag auf Erweiterung der bedingten Zulassung des Covid-19-Impfstoffs in der Europäischen Union auf Jugendliche (12-17 Jahre)
Im Falle einer Genehmigung, wäre der Nuvaxovid™ Covid-19-Impfstoff (rekombinant, adjuvant) die erste proteinbasierte Option für Jugendliche im Alter von 12-17 Jahren in Europa GAITHERSBURG, Maryland, 1. April 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieu
Read more →NVAXNovavax presenta una solicitud para ampliar la autorización condicional de comercialización de la vacuna contra la COVID-19 en la Unión Europea a adolescentes (de 12 a 17 años)
De otorgarse, la vacuna Nuvaxovid™ contra la COVID-19 (recombinante y adyuvada) sería la primera opción basada en proteínas para adolescentes de 12 a 17 años en Europa GAITHERSBURG, Maryland, 1 de abril de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecn
Read more →NVAXNovavax solicita autorización para vacunar contra la COVID-19 a los adolescentes en la UE
- Novavax presenta una solicitud para ampliar la autorización de comercia lización condicional de la vacuna contra la COVID-19 en la Unión Europea a los adolescentes (de 12 a 17 años) En caso de aprobarse, la vacuna Nuvaxovid™ COVID-19 (recombinante, adyuvada) sería la primera o
Read more →NVAXNovavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in Europe GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing an
Read more →NVAX▼ -9%on this news
Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current FDA approved or emergency use authorized-vaccines NVX-CoV2373 will be evaluated in a head-to-head boosting trial in the United Arab Emirates to assess
Read more →NVAXNovavax und Serum Institute of India geben die erste Notfallzulassung des Impfstoffs COVID-19 von Novavax für Jugendliche ≥12 bis <18 in Indien bekannt
Erste Zulassung von Novavax' COVID-19-Impfstoff für Jugendliche erhalten Covovax™ (SARS-CoV-2 rS Protein (COVID-19) rekombinanter Spike-Protein-Nanopartikel-Impfstoff) ist der erste proteinbasierte COVID-19-Impfstoff, der in Indien für Jugendliche ≥12 bis <18 Jahre zugelassen is
Read more →NVAXNovavax e Serum Institute of India anunciam primeira autorização de uso emergencial da vacina da Novavax contra a COVID-19 em adolescentes com idade ≥12 a <18 anos na Índia
Recebida a primeira autorização da vacina da Novavax contra a COVID-19 em adolescentes A vacina Covovax™ (recombinante de nanopartículas à base de proteína do SARS-CoV-2 rS, o COVID-19) é a primeira vacina à base de proteína contra a COVID-19 autorizada para uso em adolescentes
Read more →NVAXAutorizada la vacuna de la COVID-19 de Novavax en adolescentes de ≥12 a <18 años en India
Novavax y Serum Institute of India anuncian la primera autorización de uso de emergencia de la vacuna de la COVID-19 de Novavax en adolescentes de ≥12 a <18 años en India Recibida la primera autorización de la vacuna de la COVID-19 de Novavax en población adolescente Covovax™ (
Read more →NVAXNovavax y Serum Institute of India reciben la primera Autorización de Uso de Emergencia de la vacuna de Novavax contra la COVID-19 para adolescentes ≥12 y <18 años en India
Se recibe la primera autorización de la vacuna de Novavax contra la COVID-19 para la población adolescente Covovax™ (vacuna de nanopartículas recombinantes de la proteína espiga del SARS-CoV-2 rS [COVID-19]) es la primera vacuna contra la COVID-19 basada en proteínas autorizada
Read more →NVAXNovavax et Serum Institute of India annoncent la première autorisation d
Obtention de la première autorisation du vaccin COVID-19 de Novavax pour la population adolescente Covovax™ (vaccin à nanoparticules à base de protéine de pointe recombinante du SRAS-CoV-2 (COVID-19)) est le premier vaccin protéique COVID-19 autorisé pour les adolescents âgés de
Read more →NVAX▲ +6.7%on this newsshared move
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax
First authorization of Novavax' COVID-19 vaccine in adolescent population received Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India Authorization
Read more →NVAXNovavax kündigt weltweite Informationsprogramme über Impfungen an
- „We Do Vaccines" und „Know Our Vax" sind neue Bildungsprogramme, die Informationen zu den Impfstoffen liefern - Die Programme erläutern das Engagement von Novavax für Impfstoffentwicklung und Innovation GAITHERSBURG, Maryland, 11. März 2022 /PRNewswire/ -- Novavax, Inc. (Nasd
Read more →NVAXNovavax Announces Launch of Global Vaccine Education Programs
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines - Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechno
Read more →NVAXNovavax anuncia el lanzamiento de programas globales de educación sobre vacunas
- 'We Do Vaccines' y 'Know Our Vax' son nuevos esfuerzos educativos que ofrecen información sobre las vacunas - Los programas explican el compromiso de Novavax con el desarrollo y la innovación de vacunas GAITHERSBURG, Md., 10 de marzo de 2022 /PRNewswire/ -- Novavax, Inc. (Nas
Read more →NVAXNovavax anuncia el lanzamiento a nivel mundial de programas educativos sobre las vacunas
- "We Do Vaccines" y "Know Our Vax" son nuevos esfuerzos educacionales que proporcionan información sobre las vacunas - Los programas explican el compromiso de Novavax con el desarrollo y la innovación en el campo de las vacunas GAITHERSBURG, Maryland, 10 de marzo de 2022 /PRNe
Read more →NVAXNovavax anuncia o lançamento de programas globais de informações sobre vacinas
- "We Do Vaccines" e "Know Our Vax" são novos esforços educativos que fornecem informações sobre vacinas - Os programas explicam o compromisso da Novavax com o desenvolvimento e a inovação de vacinas GAITHERSBURG, Maryland, 10 de março de 2022 /PRNewswire/ -- A Novavax, Inc. (N
Read more →NVAXNovavax annonce le lancement de programmes d
- « We Do Vaccines » et « Know Our Vax » sont de nouveaux efforts éducatifs qui fournissent des informations sur les vaccins - Les programmes expliquent l'engagement de Novavax envers le développement et l'innovation en matière de vaccins GAITHERSBURG, Maryland, 11 mars 2022 /P
Read more →NVAXNovavax to Participate in Cowen
GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen's 42nd Annual Healthcare
Read more →NVAXNovavax anuncia durabilidade prolongada da proteção contra a infecção e doença em estudo clínico de Fase 3 da vacina contra a COVID-19 do Reino Unido
GAITHERSBURG, Maryland, 2 de março de 2022 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, compartilhou hoje a análise prolongada de seu import
Read more →NVAXNovavax anuncia una mayor durabilidad de la protección contra infecciones y enfermedades en el ensayo clínico de fase 3 de la vacuna contra la COVID-19 del Reino Unido
GAITHERSBURG, Maryland, 2 de marzo de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología dedicada al desarrollo y la comercialización de vacunas de última generación para prevenir enfermedades infecciosas graves, compartió hoy un amplio análisis de s
Read more →NVAXNovavax: Anhaltender Schutz vor Infektionen und Krankheiten in klinischer Phase-III-Studie mit COVID-19-Impfstoff in Großbritannien
- NVX-CoV2373 schützt vor symptomatischer und asymptomatischer Infektion - Gleichbleibend hohe Wirksamkeit des Impfstoffs über einen Überwachungszeitraum von sechs Monaten - Anhaltend beruhigendes Sicherheitsprofil im Einklang mit früheren Studien GAITHERSBURG, Maryland, 1. Mä
Read more →NVAXNovavax annonce une protection durable prolongée contre l
- Le NVX-CoV2373 démontre une protection contre les formes symptomatique et asymptomatique de l'infection - Niveau élevé d'efficacité du vaccin maintenu sur une période de surveillance de 6 mois - Maintien d'un profil d'innocuité rassurant conformément aux essais précédents GA
Read more →NVAXNovavax anuncia la eficacia de la vacuna de COVID-19
- Novavax anuncia la prolongación de la protección contra la infección y la enfermedad en el ensayo clínico de fase 3 de la vacuna de COVID-19 en Reino Unido - NVX-CoV2373 demuestra protección contra la infección sintomática y asintomática - El alto nivel de eficacia de la vacu
Read more →NVAXNovavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights GAITHERSBURG, Md., February 28, 2022 - Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infecti
Read more →NVAXNovavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today shared extended analysis from its pivotal Phase 3 clinical trial cond
Read more →NVAXNovavax kündigt Auslieferung des Covid-19 Impfstoffs in die Mitgliedstaaten der Europäischen Union an
Impfungen mit Nuvaxovid™ beginnen in den nächsten Tagen GAITHERSBURG, Maryland, 25. Februar 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infekt
Read more →NVAX▼ -7.4%on this newsshared move
Novavax anuncia el envío de su vacuna de COVID-19 a Estados miembros de la Unión Europea
Las inmunizaciones con Nuvaxovid™ comenzarán en los próximos días GAITHERSBURG, Md., 23 de febrero de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de nueva generación contra enfermedades infecciosa
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022
GAITHERSBURG, Md., Feb. 21, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter and full year 2021 financ
Read more →NVAXHealth Canada Authorizes Novavax COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Canada GAITHERSBURG, Md., Feb. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious
Read more →NVAX▲ +8.8%on this newsshared move
Novavax dépose une demande d
GAITHERSBURG, Maryland, 15 février 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération contre les maladies infectieuses graves, a annoncé aujourd'hui qu'elle avai
Read more →NVAX▲ +8.8%on this newsshared move
Novavax beantragt bedingte Marktzulassung für COVID-19-Impfstoff in der Schweiz
GAITHERSBURG, Maryland, 15. Februar 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute bekannt, das
Read more →NVAX▼ -11.4%on this newsshared move
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Feb. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Singapore Health Sciences Authority (HSA) has issu
Read more →NVAX▼ -11.4%on this newsshared move
Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland
GAITHERSBURG, Md., Feb. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to Swissmedic, the Swiss Agency for Therapeu
Read more →NVAX▼ -11.4%on this newsshared move
Novavax annonce des résultats positifs pour le vaccin contre la COVID-19 dans la population pédiatrique de l
- L'expansion des essais pédiatriques PREVENT-19 chez les adolescents âgés de 12 à 17 ans a atteint le critère principal d'efficacité démontrant la similitude avec la population adulte - L'essai a démontré une efficacité clinique de 82 % contre le variant Delta - Les réponses i
Read more →NVAX▼ -11.4%on this newsshared move
Novavax anuncia resultados positivos de la vacuna contra la COVID-19 en la población pediátrica en el ensayo clínico PREVENT-19 de fase 3
- La expansión pediátrica de PREVENT-19 en adolescentes de 12 a 17 años logró el criterio de valoración primario de efectividad que demuestra su comparabilidad con la población adulta - El ensayo demostró una eficacia clínica del 82 % contra la variante delta - Las respuestas i
Read more →NVAX▼ -11.4%on this newsshared move
Novavax anuncia resultados positivos da vacina contra a COVID-19 na população pediátrica do estudo clínico PREVENT-19 de Fase 3
- A expansão pediátrica PREVENT-19 em adolescentes com idade entre 12 e 17 anos atingiu o desfecho de imunogenicidade primária, demonstrando comparabilidade com a população adulta - O estudo demonstrou 82% de eficácia clínica contra a variante Delta - As respostas imunes em ado
Read more →NVAXNovavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
GAITHERSBURG, Md., Feb. 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 11th Ann
Read more →NVAXNovavax gibt positive Ergebnisse des Impfstoffs COVID-19 in der pädiatrischen Population der klinischen Phase-3-Studie PREVENT-19 bekannt
- PREVENT-19 pädiatrische Erweiterung bei Jugendlichen im Alter von 12 bis 17 Jahren erreicht primären Wirksamkeitsendpunkt, der die Vergleichbarkeit mit der Erwachsenenpopulation belegt - Studie zeigte 82% klinische Wirksamkeit gegen Delta-Variante - Die Immunreaktionen waren
Read more →NVAXNovavax anuncia resultados positivos de la vacuna de la COVID-19 en niños en el ensayo PREVENT-19
- Novavax anuncia resultados positivos de la vacuna de la COVID-19 en la población pediátrica del ensayo clínico de fase 3 PREVENT-19 - La expansión pediátrica de PREVENT-19 en adolescentes de 12 a 17 años logró el criterio principal de valoración de la eficacia demostrando la c
Read more →NVAXNovavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in
Read more →NVAXForward - looking statements are based on current expectations and assumptions and currently available data and are neither predic tions nor guarantees of future events or performa
Forward - looking statements are based on current expectations and assumptions and currently available data and are neither predic tions nor guarantees of future events or performance. Current results may not be predictive of future results. You should not place considerable reli
Read more →NVAXAgência reguladora de medicamentos e produtos de saúde concede autorização de comercialização condicional para a vacina contra a COVID-19 da Novavax na Grã-Bretanha*
A vacina Nuvaxovid™ contra a COVID-19 (recombinante, com adjuvante)▼ é a primeira vacina contra a COVID-19 à base de proteína autorizada para a Grã-Bretanha Novavax e U.K. Vaccines Taskforce anunciaram anteriormente um acordo de até 60 milhões de doses Autorização com base em d
Read more →NVAXLa agencia reguladora de medicamentos y productos para el cuidado de la salud concede autorización condicional de comercialización para la vacuna contra la COVID-19 de Novavax en Gran Bretaña*
La vacuna contra la COVID-19 Nuvaxovid™ (recombinante y adyuvada)▼ es la primera vacuna contra la COVID-19 basada en proteínas autorizada en Gran Bretaña Novavax y el equipo de trabajo de vacunas del Reino Unido anunciaron anteriormente un acuerdo por un máximo de 60 millones de
Read more →NVAXLa Medicines and Healthcare products Regulatory Agency (MHRA) accorde une autorisation de mise sur le marché conditionnelle du vaccin contre la COVID-19 de Novavax en Grande-Bretagne*
Le vaccin Nuvaxovid™ (recombinant avec adjuvant)▼ est le premier vaccin contre la COVID-19 à base de protéines dont l'utilisation est autorisée en Grande-Bretagne Novavax et le U.K. Vaccines Taskforce ont annoncé précédemment un accord pour un maximum de 60 millions de doses Ce
Read more →NVAXMedicines and Healthcare products Regulatory Agency erteilt bedingte Marktzulassung für Novavax COVID-19 Impfstoff in Großbritannien*
Der COVID-19-Impfstoff Nuvaxovid™ (rekombinant, adjuvantiert) ist der erste proteinbasierte COVID-19-Impfstoff, der in Großbritannien zugelassen wird Novavax und die UK Vaccines Taskforce haben zuvor einen Vorabkaufvertrag für bis zu 60 Millionen Dosen angekündigt Die Zulassung
Read more →NVAXNew Zealand
GAITHERSBURG, Md., Feb. 3, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted provisional approval
Read more →NVAXMHRA concede la autorización condicional de comercialización de la vacuna Novavax COVID-19 en Gran Bretaña
-La Agencia Reguladora de Medicamentos y Productos Sanitarios concede la autorización condicional de comercialización de la vacuna Novavax COVID-19 en Gran Bretaña* La vacuna Nuvaxovid™ COVID-19 (recombinante, adjuvada)▼ es la primera vacuna COVID-19 basada en proteínas autoriza
Read more →NVAX▼ -6%on this newsshared move
Novavax stellt Antrag auf Notfallzulassung für COVID-19-Impfstoff bei der US-amerikanischen FDA
- NVX-CoV2373 zeigte in der klinischen Studie PREVENT-19, die während der Entstehung von Variantenstämmen durchgeführt wurde, eine Gesamtwirksamkeit von rund 90 % GAITHERSBURG, Maryland, 2. Februar 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen,
Read more →NVAXNovavax envia solicitação à FDA dos EUA para autorização de uso emergencial de vacina contra a COVID-19
- A NVX-CoV2373 demonstrou eficácia em geral de ~90% no estudo clínico PREVENT-19 realizado durante o surgimento de cepas variantes GAITHERSBURG, Maryland, 1 de fevereiro de 2022 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvim
Read more →NVAXNovavax presenta solicitud ante la FDA de los Estados Unidos para autorización de uso de emergencia de la vacuna contra la COVID-19
- La NVX-CoV2373 demostró una eficacia general de ~90 % en el ensayo clínico PREVENT-19 realizado durante el surgimiento de cepas variantes GAITHERSBURG, Maryland, 1 de febrero de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrol
Read more →NVAXNovavax solicita a la FDA de Estados Unidos la autorización de uso de emergencia de la vacuna de la COVID-19
- NVX-CoV2373 demostró una eficacia general de ~90 % en el ensayo clínico PREVENT-19 realizado durante la aparición de cepas variantes GAITHERSBURG, Md., 1 de febrero de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y come
Read more →NVAX▲ +13%on this newsshared move
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Jan. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing n
Read more →NVAX▲ +13.7%on this news· ran to +28% by day 1shared move
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Israel's Ministry of Health today announced an agreement for the purcha
Read more →NVAX▼ -6.2%on this news· ran to -19% by day 3
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Australia's Therapeutic Goods Administration (TGA) has
Read more →NVAXSouth Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-base
Read more →NVAX▲ +6.5%on this newsshared move
NOVAVAX. All rights reserved. J.P. MORGAN 40 TH ANNUAL HEALTHCARE CONFERENCE NASDAQ: NVAX | JANUARY 2022 2 2022 NOVAVAX. All rights reserved. SAFE HARBOR STATEMENT Certain information, particularly information relating t
Protocol version 8.0 posted on Novavax.com Pediatric Vaccination After 2 doses: functional immune responses 2.4 - 4x higher than in adults, including against Delta and Omicron April 2021 First dose June 2021 Completed enrollment October 2021 Completed blinded crossover Expected 1
Read more →NVAX▲ +6.5%on this newsshared move
Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax
GAITHERSBURG, Md. and PUNE, India, Jan. 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's l
Read more →NVAXNovavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the virtual 40th Annual J.P. Mor
Read more →NVAX▼ -7.6%on this news· ran to -21% by day 3shared move
Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
GAITHERSBURG, Md., Dec. 31, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has completed submission of the final data package,
Read more →NVAXNovavax e Serum Institute of India recebem autorização de uso emergencial para vacina contra a COVID-19 na Índia
GAITHERSBURG, Maryland, e PUNE, Índia, 29 de dezembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e à comercialização de vacinas de última geração para doenças infecciosas graves, e o Serum Institute of India Pv
Read more →NVAXNovavax et le Serum Institute of India reçoivent une autorisation d
GAITHERSBURG, Maryland et PUNE, Inde, 29 décembre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une entreprise de biotechnologie qui se consacre à la mise au point et à la commercialisation de vaccins de prochaine génération pour des maladies infectieuses graves, et le Serum
Read more →NVAXNovavax und Serum Institute of India erhalten Notfallzulassung für Covid-19-Impfstoff in Indien
GAITHERSBURG, Maryland und PUNE, Indien, 29. Dez. 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich der Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten widmet, und Serum Institute of
Read more →NVAXNovavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
GAITHERSBURG, Md. and PUNE, India, Dec. 28, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's l
Read more →NVAXNovavax y Serum Institute of India reciben la autorización de uso en emergencia de la vacuna contra la COVID-19 en India
GAITHERSBURG, Maryland, y PUNE, India, 28 de diciembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología que se dedica a desarrollar y comercializar vacunas de última generación contra enfermedades infecciosas graves, y Serum Institute of India Pv
Read more →NVAXNovavax y SII reciben autorización de uso de emergencia para la vacuna de COVID-19 en India
- Novavax y Serum Institute of India reciben autorización de uso de emergencia para la vacuna de COVID-19 en India GAITHERSBURG, Md. y PUNE, India, 28 de diciembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comerci
Read more →NVAX▼ -11%on this newsshared move
NOVAVAX, INC. (NASDAQ: NVAX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Novavax, Inc.
NEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) -- -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf
Read more →NVAX▼ -11%on this newsshared move
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) in the United States District Court
Read more →NVAX▼ -11%on this newsshared move
Novavax annonce des données initiales sur la réactivité croisée au variant Omicron provenant d
- Le schéma initial à deux doses du vaccin NVX-CoV2373 a démontré des réponses immunitaires croisées contre Omicron (B.1.1.529) et d'autres variants - La troisième dose a produit une augmentation des réponses immunitaires comparable ou supérieure aux niveaux de protection consta
Read more →NVAX▼ -11%on this newsshared move
Novavax anuncia dados iniciais de reatividade cruzada da Ômicron no reforço da vacina contra a COVID-19 e estudos em adolescentes
- Regime primário de duas doses de NVX-CoV2373 demonstrou respostas imunológicas multirreativas contra a ômicron (B.1.1.529) e outras variantes - A terceira dose produziu respostas imunológicas aumentadas comparáveis ou superiores aos níveis associados à proteção em ensaios clín
Read more →NVAXNovavax anuncia los datos iniciales de reactividad cruzada contra ómicron de la vacuna de refuerzo contra la COVID-19 y los estudios en adolescentes
GAITHERSBURG, Md., 23 de diciembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy datos iniciales que evalúan la respuesta inm
Read more →NVAXNovavax and SK bioscience Expand Manufacturing Agreement
GAITHERSBURG, Md., Dec. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-base
Read more →NVAXSAGE da Organização Mundial da Saúde emite recomendações provisórias para a vacina contra a COVID-19 da Novavax
GAITHERSBURG, Maryland, 23 de dezembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e à comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje que o Grupo Consultivo Estratégi
Read more →NVAXNovavax gibt erste Daten zur Kreuzreaktivität von Omicron aus COVID-19-Impfstoff-Booster- und Jugendstudien bekannt
- Zweidosis-Primärregime von NVX-CoV2373 zeigte kreuzreaktive Immunreaktionen gegen Omicron (B.1.1.529) und andere Varianten - Die dritte Dosis führte zu verstärkten Immunreaktionen, die mit dem Schutz in klinischen Phase-3-Studien vergleichbar waren oder diesen sogar übertrafen
Read more →NVAXEl SAGE de la Organización Mundial de la Salud emite recomendaciones provisionales para la vacuna contra la COVID-19 de Novavax
GAITHERSBURG, Maryland, 22 de diciembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy que el Grupo de Expertos de Asesoramie
Read more →NVAXLa Commission européenne accorde une autorisation de mise sur le marché conditionnelle pour le vaccin contre la COVID-19 de Novavax
Le vaccin NuvaxovidTM (recombinant avec adjuvant) est le premier vaccin contre la COVID-19 à base de protéines dont l'utilisation est autorisée en Europe Novavax et la Commission européenne ont annoncé précédemment un accord d'achat anticipé d'un maximum de 200 millions de doses
Read more →NVAXEuropäische Kommission erteilt bedingte Marktzulassung für COVID-19-Impfstoff von Novavax
Der COVID-19-Impfstoff Nuvaxovid™ (rekombinant, adjuvantiert) ist der erste proteinbasierte COVID-19-Impfstoff, der in Europa zugelassen ist Novavax und die Europäische Kommission haben zuvor einen Vorabkaufvertrag für bis zu 200 Millionen Dosen bis 2023 angekündigt Die Zulassu
Read more →NVAXL'Organisation mondiale de la Santé accorde une deuxième utilisation d'urgence pour le vaccin Novavax contre la COVID-19 Novavax, Inc. (Nasdaq : NVAX), une société de biotechnologie spécialisée dans le développement et la commercialisation de vaccins de nouvelle...
- Le vaccin Nuvaxovid™ contre la COVID-19 (SARS-CoV-2 [recombinant avec adjuvant]) est autorisé pour utilisation d'urgence auprès de l'OMS - L'autorisation d'utilisation d'urgence pour le Nuvaxovid complète l'autorisation du vaccin de Novavax qui est fabriqué et commercialisé pa
Read more →NVAXWeltgesundheitsorganisation erteilt zweite Notfallzulassung für Novavax-Covid-19-Impfstoff
- Nuvaxovid™ Covid-19-Impfstoff (SARS-CoV-2 rS [rekombinant, adjuvant]), der von der WHO für den Notfalleinsatz gelistet ist - EUL für Nuvaxovid ergänzt Liste für Novavax-Impfstoff, der von Serum Institute of India als Covovax™ hergestellt und vermarktet wird - Die EUL der WHO
Read more →NVAXLa OMS emite recomendaciones provisionales para la vacuna Novavax COVID-19
- El Grupo Asesor Estratégico de Expertos en Inmunización (SAGE) de la OMS emite recomendaciones provisionales para la vacuna Novavax COVID-19 - El Grupo Asesor Estratégico de Expertos en Inmunización (SAGE) de la OMS recomienda una serie de vacunación primaria de dos dosis de N
Read more →NVAXNovavax reçoit une recommandation positive de l
La décision de la Commission européenne sur l'autorisation conditionnelle de mise sur le marché est attendue de manière imminente Après autorisation, Nuvaxovid™ (également connu sous le nom de NVX-CoV2373) sera le premier vaccin protéique contre la COVID-19 disponible en Europe
Read more →NVAXWeltgesundheitsorganisation SAGE gibt vorläufige Empfehlungen für Novavax Covid-19-Impfstoff heraus
- Die Strategische Beratende Expertengruppe für Impfungen (SAGE) der WHO empfiehlt eine primäre Impfserie von zwei Dosen NVX-CoV2373 für Personen ab 18 Jahren - SAGE empfiehlt zusätzliche dritte Dosis von NVX-CoV2373 für immungeschwächte Personen - Empfehlung folgt auf die Erte
Read more →NVAXLe SAGE de l
- Le Groupe consultatif stratégique d'experts de l'OMS sur la vaccination (SAGE) recommande une série de primovaccination à deux doses de NVX-CoV2373 chez les personnes âgées de 18 ans et plus. - SAGE recommande d'administrer une troisième dose supplémentaire de NVX-CoV2373 aux
Read more →NVAXNovavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
La Organización Mundial de la Salud concede la segunda autorización de uso de emergencia para la vacuna contra la COVID-19 de Novavax
GAITHERSBURG, Maryland, 21 de diciembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy que la Organización Mundial de la Salud
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
GAITHERSBURG, Md., Dec. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the first booster doses of NVX-CoV2373, the company's
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine
- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
Comissão Europeia concede autorização de comercialização condicional para a vacina contra a COVID-19 da Novavax
A vacina Nuvaxovid™ contra a COVID-19 (recombinante, com adjuvante) é a primeira vacina contra a COVID-19 à base de proteína autorizada para uso na Europa A Novavax e a Comissão Europeia já havia anunciado um acordo de compra antecipada de até 200 milhões de doses até 2023 A au
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
Organização Mundial da Saúde concede segunda permissão de uso emergencial para vacina da Novavax contra a COVID-19
GAITHERSBURG, Maryland, 21 de dezembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje que a Organização Mundial da Saúde
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
Novavax recibe recomendación positiva de la Agencia Europea de Medicamentos con respecto a la autorización condicional de comercialización de su vacuna contra la COVID-19
Se espera que la decisión de la Comisión Europea sobre la autorización condicional de comercialización sea inmediata Tras la autorización, Nuvaxovid™ (también conocida como NVX-CoV2373) será la primera vacuna de base proteica contra la COVID-19 disponible en Europa GAITHERSBURG
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
Novavax erhält positive Empfehlung der Europäischen Arzneimittelagentur für die bedingte Marktzulassung seines Impfstoffs gegen COVID-19
Entscheidung der Europäischen Kommission über bedingte Marktzulassung in Kürze erwartet Nach der Zulassung wird Nuvaxovid™ (auch bekannt als NVX-CoV2373) der erste proteinbasierte COVID-19-Impfstoff sein, der in Europa erhältlich ist GAITHERSBURG, Maryland, 21. Dezember 2021 /P
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
La Comisión Europea otorga autorización condicional de comercialización para la vacuna contra la COVID-19 de Novavax
La vacuna contra la COVID-19 Nuvaxovid™ (recombinante y adyuvada) es la primera vacuna contra la COVID-19 basada en proteínas autorizada para su uso en Europa Novavax y la Comisión Europea anunciaron anteriormente un acuerdo de compra anticipada de hasta 200 millones de dosis ha
Read more →NVAX▼ -5.4%on this news· ran to -22% by day 3shared move
La OMS concede la segunda Lista de Uso de Emergencia a la vacuna de COVID-19 de Novavax
- La Organización Mundial de la Salud concede la segunda Lista de Uso de Emergencia a la vacuna de COVID-19 de Novavax - Lista de Uso de Emergencia de la vacuna Nuvaxovid™ COVID-19 (SARS-CoV-2 rS [Recombinante, adyuvante]) por la OMS - La EUL para Nuvaxovid complementa el lista
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax und Serum Institute of India geben bekannt, dass die Weltgesundheitsorganisation den Impfstoff NVX-CoV2373 COVID-19 für den Notfall zugelassen hat
Erste EUL-Genehmigung der WHO für einen proteinbasierten COVID-19-Impfstoff EUL-Impfstoff, der von SII als COVOVAX™ hergestellt und vermarktet wird WHO EUL für Nuvaxovid™ wird derzeit geprüft; wird nach Prüfung durch die Europäische Arzneimittelagentur (EMA) abgeschlossen GAIT
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax et Serum Institute of India annoncent l
Premier EUL accordée par l'OMS pour un vaccin COVID-19 à base de protéines Le vaccin EUL fabriqué et commercialisé par SII sous le nom de COVOVAX™ La licence européenne de l'OMS pour Nuvaxovid™ est en cours d'évaluation ; elle sera complétée après l'examen de l'Agence européenn
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax y SII anuncian que la OMS concede la lista de uso de emergencia para la vacuna NVX-CoV2373
-Novavax y Serum Institute of India anuncian que la Organización Mundial de la Salud concede la lista de uso de emergencia para la vacuna NVX-CoV2373 de COVID-19 Primera EUL concedida por la OMS para una vacuna de COVID-19 basada en proteínas Vacuna EUL fabricada y comercializa
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax y Serum Institute of India anuncian que la Organización Mundial de la Salud concede la inclusión en la lista de uso de emergencia de la vacuna NVX-CoV2373 contra la COVID-19
Se trata de la primera inclusión en la lista de uso en emergencias (EUL) otorgada por la OMS para una vacuna de base proteica contra la COVID-19 La vacuna para uso en emergencias es fabricada y comercializada por SII como COVOVAX™ La inclusión de Nuvaxovid™ en la lista de uso e
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax e Serum Institute of India anunciam o subsídio para o pedido de utilização emergencial da vacina NVX-CoV2373 contra COVID-19 listada pela Organização Mundial da Saúde
Primeira vacina contra a COVID-19 de proteína da EUL (lista de uso emergencial) da OMS Vacina da EUL fabricada e comercializada por SII como COVOVAX™ EUL da OMS da Nuvaxovid™ atualmente em avaliação será concluída após análise da Agência Europeia de Medicamentos (EMA) GAITHERS
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc.
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax recebe recomendação positiva da Agência Europeia de Medicamentos para autorização de comercialização condicional de sua vacina contra a COVID-19
Decisão da Comissão Europeia sobre autorização de comercialização condicional esperada em breve Após a autorização, a Nuvaxovid™ (também conhecida como NVX-CoV2373) será a primeira vacina contra a COVID-19 à base de proteína disponível na Europa GAITHERSBURG, Maryland, 20 de de
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe No
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine - Dec. 20, 2021 - Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today annou
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
Novavax recibe una recomendación positiva de la EMA para la comercialización de su vacuna COVID-19
- Novavax recibe una recomendación positiva de la Agencia Europea de Medicamentos para la autorización de comercialización condicional de su vacuna COVID-19 Se espera de forma inminente la decisión de la Comisión Europea sobre la autorización de comercialización condicional Tra
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine
- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports t
Read more →NVAX▼ -7.1%on this news· ran to -18% by day 3shared move
La CE concede la autorización de comercialización condicional de la vacuna de COVID-19 de Novavax
- La Comisión Europea concede la autorización de comercialización condicional de la vacuna de COVID-19 de Novavax La vacuna Nuvaxovid™ de COVID-19 (recombinante, adyuvante) es la primera vacuna COVID-19 basada en proteínas autorizada para su uso en Europa Novavax y la Comisión
Read more →NVAX▲ +11.5%on this newsshared move
Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine
First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review GAITHERSBURG, Md. and PUNE, India, Dec.
Read more →NVAX▲ +6.6%on this news· ran to +20% by day 3shared move
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the submission of a New Drug Application (NDA) to the Minis
Read more →NVAXNovavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates
GAITHERSBURG, Md., Dec. 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a regulatory filing to the Ministry o
Read more →NVAXNovavax Files for Interim Authorization of COVID-19 Vaccine in Singapore
GAITHERSBURG, Md., Nov. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to the Singapore Health Sciences Authority (
Read more →NVAXNovavax to Participate in Evercore ISI
GAITHERSBURG, Md., Nov. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Evercore ISI's 4th Annual Healt
Read more →NVAXNovavax bestätigt Prüfung des Antrags auf bedingte Marktzulassung des Covid-19-Impfstoffs durch die Europäische Arzneimittelagentur
GAITHERSBURG, Maryland, 19. November 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute bekannt, da
Read more →NVAXNovavax und Serum Institute of India erhalten Notfallzulassung für Covid-19-Impfstoff auf den Philippinen
GAITHERSBURG, Maryland und PUNE, Indien, 19. November 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich der Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten widmet, und Serum Institute
Read more →NVAXNovavax confirma que la EMA está revisando su solicitud de comercialización de la vacuna COVID-19
- Novavax confirma la revisión por parte de la Agencia Europea de Medicamentos (EMA) de la solicitud de autorización de comercialización condicional de la vacuna COVID-19 GAITHERSBURG, Md., 19 de noviembre, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotec
Read more →NVAXNovavax y Serum Institute of India reciben autorización para la vacuna COVID-19 en Filipinas
- Novavax y Serum Institute of India reciben autorización de uso de emergencia para la vacuna COVID-19 en Filipinas GAITHERSBURG, Md. y PUNE, India, 18 de noviembre, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comercia
Read more →NVAXNovavax confirme l
GAITHERSBURG, Maryland, 19 novembre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération pour les maladies infectieuses graves, a annoncé aujourd'hui que l'Ag
Read more →NVAXNovavax confirma análise da Agência Europeia de Medicamentos do registro da vacina contra a COVID-19 para autorização de comercialização condicional
GAITHERSBURG, Maryland, 18 de novembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje que a Agência Europeia de Medicame
Read more →NVAXNovavax confirma la revisión de la Agencia Europea de Medicamentos de la solicitud de autorización condicional de comercialización de la vacuna contra la COVID-19
GAITHERSBURG, Maryland, 18 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy que la Agencia Europea de Medicamentos
Read more →NVAX▲ +7.9%on this news· ran to +22% by day 3shared move
Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization
GAITHERSBURG, Md., Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that European Medicines Agency (EMA) has begun its evaluati
Read more →NVAX▲ +7.9%on this news· ran to +22% by day 3shared move
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's l
Read more →NVAX▲ +7.9%on this news· ran to +22% by day 3shared move
Novavax y Serum Institute of India reciben la autorización de uso en emergencia para la vacuna contra la COVID-19 en Filipinas
GAITHERSBURG, Maryland y PUNE, India, 17 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología que se dedica a desarrollar y comercializar vacunas de última generación contra enfermedades infecciosas graves, y Serum Institute of India Pvt
Read more →NVAX▲ +7.9%on this news· ran to +22% by day 3shared move
Novavax e Serum Institute of India recebem autorização de uso emergencial para vacina contra a COVID-19 nas Filipinas
GAITHERSBURG, Maryland, e PUNE, Índia, 17 de novembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e à comercialização de vacinas de última geração para doenças infecciosas graves, e o Serum Institute of India Pv
Read more →NVAX▲ +7.9%on this news· ran to +22% by day 3shared move
NOVAVAX, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against Novavax, Inc.
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) in the United States District Court for the District of
Read more →NVAXNovavax annonce le dépôt d
SK bioscience soumet au MFDS de Corée du Sud une demande de BLA pour le NVX-CoV2373, premier candidat vaccin à base de protéines contre la COVID-19 GAITHERSBURG, Maryland, 17 novembre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq : NVAX), une société de biotechnologie qui se consac
Read more →NVAXNovavax anuncia envio do pedido de licença biológica na Coreia do Sul para aprovação da NVX-CoV2373
GAITHERSBURG, Maryland, 16 de novembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves e a SK bioscience, Co. Limited (SK bioscience), u
Read more →NVAXNovavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373
SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing
Read more →NVAXNovavax anuncia la presentación de la solicitud de licencia para NVX-CoV2373
- Novavax anuncia la presentación de la solicitud de licencia de productos biológicos en Corea del Sur para la aprobación de NVX-CoV2373 SK bioscience envía una solicitud para NVX-CoV2373, la primera vacuna candidata a vacuna COVID-19 basada en proteínas para BLA, al MFDS de Cor
Read more →NVAXNovavax anuncia la presentación de una solicitud de licencia biológica en Corea del Sur para la aprobación de NVX-CoV2373
SK bioscience presenta la solicitud de licencia biológica (BLA) para NVX-CoV2373, la primera candidata a vacuna contra la COVID-19 basada en proteínas, al Ministerio de Seguridad Alimentaria y Farmacéutica (MFDS) de Corea del Sur GAITHERSBURG, Maryland, 15 de noviembre de 2021 /
Read more →NVAXNovavax kündigt Einreichung eines Antrags auf biologische Zulassung in Südkorea für NVX-CoV2373 an
SK bioscience reicht Antrag für NVX-CoV2373, den ersten proteinbasierten Covid-19-Impfstoffkandidaten für BLA, bei der südkoreanischen MFDS ein GAITHERSBURG, Maryland, 16. November 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich der Ent
Read more →NVAX▲ +8.7%on this news
NOVAVAX INVESTIGATION: Block & Leviton Is Investigating Novavax Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Novavax Inc. (NASDAQ: NVAX) for potential securities law violations. Investors who have lost money in their Novavax Inc. investment should contact the firm to learn more about how they might recover those
Read more →NVAX▲ +8.7%on this newsshared move
Novavax beantragt bei der Weltgesundheitsorganisation die Zulassung des Covid-19-Impfstoffs für den Notfall
- Alle für die behördliche Prüfung des Novavax-Impfstoffs erforderlichen Module, einschließlich der CMC-Daten, sind nun für Medsafe abgeschlossen GAITHERSBURG, Maryland, 6. November 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf di
Read more →NVAX▼ -11.3%on this newsshared move
Novavax presenta la vacuna COVID-19 para su uso de emergencia en la lista de la OMS
Todos los módulos necesarios para la revisión reglamentaria de la vacuna Novavax, incluidos los datos de CMC, ya están completos para la OMS GAITHERSBURG, Md., 5 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología dedicada al desarrol
Read more →NVAX▼ -11.3%on this newsshared move
Novavax presenta la vacuna contra la COVID-19 para aprobación provisional en Nueva Zelanda
GAITHERSBURG, Maryland, 5 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy que la empresa presentó una solicitud de
Read more →NVAX▼ -11.3%on this newsshared move
Novavax dépose auprès de l
Tous les modules requis pour l'examen réglementaire du vaccin de Novavax, y compris les données de chimie, fabrication et contrôles, ont été soumis à l'OMS GAITHERSBURG, Maryland, 6 novembre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une société de biotechnologie qui se
Read more →NVAX▼ -11.3%on this newsshared move
Novavax registra vacina contra a COVID-19 para aprovação provisória na Nova Zelândia
GAITHERSBURG, Maryland, 5 de novembro de 2021 /PRNewswire/ --A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje que a empresa protocolou o pedido de
Read more →NVAX▼ -11.3%on this newsshared move
Novavax presenta su vacuna contra la COVID-19 para su inclusión en la lista de fármacos para uso de emergencia de la Organización Mundial de la Salud
- Todos los módulos de la vacuna de Novavax requeridos para la revisión normativa, incluidos los datos CMC, ya están listos para la OMS GAITHERSBURG, Maryland, 5 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrolla
Read more →NVAX▼ -11.3%on this newsshared move
Novavax registra vacina contra a COVID-19 para uso emergencial junto à Organização Mundial da Saúde
Todos os módulos necessários para análise regulatória da vacina da Novavax, inclusive dados de CMC, agora estão concluídos para a OMS GAITHERSBURG, Maryland, 5 de novembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvi
Read more →NVAX▼ -8.1%on this news· ran to -18% by day 1shared move
Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights Received EUA for NVX-CoV2373 in Indonesia in partnership with Serum Institute of India Completed regulatory submissions in the U.K., Austral
Novavax Reports Third Quarter 2021 Financial Operational Highlights GAITHERSBURG, Md., November 4, 2021 -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announc
Read more →NVAX▼ -8.1%on this news· ran to -18% by day 1shared move
Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization
GAITHERSBURG, Md., Nov. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling submission to the World Health
Read more →NVAX▼ -8.1%on this news· ran to -18% by day 1shared move
Novavax beantragt vorläufige Zulassung des Covid-19-Impfstoffs in Neuseeland
- Die Einreichung bei der neuseeländischen Medsafe ist der erste Impfstoff auf Proteinbasis gegen Covid-19, der bei den neuseeländischen Behörden zur Zulassung eingereicht wurde - Alle für die behördliche Prüfung des Novavax-Impfstoffs erforderlichen Module, einschließlich der C
Read more →NVAXNovavax et Serum Institute of India reçoivent une autorisation d
GAITHERSBURG, Maryland, et PUNE, Inde, 3 novembre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une entreprise de biotechnologie qui se consacre à la mise au point et à la commercialisation de vaccins de prochaine génération pour les maladies infectieuses graves, et Serum In
Read more →NVAXNovavax y Serum Institute of India reciben la autorización de uso en emergencia de la vacuna contra la COVID-19 en Indonesia
GAITHERSBURG, Maryland y PUNE, India, 3 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología que se dedica a desarrollar y comercializar vacunas de última generación contra enfermedades infecciosas graves, y Serum Institute of India Pvt.
Read more →NVAXNovavax Files COVID-19 Vaccine for Provisional Approval in New Zealand
- Submission to New Zealand's Medsafe marks the first protein-based COVID-19 vaccine submitted for authorization to regulatory authorities in New Zealand - All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for Medsafe GAITHERSBU
Read more →NVAXNovavax presenta la vacuna COVID-19 para aprobación provisional en Nueva Zelanda
- La presentación a Medsafe de Nueva Zelanda marca la primera vacuna de COVID-19 basada en proteínas enviada para autorización a las autoridades reguladoras en Nueva Zelanda - Todos los módulos necesarios para la revisión regulatoria de la vacuna Novavax, incluidos los datos de
Read more →NVAX▲ +13.3%on this newsshared move
Novavax und Serum Institute of India erhalten Notfallzulassung für Covid-19-Impfstoff in Indonesien
GAITHERSBURG, Maryland und PUNE, Indien, 3. November 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich der Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten widmet, und Serum Institute
Read more →NVAX▲ +13.3%on this newsshared move
Novavax e Serum Institute of India recebem autorização de uso emergencial para vacina contra a COVID-19 na Indonésia
GAITHERSBURG, Maryland, e PUNE, Índia, 2 de novembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, e o Serum Institute of India Pvt.
Read more →NVAX▲ +15.9%on this news· ran to +31% by day 1shared move
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
GAITHERSBURG, Md. and PUNE, India, Nov. 1, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's la
Read more →NVAX▲ +15.9%on this news· ran to +31% by day 1shared move
Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency
Health Canada filing marks first protein-based COVID-19 vaccine submitted for authorization to regulatory authorities in Canada Submission of all modules required for regulatory review, including CMC and clinical data, are now complete for European Medicines Agency GAITHERSBURG
Read more →NVAX▲ +15.9%on this news· ran to +31% by day 1shared move
Novavax y Serum Institute of India reciben autorización de uso para la vacuna de COVID-19 en Indonesia
-Novavax y Serum Institute of India reciben la autorización de uso de emergencia para la vacuna de COVID-19 en Indonesia GAITHERSBURGO, Md. y PUNE, India, 1 de noviembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y c
Read more →NVAXNovavax beantragt Zulassung seines COVID-19-Impfstoffs im Vereinigten Königreich
Antrag zur Zulassung des ersten proteinbasierten COVID-19-Impfstoffs bei der MHRA Alle für die regulatorische Überprüfung erforderlichen Module, einschließlich CMC-Daten, sind nun abgeschlossen Der Antrag basiert auf Phase-III-Daten von rund 45.000 Patienten, die eine hohe Wirk
Read more →NVAXNovavax Files for Provisional Approval of its COVID-19 Vaccine in Australia
GAITHERSBURG, Md., Oct. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling submission to the Therapeutic
Read more →NVAX▲ +6.4%on this news· ran to +38% by day 3shared move
Novavax registra autorização de sua vacina contra a COVID-19 no Reino Unido
Registro marca a primeira vacina contra a COVID-19 baseada em proteína enviada à MHRA para autorização Todos os módulos necessários para análise regulatória, inclusive dados de CMC, agora estão concluídos Solicitação tem como base dados de Fase 3 de ~45 mil pacientes demonstran
Read more →NVAXNovavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization All modules required for regulatory review, including CM
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom GAITHERSBURG, Md., Oct. 27, 2021 - Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today a
Read more →NVAXNovavax solicita autorización para su vacuna contra la COVID-19 en el Reino Unido
Esta es la primera solicitud para una vacuna contra la COVID-19 basada en proteínas enviada a la MHRA para su autorización Todos los módulos requeridos para la revisión normativa, incluidos los datos CMC, ya están completos Postulación basada en datos de fase 3 en aproximadamen
Read more →NVAXNovavax presenta la solicitud de autorización de su vacuna de COVID-19 en Reino Unido
La presentación marca la primera vacuna de COVID-19 basada en proteínas que se presenta a la MHRA para su autorización Se han completado todos los módulos requeridos para la revisión reglamentaria, incluidos los datos CMC La presentación se basa en los datos de la fase 3 de uno
Read more →NVAXNOVAVAX INVESTOR ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Novavax To Contact Him Directly To Discuss Their Options
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novavax (“Novavax, Inc.” or the “Company”) (NASDAQ: NVAX). If you suffered losses exceeding $200,000 investing in Novavax stock or
Read more →NVAXNovavax, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) investors that the firm has initiated an investigatio
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and
Read more →NVAXNovavax nimmt am Weltimpfstoffkongress Europa teil
GAITHERSBURG, Maryland, 18. Oktober 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das sich auf die Entwicklung und Vermarktung von Impfstoffen der nächsten Generation gegen schwere Infektionskrankheiten spezialisiert hat, gab heute bekannt, das
Read more →NVAXNovavax participera au Congrès mondial des vaccins en Europe
GAITHERSBURG, Maryland, 18 octobre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une société de biotechnologie qui se consacre au développement et à la commercialisation de vaccins de nouvelle génération contre les maladies infectieuses graves, a annoncé aujourd'hui que Vive
Read more →NVAXNovavax participará do Congresso Mundial de Vacinas Europa
GAITHERSBURG, Maryland, 18 de outubro de 2021 /PRNewswire/ --A Novavax, Inc. (Nasdaq: NVAX), empresa de biotecnologia dedicada ao desenvolvimento e comercialização de vacinas de última geração para doenças infecciosas graves, anunciou hoje que Vivek Shinde, M.D., vice-presidente
Read more →NVAXNovavax participará en el World Vaccine Congress Europe
GAITHERSBURGO, Md., 16 de octubre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada al desarrollo y comercialización de vacunas de nueva generación para enfermedades infecciosas graves, ha anunciado hoy que Vivek Shinde, M.D., Vicepreside
Read more →NVAXNovavax to Participate in World Vaccine Congress Europe
GAITHERSBURG, Md., Oct. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Developme
Read more →NVAXNovavax Announces Leadership Appointment and Updates
GAITHERSBURG, Md., Oct. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Denny Kim, M.D., MPH to the newly created
Read more →NVAXNovavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
GAITHERSBURG, Md., Sept. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a panel discussion during the
Read more →NVAX▼ -6.9%on this news· ran to -17% by day 1shared move
Les résultats de l
- L'essai pivot de phase 3 a atteint tous les critères d'évaluation principaux, démontrant la non-infériorité du vaccin quadrivalent antigrippal autorisé aux États-Unis - Le candidat vaccin NanoFlu™ induit des réponses immunitaires à médiation cellulaire significativement amélio
Read more →NVAXResultados del ensayo clínico de fase 3 de la vacuna contra la influenza de Novavax NanoFlu publicado en The Lancet Infectious Diseases
GAITHERSBURG, Maryland, 24 de septiembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología dedicada a desarrollar y comercializar vacunas de última generación para enfermedades infecciosas graves, anunció hoy en The Lancet Infectious Diseases (La
Read more →NVAXNovavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
GAITHERSBURG, Md., Sept. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, hosted HM King Carl XVI Gustaf and HM Queen Silvia for a visit to Novavax
Read more →NVAXNovavax und Serum Institute of India geben Antrag auf Notfallzulassung des Novavax-Impfstoffs COVID-19 bei der Weltgesundheitsorganisation bekannt
Novavax und Serum Institute of India reichen bei der Weltgesundheitsorganisation einen Antrag auf Notfallzulassung von Novavax' rekombinantem COVID-19-Impfstoff auf Nanopartikelbasis ein GAITHERSBURG, Maryland, 24. September 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein
Read more →NVAXNovavax et Serum Institute of India annoncent le dépôt d
Novavax et Serum Institute of India déposent une demande d'inscription sur la liste des utilisations d'urgence de l'Organisation mondiale de la santé pour le vaccin contre la COVID-19 à base de nanoparticules recombinantes de Novavax GAITHERSBURG, Maryland, 24 septembre 2021 /PR
Read more →NVAXErgebnisse der klinischen Phase-III-Studie mit dem Grippeimpfstoff NanoFlu von Novavax in The Lancet Infectious Diseases veröffentlicht
- Entscheidende Phase-III-Studie erreicht alle primären Endpunkte und zeigt Nichtunterlegenheit gegenüber einem führenden vierwertigen Grippeimpfstoff mit US-Zulassung - NanoFlu™-Impfstoffkandidat führt zu deutlich verbesserten zellvermittelten Immunreaktionen - NanoFlu war gut
Read more →NVAXResultados do estudo clínico de Fase 3 da vacina contra influenza Novavax NanoFlu publicados em The Lancet Infectious Diseases
- Importante estudo de Fase 3 alcançou todos os desfechos primários, demonstrando não-inferioridade em relação a uma vacina quadrivalente contra influenza licenciada líder nos EUA - A candidata à vacina NanoFlu™ induziu respostas imunológicas mediadas por células significativame
Read more →NVAX▲ +10.9%on this newsshared move
Novavax e Serum Institute of India anunciam apresentação de pedido para uso emergencial da vacina contra a COVID-19 da Novavax junto à Organização Mundial da Saúde
A Novavax e o Serum Institute of India protocolam apresentação de pedido regulatório para uso emergencial da vacina contra a COVID-19 à base de nanopartículas recombinantes da Novavax GAITHERSBURG, Maryland, 23 de setembro de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), um
Read more →NVAX▲ +10.9%on this newsshared move
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced publication of complete results from a pivotal Phase 3 cli
Read more →NVAX▲ +10.9%on this newsshared move
Novavax y Serum Institute of India anuncian la solicitud a la Organización Mundial de la Salud para el uso de emergencia de la vacuna de Novavax contra la COVID-19
Novavax y Serum Institute of India presentan una solicitud normativa ante la Organización Mundial de la Salud para la autorización de uso de emergencia de la vacuna basada en proteínas de nanopartículas recombinantes contra la COVID-19 de Novavax. GAITHERSBURG, Maryland, 23 de s
Read more →NVAX▲ +10.9%on this newsshared move
Novavax y SII presentan a la OMS la lista de uso de emergencia de la vacuna de COVID-19 de Novavax
- Novavax y Serum Institute of India anuncian la presentación a la Organización Mundial de la Salud de la lista de uso de emergencia de la vacuna de COVID-19 de Novavax Novavax y Serum Institute of India presentan la solicitud de inclusión en la lista de uso de emergencia de la
Read more →NVAX▲ +10.9%on this newsshared move
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax
Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology
Read more →NVAX▲ +10.9%on this newsshared move
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 2021 Cantor Virtual
Read more →NVAXNovavax participa en el Fireside Chat en Devex @ UNGA 76
GAITHERSBURG, Md., 21 de septiembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología que desarrolla y comercializa vacunas de próxima generación para enfermedades infecciosas graves, anunció hoy que John J. Trizzino, vicepresidente ejecutivo, di
Read more →NVAXNovavax participará de conversa informal durante Devex na UNGA 76
GAITHERSBURG, Maryland, 21 de setembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia que desenvolve e comercializa vacinas de última geração para doenças infecciosas graves, anunciou hoje que John J. Trizzino, vice-presidente executivo, dire
Read more →NVAXNovavax nimmt am Fireside Chat bei Devex @ UNGA 76 teil
GAITHERSBURG, Maryland, 21. September 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das Impfstoffe der nächsten Generation gegen schwere Infektionskrankheiten entwickelt und vermarktet, gab heute bekannt, dass John J. Trizzino, Executive Vice P
Read more →NVAXNovavax participará de una charla informal en Devex @ UNGA 76
GAITHERSBURG, Maryland, 21 de septiembre de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología que desarrolla y comercializa vacunas de última generación para enfermedades infecciosas graves, anunció hoy que John J. Trizzino, vicepresidente ejecutivo
Read more →NVAXNovavax participera à un webinaire à Devex @ UNGA 76
GAITHERSBURG, Maryland, 21 septembre 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), une société de biotechnologie qui développe et commercialise des vaccins de nouvelle génération pour les maladies infectieuses graves, a annoncé aujourd'hui que John J. Trizzino, Vice-présiden
Read more →NVAXNovavax to Participate in Fireside Chat at Devex @ UNGA 76
GAITHERSBURG, Md., Sept. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Offic
Read more →NVAXNovavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
GAITHERSBURG, Md., Sept. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical tri
Read more →NVAX▼ -6.4%on this news
Novavax lance l
-- Les premiers participants sont inscrits à l'essai clinique de phase 1 du vaccin combiné NanoFluTM/NVX–CoV2373 avec adjuvant Matrix-MTM -- L'étude de phases 1 et 2 évaluera l'immunogénicité et la sécurité GAITHERSBURG, Maryland, 10 septembre 2021 /PRNewswire/ -- Novavax, Inc.
Read more →NVAX▼ -6.4%on this news
Novavax startet klinische Phase I/II-Studie mit Kombinationsimpfstoff gegen Covid-19 und saisonale Grippe
Erste Teilnehmer an klinischer Phase-I-Studie des Kombinationsimpfstoffs NanoFlu™/NVX-CoV2373 mit dem Adjuvans Matrix-M™ eingeschrieben Phase I/II-Studie wird Immunogenität und Sicherheit untersuchen GAITHERSBURG, Maryland, 10. September 2021 /PRNewswire/ -- Novavax, Inc. (Nasd
Read more →NVAXNovavax inicia estudo clínico de Fase 1/2 de vacina combinada para COVID-19 e Influenza sazonal
-- Primeiros participantes são inscritos no estudo clínico de Fase 1 da vacina combinada NanoFlu™/NVX–CoV2373 com adjuvante Matrix-M™ -- Estudo de Fase 1/2 avaliará imunogenicidade e segurança GAITHERSBURG, Maryland, 9 de setembro de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq
Read more →NVAXNovavax inicia ensayo clínico de fase 1/2 para la vacuna combinada contra la COVID-19 y la influenza estacional
-- Primeros participantes inscritos en el ensayo clínico de fase 1 para la vacuna combinada NanoFlu™/NVX–CoV2373 con adyuvante Matrix-M™ -- El estudio de fase 1/2 evaluará la inmunogenicidad y la seguridad GAITHERSBURG, Maryland, 9 de septiembre de 2021 /PRNewswire/ -- Novavax,
Read more →NVAXNasdaq: NVAX | September 2021 CORPORATE OVERVIEW AND INVESTOR DECK 2 novavax.com Safe Harbor Statement Certain information, particularly information relating to the future of Novavax, its operating plans and prospects, t
Nasdaq: NVAX | September 2021 CORPORATE OVERVIEW AND INVESTOR DECK 2 novavax.com Safe Harbor Statement Certain information, particularly information relating to the future of Novavax, its operating plans and prospects, the ongoing development of NVX - CoV2373 and other Novavax v
Read more →NVAXNovavax inicia un ensayo clínico de una vacuna combinada para COVID-19 y gripe estacional
- Novavax inicia un ensayo clínico de fase 1/2 de una vacuna combinada para la COVID-19 y la gripe estacional -- Primeros participantes inscritos en el ensayo clínico de fase 1 de la vacuna combinada NanoFlu™/NVX–CoV2373 con adyuvante Matrix-M™ -- El estudio de fase 1/2 evaluar
Read more →NVAXNovavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study t
Read more →NVAX▲ +7.6%on this newsshared move
Novavax to Participate in Citi
GAITHERSBURG, Md., Sept. 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in Citi's 16th Annual BioPharma Virtual Conference 2021 investor co
Read more →NVAXNovavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Control and Prevention (CDC) has provided updated guidance
Read more →NVAXNovavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax' recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-
Read more →NVAX▼ -10.9%on this news
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance GAITHERSBURG, Md.
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance GAITHERSBURG, Md., August 16, 2021 - Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines
Read more →NVAX▲ +12.2%on this news· ran to +30% by day 3
Novavax gibt Daten zum COVID-19-Auffrischimpfung bekannt, die einen vierfachen Anstieg der neutralisierenden Antikörperspiegel im Vergleich zu den Spitzenwerten nach der Erstimpfung belegen
Einmalige Auffrischungsdosis von NVX-CoV2373 nach 6 Monaten erhöht neutralisierende Wildtyp-Antikörper um mehr als das Vierfache im Vergleich zur ersten Impfserie Sechsfacher Anstieg der kreuzreaktiven funktionellen Antikörper gegen die Delta-Variante im Vergleich zur Erstimpfun
Read more →NVAX▲ +12.2%on this news· ran to +30% by day 3
Novavax und Serum Institute of India kündigen Antrag auf Notfallzulassung des rekombinanten Nanopartikel-COVID-19-Impfstoffs von Novavax bei den Zulassungsbehörden in Indien, Indonesien und auf den Philippinen an
- Novavax und Serum Institute of India reichen Zulassungsanträge für den rekombinanten Nanopartikel-COVID-19-Impfstoff von Novavax beim Drugs Controller General of India und bei den Zulassungsbehörden in Indonesien und auf den Philippinen ein - Antrag auf Notfallaufnahme bei der
Read more →NVAX▲ +12.2%on this news· ran to +30% by day 3
Novavax publie des données sur les doses de rappel du vaccin contre la COVID-19 démontrant une augmentation de quatre fois des niveaux d
Une seule dose de rappel à 6 mois du vaccin NVX-CoV2373 a multiplié par plus de 4 les anticorps neutralisants de type sauvage par rapport à la série de primovaccination Les anticorps fonctionnels à réaction croisée contre la variante Delta ont été multipliés par six par rapport
Read more →NVAX▼ -19.6%on this newsshared move
Novavax y Serum Institute of India anuncian la solicitud de la autorización de uso de emergencia de la vacuna de nanopartículas recombinantes contra la COVID-19 de Novavax a los organismos reguladores de India, Indonesia y Filipinas
GAITHERSBURG, Maryland, 6 de agosto de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología que desarrolla vacunas de última generación contra enfermedades infecciosas graves, con su socio Serum Institute of India Pvt. Ltd. (SII), anunció hoy que las em
Read more →NVAX▼ -19.6%on this newsshared move
Novavax e Serum Institute of India anunciam pedido de autorização de uso emergencial da vacina contra a COVID-19 à base de nanopartícula recombinante da Novavax em agências reguladoras na Índia, Indonésia e nas Filipinas
- Novavax e Serum Institute of India apresentam pedidos regulatórios para uso da vacina contra a COVID-19 à base de nanopartícula recombinante da Novavax para o controlador geral de medicamentos da Índia e para agências reguladoras da Indonésia e das Filipinas - Apresentação do
Read more →NVAX▼ -19.6%on this newsshared move
Novavax anuncia dados de reforço da vacina contra a COVID-19 que demonstram aumento de quatro vezes nos níveis de anticorpos neutralizantes em comparação às respostas de pico após a vacinação primária
Dose de reforço única de NVX-CoV2373 após seis meses aumentou os anticorpos neutralizantes do tipo selvagem mais de quatro vezes em comparação com a série de vacinação primária Aumento de seis vezes na reação cruzada de anticorpos funcionais para a variante Delta em comparação c
Read more →NVAX▼ -19.6%on this newsshared move
Novavax anuncia datos de las vacunas de refuerzo contra la COVID-19, que demuestran un aumento cuatro veces mayor en los niveles de anticuerpos neutralizantes en comparación con las respuestas máximas después de la primovacunación
Una sola dosis de refuerzo a los seis meses de la administración de NVX-CoV2373 aumentó los anticuerpos neutralizantes de tipo silvestre más de cuatro veces en comparación con las series de primovacunación Incremento de seis veces en los anticuerpos funcionales de reacción cruza
Read more →NVAX▼ -19.6%on this newsshared move
Novavax y Serum Institute of India solicitan la autorización de la vacuna COVID-19 de Novavax
- Novavax y Serum Institute of India anuncian la presentación a las agencias reguladoras en India, Indonesia y Filipinas para la autorización de uso de emergencia de la vacuna COVID-19 de nanopartículas recombinantes de Novavax - Novavax y Serum Institute of India presentan pres
Read more →NVAX▼ -19.6%on this newsshared move
Novavax anuncia datos de refuerzo de la vacuna COVID-19
- Novavax anuncia datos de refuerzo de la vacuna COVID-19 que demuestran un aumento de cuatro veces en los niveles de anticuerpos neutralizantes frente a las respuestas máximas después de la vacunación primaria · La dosis de refuerzo única a los 6 meses de NVX-CoV2373 aumentó lo
Read more →NVAX▲ +5.5%on this newsshared move
Novavax und die Europäische Kommission schließen einen Vorabkaufvertrag über bis zu 200 Millionen Dosen des Impfstoffs gegen COVID-19 ab
-- Vereinbarung über 100 Millionen Dosen mit Option für weitere 100 Millionen Dosen bis 2023 -- Wahrscheinlich der erste in der Europäischen Union erhältliche COVID-19-Impfstoff mit Proteinuntereinheiten GAITHERSBURG, Maryland, 5. August 2021 /PRNewswire/ -- Novavax, Inc. (Nasd
Read more →NVAX▲ +5.5%on this newsshared move
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series Six-fold increase in cross-reactive functional antibodies to Delta variant compared to primary vaccination series Analysis of sera from
Read more →NVAX▲ +5.5%on this newsshared move
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax
- Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant nanoparticle COVID-19 vaccine - Filing for World Health Organization Emergency Use Listing
Read more →NVAX▲ +5.5%on this newsshared move
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights Filed regulatory submissions for EUA in India, Indonesia and the Philippines, in partnership with Serum Institute of India Demonstrated gre
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights GAITHERSBURG, Md., August 5, 2021 -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial resul
Read more →NVAX▲ +18.7%on this newsshared move
Novavax et la Commission européenne concluent un accord d
-- Accord pour 100 millions de doses avec une option pour 100 millions de doses supplémentaires jusqu'en 2023 -- Il s'agit du premier vaccin contre la COVID-19 à sous-unités protéiques disponible dans l'Union européenne GAITHERSBURG, Maryland, 5 août 2021 /PRNewswire/ -- Novava
Read more →NVAX▲ +18.7%on this newsshared move
Novavax y la Comisión Europea finalizan acuerdo de compra anticipada de hasta 200 millones de dosis de vacuna contra la COVID-19
GAITHERSBURG, Maryland, 4 de agosto de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología que desarrolla vacunas de última generación para enfermedades infecciosas graves, anunció hoy que ha logrado un acuerdo con la Comisión Europea (CE) para la comp
Read more →NVAX▲ +18.7%on this newsshared move
Novavax e Comissão Europeia finalizam acordo de compra antecipada para até 200 milhões de doses de vacina contra a COVID-19
GAITHERSBURG, Maryland, 4 de agosto de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), empresa de biotecnologia que desenvolve vacinas de última geração para doenças infecciosas graves, anunciou hoje que firmou um acordo com a Comissão Europeia (CE) para a compra de até 200
Read more →NVAX▲ +18.7%on this newsshared move
Novavax y la Comisión Europea concluyen un acuerdo de compra de 200 millones de dosis de vacuna de COVID-19
-Novavax y la Comisión Europea concluyen un acuerdo de compra anticipada de hasta 200 millones de dosis de la vacuna de COVID-19 -- Acuerdo por 100 millones de dosis con opción a 100 millones de dosis adicionales hasta 2023 -- Se espera que sea la primera vacuna de subunidad pr
Read more →NVAX▲ +18.7%on this newsshared move
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results and operational highlights on Thursd
Read more →NVAXNovavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of it
Read more →NVAXNovavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Va
Read more →NVAXNovavax to Participate in National Vaccine Advisory Committee Meeting
GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a sess
Read more →NVAXPREVENT-19-Phase-III-Studie: Der COVID-19-Impfstoff von Novavax zeigt eine Gesamtwirksamkeit von 90 % und einen 100 %igen Schutz vor mittelschweren und schweren Krankheitsverläufen
93 % Wirksamkeit gegen überwiegend zirkulierende, besorgniserregende Varianten und unter Beobachtung stehende Varianten 91 % Wirksamkeit bei den Hochrisikogruppen 100 % Wirksamkeit gegen Varianten, die nicht als „besorgniserregend" oder „unter Beobachtung stehend" gelten Alle
Read more →NVAXLe vaccin Novavax contre la COVID-19 démontre une efficacité globale de 90 % et une protection complète contre les formes modérées et graves de la maladie dans l
Efficacité de 93 % contre les variants préoccupants et les variants d'intérêt principalement en circulation Efficacité de 91 % chez les populations à risque élevé Efficacité de 100 % contre les variants « non considérés comme des variants préoccupants/d'intérêt » Toutes les ho
Read more →NVAXNovavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial 93% efficacy against predominantly circulating Variants of Concern and Varian
COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial GAITHERSBURG, Md., June 14, 2021 - Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based
Read more →NVAXLa vacuna de Novavax contra la COVID-19 demuestra una eficacia general del 90 % y una protección del 100 % contra enfermedades moderadas y graves en el ensayo PREVENT-19 fase 3
Eficacia del 93 % contra Variantes de Preocupación y Variantes de Interés predominantemente circulantes Eficacia del 91 % en poblaciones de alto riesgo Eficacia del 100 % contra variantes que "no son consideradas Variantes de Interés/Preocupación" Todas las hospitalizaciones/m
Read more →NVAXNovavax apresenta 90% de eficácia geral e 100% de proteção contra casos moderados e graves da COVID-19 no estudo de Fase 3 PREVENT-19
93% de eficácia contra as variantes de preocupação e de interesse predominantes 91% de eficácia em populações de alto risco 100% de eficácia contra as variantes "não consideradas de preocupação/interesse" Todas as hospitalizações/mortes pela COVID-19 ocorreram no grupo placebo
Read more →NVAXNovavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-
Read more →NVAXLa vacuna de Novavax para la COVID-19 demuestra una eficacia global del 90%
-La vacuna de Novavax para la COVID-19 demuestra una eficacia global del 90% y una protección del 100% contra la enfermedad moderada y grave en el ensayo de fase 3 PREVENT-19 93% de eficacia contra las Variantes Preocupantes y las Variantes de Interés predominantemente circulant
Read more →NVAXNovavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
GAITHERSBURG, Md., June 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preclinical and clinical data on the company's original recombinant protein COVID-19 vaccine
Read more →NVAXNovavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
GAITHERSBURG, Md., June 9, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, will host Maryland Governor Larry Hogan at the site of the company's planned Vaccines Innovation Campus and g
Read more →NVAXNovavax to Participate in Panel at BIO Digital 2021
GAITHERSBURG, Md., June 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel disc
Read more →NVAXNovavax to Participate in Jefferies Virtual Healthcare Conference
GAITHERSBURG, Md., May 27, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat and host meetings with investors at the upcoming
Read more →NVAXNovavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
GAITHERSBURG, Md., May 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will present on NVX-CoV23
Read more →NVAXNovavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
GAITHERSBURG, Md., May 22, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding memorandum of understanding (MoU) with the Ministry of Health an
Read more →NVAXNovavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
GAITHERSBURG, Md., May 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Maryland Tech Council's (MTC's) nominating committee chose Novavax as the recipient
Read more →NVAXNovavax annonce des données précliniques positives pour l
- Le manuscrit met en évidence le développement de réactions efficaces face à la grippe et à la COVID-19 et la protection contre le virus du SRAS-CoV-2 - Données partagées via le serveur de prépublication en biologie, bioRxiv, avant publication GAITHERSBURG, Maryland, 12 mai 20
Read more →NVAXNovavax gibt positive präklinische Daten für Kombinations-Impfstoffkandidaten gegen Influenza und COVID-19 bekannt
- Manuskript zeigt Entwicklung überzeugender Reaktionen auf Influenza und COVID-19 und Schutz gegen das SARS-CoV-2-Virus - Daten stehen vor Veröffentlichung über den Preprint-Server für Biologie, bioRxiv, zur Verfügung GAITHERSBURG, Maryland, 11. Mai 2021 /PRNewswire/ -- Novava
Read more →NVAXNovavax anuncia dados pré-clínicos positivos em relação a candidata a vacina combinada contra gripe e COVID-19
GAITHERSBURG, Maryland, 11 de maio de 2021 /PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia que desenvolve vacinas de última geração para doenças infecciosas graves, anunciou hoje os dados de um estudo pré-clínico da vacina contra a gripe sazonal quadr
Read more →NVAXNovavax anuncia datos preclínicos positivos para la candidata a la vacuna combinada contra la influenza y la COVID-19
GAITHERSBURG, Maryland, 11 de mayo de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compañía de biotecnología que desarrolla vacunas de última generación para enfermedades infecciosas graves, anunció hoy los datos de un estudio preclínico de la combinación tetravalente d
Read more →NVAXNovavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of publication GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq:
Read more →NVAXNovavax Reports First Quarter 2021 Financial Results and Operational Highlights Significant progress in PREVENT-19 study; final data expected in the second quarter of 2021 Initiated pediatric extension of PREVENT-19 in t
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights May 10, 2021 -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational high
Read more →NVAXNovavax y Gavi ejecutan el acuerdo de compra anticipada de la vacuna contra la COVID-19 para la COVAX Facility
Novavax entregará 350 millones de dosis a partir del tercer trimestre de 2021 Estarán disponibles 1.100 millones de dosis de la vacuna Novavax para los países que participan en COVAX El Serum Institute de la India proporcionará el resto de las dosis a países de bajos y medianos
Read more →NVAXNovavax e Gavi assinam contrato de compra antecipada para vacina contra COVID-19 para o COVAX Facility
Novavax entregará 350 milhões de doses a partir do terceiro trimestre de 2021 1,1 bilhão de doses de vacina Novavax a serem disponibilizadas aos países participantes da COVAX Serum Institute, da Índia, deverá fornecer saldo de doses para países de baixa e média renda. Destaca
Read more →NVAXNovavax y Gavi ejecutan un acuerdo avanzado de compra para la vacuna de la COVID-19 para COVAX Facility
Novavax va a desplegar 350 millones de dosis a partir del tercer trimestre de 2021 1.100 millones de dosis de la vacuna de Novavax van a estar disponibles para los países que participen en COVAX El Serum Institute of India proporciona el equilibrio de las dosis para LMICs Subr
Read more →NVAXNovavax et Gavi signent un accord d
Novavax va livrer 350 millions de doses à partir du troisième trimestre 2021 1,1 milliard de doses de vaccin Novavax seront mises à la disposition des pays participant au programme COVAX Le Serum Institute of India fournira le nombre de doses nécessaires pour les PFR-PRI Souli
Read more →NVAXNovavax und Gavi schließen Vorabkaufvertrag über COVID-19-Impfstoff für COVAX-Facility ab
Novavax liefert ab Q3 2021 350 Millionen Dosen 1,1 Milliarden Impfstoffdosen von Novavax für die an COVAX teilnehmenden Länder verfügbar Serum Institute of India wird restliche Dosen für Länder mit niedrigem Einkommen liefern Unterstreicht Engagement für weltweiten gleichberec
Read more →NVAXNovavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
Novavax to deliver 350 million doses beginning Q3 2021 1.1 billion doses of Novavax vaccine to be available to countries participating in COVAX Serum Institute of India to provide balance of doses for LMICs Underscores commitment to global equitable access to Novavax vaccine
Read more →NVAXNew England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
GAITHERSBURG, Md., May 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the initial primary analysis of a Phase 2b clinical trial cond
Read more →NVAXNovavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021
GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2021 financial results and operational highlights on Monda
Read more →NVAXMalaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating
Read more →NVAXNovavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
GAITHERSBURG, Md., April 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called
Read more →NVAXNovavax Announces Leadership Updates
GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical
Read more →NVAXNovavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: Th
Read more →NVAXNovavax lance un essai clinique croisé pour son vaccin contre la COVID-19
L'essai croisé, mené à l'insu, permet aux participants de poursuivre les essais Il veille à ce que tous les participants à l'essai reçoivent un vaccin actif Les essais croisés ont débuté pour les groupes en Afrique du Sud et au Royaume-Uni; ils sont prévus pour l'étude PREVENT-
Read more →NVAXNovavax initiiert Cross-over der klinischen Studie mit dem Impfstoff COVID-19
Cross-over ermöglicht es den Teilnehmern, weiterhin an Studien teilzunehmen und verblindet zu bleiben Stellt sicher, dass alle Studienteilnehmer einen aktiven Impfstoff erhalten Cross-over-Gruppen in Südafrika und Großbritannien initiiert; US/Mexiko PREVENT-19 Cross-over geplan
Read more →NVAXNovavax inicia crossover de estudo clínico da vacina contra a COVID-19
O crossover permite que os participantes continuem em testes e permaneçam cegos Ele garante que todos os participantes recebam vacina ativa Braços de crossover do sul da África e Reino Unido iniciados; crossover PREVENT-19 entre EUA/México planejado GAITHERSBURG, Md., 6 de abr
Read more →NVAXNovavax inicia el cruce del ensayo clínico de la vacuna COVID-19
El cruce permite que los participantes continúen en los ensayos y permanezcan cegados Garantiza que todos los participantes del ensayo reciban la vacuna activa. Se iniciaron los grupos de cruce de Sudáfrica y el Reino Unido; Cruce PREVENT-19 entre Estados Unidos y México planea
Read more →NVAXNovavax inicia el ensayo clínico cruzado de la vacuna contra la COVID-19
El ensayo cruzado les permite a los participantes continuar en las pruebas y permanecer cegados Esto garantiza que todos los participantes del ensayo reciban una vacuna activa Los brazos cruzados de Sudáfrica y del Reino Unido ya se iniciaron; el ensayo cruzado PREVENT-19 para
Read more →NVAXNovavax CEO Stan Erck to Participate in Longwood Healthcare Leaders Meeting
GAITHERSBURG, Md., April 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel dis
Read more →NVAXNovavax Initiates COVID-19 Vaccine Clinical Trial Crossover
Crossover allows participants to continue in trials and remain blinded Ensures that all trial participants receive active vaccine South Africa and UK crossover arms initiated; US/Mexico PREVENT-19 crossover planned GAITHERSBURG, Md., April 5, 2021 /PRNewswire/ -- Novavax, Inc.
Read more →NVAXGSK to support manufacture of Novavax
LONDON and GAITHERSBURG, Md., March 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in pr
Read more →NVAXNovavax confirma altos niveles de eficacia contra las cepas de COVID-19 originales y variantes en ensayos realizados en el Reino Unido y Sudáfrica
- 100 % de protección contra enfermedad grave - El análisis final en el ensayo del Reino Unido confirma una eficacia del 96 % contra la cepa original de la COVID-19 - Eficacia contra variantes confirmadas en el Reino Unido y Sudáfrica GAITHERSBURG, Maryland, 14 de marzo de 202
Read more →NVAXNovavax confirme le haut niveau d
- Protection totale contre les formes graves de la maladie - L'analyse finale effectuée au Royaume-Uni confirme une efficacité de 96 % contre la souche originale de la COVID-19 - Efficacité confirmée contre les souches variantes britanniques et sud-africaines GAITHERSBURG, Mar
Read more →NVAXNovavax confirma alta eficacia contra las cepas de COVID-19 originales y variantes
- Novavax confirma alta eficacia contra las cepas de COVID-19 originales y variantes en ensayos en Reino Unido y Sudáfrica - 100% de protección frente a una enfermedad grave - El análisis final en el ensayo del Reino Unido confirma una eficacia del 96% frente a la cepa original
Read more →NVAXNovavax confirma altos níveis de eficácia contra cepas de COVID-19 originais e variantes no Reino Unido e na África do Sul
GAITHERSBURG, Maryland, 12 de março de 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia que desenvolve vacinas de última geração para doenças infecciosas graves, anunciou hoje a eficácia final de 96,4% contra doenças leves, moderadas e graves causad
Read more →NVAXNovavax bestätigt hohe Wirksamkeit gegen Original- und Variant-COVID-19-Stämme in Studien in Großbritannien und Südafrika
- 100 % Schutz gegen schwere Krankheiten - Abschließende Analyse in britischer Studie bestätigt 96%ige Wirksamkeit gegen Originalstamm von COVID-19 - Wirksamkeit gegen Varianten in Großbritannien und Südafrika bestätigt GAITHERSBURG, Maryland, 13. März 2021 /PRNewswire/ -- Nov
Read more →NVAXNovavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
- 100% protection against severe disease - Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19 - Efficacy against variants confirmed in U.K. and South Africa GAITHERSBURG, Md., March 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi
Read more →NVAXNovavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
Novavax, Inc. announced its participation in the H.C. Wainwright Virtual Global Life Sciences conference, where it will discuss its COVID-19 vaccine candidate, NVX-CoV2373. The company is also advancing its NanoFlu™ vaccine, which successfully met its Phase 3 trial objectives. A replay of the session will be available on Novavax's website for 90 days.
Read more →NVAXノヴァヴァックスと武田がノヴァヴァックスのCOVID-19ワクチン候補のライセンス契約を確定し、武田は日本で第I/Ⅱ相試験を開始
Novavax, Inc. has announced a partnership with Takeda Pharmaceutical Company to advance its COVID-19 vaccine candidate, NVX-CoV2373, in Japan. The collaboration includes the development, manufacturing, and distribution of the vaccine. Additionally, Novavax has initiated the first Phase 1 clinical trial for NVX-CoV2373 in Japan, focusing on safety and immunogenicity.
Read more →NVAXNovavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights 96% vaccine efficacy against original COVID-19 in UK Phase 3 trial Vaccine cross-protection demonstrated against both variant
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Md., March 1, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its
Read more →NVAXNovavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Novavax has entered into an exclusive license agreement with Takeda for the development and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373, in Japan. Takeda has commenced a Phase 1/2 trial to evaluate the vaccine's safety and immunogenicity. The collaboration aims to manufacture over 250 million doses annually, enhancing vaccine access in Japan.
Read more →NVAXNovavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Novavax has completed enrollment for its pivotal Phase 3 trial, PREVENT-19, evaluating the efficacy and safety of its COVID-19 vaccine, NVX-CoV2373, in the U.S. and Mexico. The trial enrolled 30,000 participants, focusing on diverse and high-risk populations. This milestone is supported by government partnerships and aims to enhance vaccine trust globally.
Read more →NVAXNovavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Novavax has signed a Memorandum of Understanding with Gavi to supply 1.1 billion doses of its COVID-19 vaccine, NVX-CoV2373, to the COVAX Facility. This collaboration aims to ensure equitable access to vaccines globally, with doses manufactured by Novavax and the Serum Institute of India. The agreement supports Gavi's goal of delivering two billion doses in 2021.
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
Novavax, Inc. will announce its fourth quarter 2020 financial results and operational highlights on March 1, 2021. The company is known for developing vaccines for serious infectious diseases and is currently conducting late-stage trials for its COVID-19 vaccine candidate, NVX-CoV2373. Additionally, its NanoFlu™ vaccine has met primary objectives in a Phase 3 trial.
Read more →NVAXNovavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
Novavax has expanded its collaboration with SK Bioscience to manufacture and commercialize its COVID-19 vaccine, NVX-CoV2373, for South Korea. The agreement includes a license for SK Bioscience to produce 40 million doses, alongside technology transfer and support for regulatory approval. Positive interim results from ongoing Phase 3 trials bolster confidence in the vaccine's efficacy.
Read more →NVAXNovavax und die Regierung der Schweiz geben eine Grundsatzvereinbarung zur Bereitstellung des COVID-19-Impfstoffes bekannt
Novavax has entered into a framework agreement with the Swiss government to supply six million doses of its COVID-19 vaccine candidate, NVX-CoV2373. This agreement underscores Switzerland's commitment to ensuring adequate vaccine supply for its citizens. The vaccine is currently in Phase III clinical trials and has demonstrated efficacy against the original COVID-19 strain and emerging variants.
Read more →NVAXNovavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
Novavax, Inc. has initiated a rolling review for its COVID-19 vaccine NVX-CoV2373 by several regulatory authorities, including the FDA and EMA. This process will continue alongside ongoing Phase 3 trials in the U.S. and U.K. The vaccine has shown high efficacy rates against COVID-19 and its variants, aiming to expedite access to vaccination worldwide.
Read more →NVAXNovavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
GAITHERSBURG, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has executed a binding Heads of Terms agreement with the government of
Read more →NVAXNovavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
GAITHERSBURG, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced memorandum of understanding with the Canadian government to produce NVX-CoV2373, the Com
Read more →NVAXNovavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV
Read more →NVAXNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrate
Read more →NVAXNovavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior
Read more →NVAXNovavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an agreement with the Government of Canada to supply up
Read more →NVAXNasdaq: NVAX | January 2021 J.P. MORGAN 39 TH ANNUAL HEALTHCARE CONFERENCE - VIRTUAL 2 novavax.com Safe Harbor Statement Certain information, particularly information relating to future performance and other business mat
Nasdaq: NVAX | January 2021 J.P. MORGAN 39 TH ANNUAL HEALTHCARE CONFERENCE - VIRTUAL 2 novavax.com Safe Harbor Statement Certain information, particularly information relating to future performance and other business matters, including expectations regarding clinical development
Read more →NVAXNovavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
Advance Purchase Agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate Initial doses expected to be delivered as early as mid-2021 GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company dev
Read more →NVAXNovavax to Participate in Upcoming Conferences
GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID
Read more →NVAXNovavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
PREVENT-19 will assess the efficacy, safety and immunogenicity of NVX-CoV2373 in the prevention of COVID-19 Trial to enroll up to 30,000 volunteers across approximately 115 sites in the U.S. and Mexico Two-thirds of enrollees to receive active vaccine GAITHERSBURG, Md., Dec. 2
Read more →NVAXNovavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
GAITHERSBURG, Md., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purc
Read more →NVAXNovavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors Gaithersburg, Md.
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors Gaithersburg, Md., December 9, 2020 -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the
Read more →NVAXNovavax Announces COVID-19 Vaccine Clinical Development Progress
Pivotal Phase 3 trial in United Kingdom completes enrollment Phase 2b efficacy trial in South Africa completes enrollment U.S./Mexico Phase 3 trial expected to begin in the coming weeks GAITHERSBURG, Md., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-s
Read more →NVAXNovavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
GAITHERSBURG, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, will host a conference call for the investment community to pose questions related to the Com
Read more →NVAXNovavax Reports Third Quarter 2020 Financial and Operational Results Advanced clinical development of NVX - CoV2373 with initiation of first Phase 3 trial to evaluate efficacy, safety and immunogenicity U.K. Phase 3 inte
Novavax Reports Third Quarter 2020 Financial and Operational Results Md., November 9, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial re
Read more →NVAXNovavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Desig
Read more →NVAXNovavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
Covino brings global biopharmaceutical finance experience to Novavax John Trizzino, Chief Business Officer, takes on additional role as Chief Commercial Officer Filip Dubovsky, M.D. promoted to Executive Vice President, Chief Medical Officer Biegie Lee promoted to Senior Vice
Read more →NVAXNovavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Gove
Read more →NVAXNovavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors GAITHERSBURG, Md.
Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors GAITHERSBURG, Md., November 3, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases,
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2020 financial and operating results followi
Read more →NVAXNovavax Announces Facility Expansion to Support Global Vaccine Development
Expands campus with two properties to support vaccine research and development, manufacturing, business operations GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for seriou
Read more →NVAXNovavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
5,500 volunteers enrolled to date in pivotal Phase 3 clinical trial in the U.K. Study expanded to 15,000 participants Full enrollment expected by end of November Event-driven interim data expected as soon as early first quarter 2021 U.S. pivotal Phase 3 clinical trial planned
Read more →NVAXNovavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
GAITHERSBURG, Md., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present
Read more →NVAXNovavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure
Team will focus on global NanoFlu licensure and evaluation of post-pandemic influenza/COVID-19 combination vaccine with NVX-CoV2373 Russell (Rip) Wilson promoted to Executive Vice President and NanoFlu General Manager GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Novavax
Read more →NVAXNovavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020
GAITHERSBURG, Md., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ a
Read more →NVAXNovavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom
GAITHERSBURG, Md., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safe
Read more →NVAXNovavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021 Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in 2021 Agreement expands Novavax partnership with world’s largest vaccine developer
Read more →NVAXNasdaq: NVAX | September 10, 2020 Corporate Overview and Investor Deck
Nasdaq: NVAX | September 10, 2020 Corporate Overview and Investor Deck 2 novavax.com Safe Harbor Statement Certain information, particularly information relating to future performance and other business matters, including expectations regarding clinical development, market oppor
Read more →NVAXNovavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine
GAITHERSBURG, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication in The New England Journal of Medicine of Phase 1 data from
Read more →NVAXNovavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine
• Canadian government to purchase up to 76 million doses of NVX-CoV2373 GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it
Read more →NVAXNovavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
Primary objectives expand evaluation of immunogenicity and safety Secondary objectives include preliminary efficacy assessment Trial to enroll up to 1,500 volunteers in United States and Australia, with approximately 50 percent between 60 and 84 years of age Interim immunogeni
Read more →NVAXNovavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
Phase 2b clinical trial in collaboration with Professor Shabir Madhi and Wits University Bill & Melinda Gates Foundation providing $15 million grant toward trial Mature trial infrastructure along with significant levels of seasonal transmission may allow for rapid efficacy eval
Read more →NVAXNovavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate
UK government to purchase 60 million doses of NVX-CoV2373 Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UK Novavax and UK government to collaborate on Phase 3 clinical trial in UK commencing in the third quarter
Read more →NVAXNovavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
SK bioscience to manufacture antigen component of NVX-CoV2373 Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373 Novavax, SK bioscience and Republic of Korea intend to partner for manufacture and supply of vaccine for global markets inclu
Read more →NVAXNovavax Reports Second Quarter 2020 Financial and Operational Results Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373 Secured $2 billion in funding for global coronavirus vaccine program throug
Reports Second Quarter 2020 Financial and Operational Results Md., August 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and
Read more →NVAXNovavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan Matrix-M adjuvant to be supplied from Novavax Government of Japan will provide funding to Takeda for technology transfer, establishment of infrastructure and scale-up
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020
GAITHERSBURG, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results follow
Read more →NVAXNovavax and Serum Institute of India Announce Development and Commercial Collaboration
Expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries Leverages Serum Institute’s existing reach and infrastructure Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373 for low- and mid
Read more →NVAXNovavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 years NVX-CoV2373 was generally well-tolerated and had a reassuring safety profile The vaccine induced neutrali
Read more →NVAXNovavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
GAITHERSBURG, Md. and MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading contract d
Read more →NVAXNovavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress
GAITHERSBURG, Md., July 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will pres
Read more →NVAXNovavax Announces $1.6 Billion Funding from Operation Warp Speed
Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020 GAITHERSBURG, Md., July 07, 2020 (GLOBE NEWS
Read more →NVAXNovavax Announces Updates to Leadership Team
Frank Czworka appointed SVP, Global Sales Brian Webb promoted to SVP, Manufacturing GAITHERSBURG, Md., July 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today a
Read more →NVAXNovavax Expands Executive Leadership and Announces Key Promotions
GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with respo
Read more →NVAXNovavax to Participate in H.C. Wainwright Fireside Chat Series
GAITHERSBURG, Md., June 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chie
Read more →NVAXNovavax Announces Additions to Executive Leadership
GAITHERSBURG, Md., June 17, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of two senior executives to the leadership team. Filip Dubovs
Read more →NVAXNovavax Appoints Biotechnology Veteran David Mott to Board of Directors GAITHERSBURG, Md.
Novavax Appoints Biotechnology Veteran to Board of Directors Md., June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David
Read more →NVAXNovavax to Raise $200 Million from Private Placement with RA Capital GAITHERSBURG, Md.
Novavax to Raise $200 Million from Private Placement with GAITHERSBURG, Md., June 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has ente
Read more →NVAXNovavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital
GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join
Read more →NVAXNovavax Awarded Department of Defense Contract for COVID-19 Vaccine
$60 million funding for manufacturing of NVX-CoV2373 10 million doses to be delivered to DoD in 2020 GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious
Read more →NVAXNovavax Expands Large-Scale Global Manufacturing Capacity Novavax acquires Praha Vaccines in Czech Republic Annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md.
Novavax Expands Large-Scale Global Manufacturing Novavax acquires Praha Vaccines Annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen Md., May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing nex
Read more →NVAXNovavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373 Preliminary immunogenicity and safety results expected in July 2020 Phase 2 portion to begin promptly following successful Phase 1 results GAITHERSBURG, Md., May 25, 2020 (GLOBE NEWSWIRE) -- Novava
Read more →NVAXNovavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory Glenn, M.D., President of Research and Development, will present
Read more →NVAXNVX - CoV2373 Vaccine for COVID - 19 Dr. Gregory Glenn, World Vaccine Congress Webcast 13 May 2020 2 novavax.com Executive summary Novavax has a prefusion, stable recombinant SARS - CoV - 2 Spike protein nanoparticle vac
NVX - CoV2373 Vaccine for COVID - 19 Dr. Gregory Glenn, World Vaccine Congress Webcast 13 May 2020 2 novavax.com Executive summary Novavax has a prefusion, stable recombinant SARS - CoV - 2 Spike protein nanoparticle vaccine candidate (NVX - CoV2373) that has been highly immunog
Read more →NVAXNovavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing Funds clinical development of NVX-CoV2373 through Phase 2 Supports rapid scale-up of vaccine manufacturing Allows
Novavax to Receive up to $388 Million for COVID-19 Vaccine Development and MD, May 11, 2020 - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic P
Read more →NVAXNovavax Reports First Quarter 2020 Financial Results CEPI increases investment up to $388 million for NVX-CoV2373 vaccine development & manufacturing NVX - CoV2373 Phase I trial initiating in May with preliminary results
Novavax Reports First Quarter 2020 Financial CEPI increases investment up to $388 million for NVX-CoV2373 vaccine development & Phase I trial initiating in May with preliminary results in July NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial C
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
GAITHERSBURG, Md., May 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2020 financial and operating results followin
Read more →NVAXNovavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trial In preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing antibodies First-in-human Phase 1 clinical trial accelerated to mid-May with preliminary res
Read more →NVAXNovavax' NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial Trial also achieves statistical significance in key secondary endpoints Novavax to submit a U.S. BLA under FDA's accelerated approval pathway Comp
Novavax' NanoFlu Achieves All Primary Phase 3 Clinical Trial MD, March 24, 2020 - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phas
Read more →NVAXNovavax Reports Fourth Quarter and Full Year 2019 Financial Results NanoFlu top-line data from Phase 3 clinical trial expected by the end of this month Novavax awarded CEPI funding to support COVID-19 vaccine program COV
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results MD, March 11, 2020 (GLOBE NEWSWIRE) - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results
Read more →NVAXNovavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso GAITHERSBURG, Md., Mar
Read more →NVAXNovavax Awarded Funding from CEPI for COVID-19 Vaccine Development
CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1 Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials Phase 1 clinical trial expected to initiate in late spring of 2020 GAITHERSBURG, Md
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
GAITHERSBURG, Md., March 05, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2019 financial and operating results follo
Read more →NVAXNovavax Advances Development of Novel COVID-19 Vaccine
Vaccine candidate derived from coronavirus spike (S) protein Matrix-M™ adjuvant expected to boost immune responses Phase 1 clinical trial planned for late spring GAITHERSBURG, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology compa
Read more →NVAXNovavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a publication in Vaccines describing the immunogenic potential of NanoFlu™, N
Read more →NVAXNovavax Granted Fast Track Designation for NanoFlu in Older Adults
GAITHERSBURG, Md., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Desig
Read more →NVAXNovavax to Present at the 38th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference. P
Read more →NVAXNovavax Reports Third Quarter 2019 Financial Results NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020 Company to host conference call today at 4:30 p.
Reports Third Quarter 2019 Financial Results MD, November 7, 2019 (GLOBE NEWSWIRE) - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highl
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019
GAITHERSBURG, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2019 financial and operating results followi
Read more →NVAXNovavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu Top-line clinical data expected in the first quarter of 2020 Phase 3 results expected to support a future BLA and licensure of NanoFlu using the FDA’s accelerated approval pathway GAITHERSBURG, Md., Oct.
Read more →NVAXNovavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference
GAITHERSBURG, Md., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will present at
Read more →NVAXNovavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will present at
Read more →NVAXNovavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting
GAITHERSBURG, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Louis F. Fries III, M.D., Senior Vice President, Chief Medical Officer,
Read more →NVAXNovavax Reports Second Quarter 2019 Financial Results Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third qua
Reports Second Quarter 2019 Financial Results MD, August 7, 2019 (GLOBE NEWSWIRE) - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highli
Read more →NVAXNovavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S. Food and Drug Administration (FDA) on it
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019
Gaithersburg, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2019 financial and operating results follow
Read more →NVAXNovavax and Catalent Announce Closing of Strategic Partnership GAITHERSBURG, MD
and Catalent Announce Closing of Strategic Partnership MD, July 31, 2019 (GLOBE NEWSWIRE) - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics' Paragon Gene Therapy unit, t
Read more →NVAXNovavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
Pivotal Phase 3 clinical trial expected to initiate in the fall of 2019 Top-line clinical data expected in the first quarter of 2020 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation
Read more →NVAXNovavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax' Manufacturing Assets and Capabilities Manufacturing equipment and rela
and Catalent Biologics Enter Strategic Partnership: Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax' Manufacturing Assets and Capabilities MD, June 27, 2019 (GLOBE NEWSWIRE) - Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company devel
Read more →NVAXNovavax Provides Updates on the Global Pathways to Licensure for ResVax™
GAITHERSBURG, Md., June 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™
Read more →NVAXNovavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine industry leaders for a panel discussion at the 2019 BIO Inte
Read more →NVAXNovavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023
GAITHERSBURG, Md., May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New
Read more →NVAXNovavax Announces Reverse Stock Split of Common Stock
GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated C
Read more →NVAXNovavax Reports First Quarter 2019 Financial Results Company to Host Conference Call Today at 4:30 p.m. ET Gaithersburg, MD
Reports First Quarter 2019 Financial Results Company to Host Conference Call Today at 4:30 p.m. ET MD, May 2, 2019 - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2019. Quarter 2019 and Su
Read more →NVAXNovavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
GAITHERSBURG, Md., May 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and Microbiology at Baylor College of Medicine and Medical Director, Transplant Infectious Diseas
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019
GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019. Conference call details are as follows
Read more →NVAXPhase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization Presentation at World Vaccine Congress
Phase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization Presentation at World Vaccine Congress April 16, 2019 RSV disease burden in infants ResVax - the RSV prefusogenic F nanoparticle v accine Structure Antigenicity Immunogenicity Prepare trial
Read more →NVAXNovavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
GAITHERSBURG, Md., April 09, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn, M.D., President of Research and Development, will share data from its global Phase 3 clinical trial of ResVax™, the respiratory syncytial virus (RSV) fusion (
Read more →NVAXNovavax Reports Fourth Quarter and Year-End 2018 Financial Results Company to Host Conference Call Today at 4:30 p.m. ET Gaithersburg, MD
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results Company to Host Conference Call Today at 4:30 p.m. ET MD, March 18, 2019 - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve mont
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019
GAITHERSBURG, Md., March 11, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial markets opening on Monday, March 18, 2019. Conference call details are as follows: D
Read more →NVAXNovavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization
Trial did not meet primary objective of prevention of medically significant RSV LRTI Trial did show efficacy against secondary objective (RSV LRTI hospitalization); first RSV vaccine to show Phase 3 efficacy Other pre-specified exploratory endpoints and post-hoc analyses highli
Read more →NVAXPrepare Trial Topline Results February 28, 2019
Prepare Trial Topline Results February 28, 2019 Safe harbor statement Certain information, particularly information relating to future performance and other business matters, including expectatio ns regarding clinical development, our planned use of the proceeds from the offerin
Read more →NVAXNovavax Announces Positive Phase 2 NanoFlu Results in Older Adults
Phase 2 clinical trial confirmed Phase 1/2 results, again demonstrating improved immune responses over Fluzone® High-Dose End-of-Phase 2 meeting with the FDA expected in the first half of 2019 Pivotal Phase 3 clinical trial expected to initiate in 2019 GAITHERSBURG, Md., Jan.
Read more →NVAXNovavax to Present at the 37th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference. Presentation details are as follows: Date and time: Wednesday, January 9, 3:00 p.m. – 3:25 p.m. P.T. Loca
Read more →NVAXNovavax Announces Leadership Promotions
GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. “I am thrilled to announce these two important man
Read more →NVAXNovavax Expands Leadership with Several Key Management Promotions
GAITHERSBURG, Md., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions. “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into co
Read more →NVAXNovavax Reports Third Quarter 2018 Financial Results Company to Host Conference Call Today at 4:30 p.m. ET Gaithersburg, MD
Novavax Reports Third Quarter 2018 Financial Company to Host Conference Call Today MD, November 7, 2018 - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2018. remain on t
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018
GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, November 7, 2018. Conference call details are as fol
Read more →NVAXNovavax Appoints Rachel King to Board of Directors Gaithersburg, MD
Novavax Appoints Rachel King to Board MD, November 1, 2018 - Novavax, Inc., (Nasdaq: NVAX) today announced the appointment of Rachel King, Co-Founder and Chief Executive Officer of GlycoMimetics, Inc., to its Board of Directors. In addition to extensive experience as an executi
Read more →NVAXNovavax to Highlight RSV Program Data at Two Upcoming Meetings
GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at
Read more →NVAXNovavax to Present at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the first week of October. Conference details ar
Read more →NVAXNovavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults
First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical tr
Read more →NVAXNovavax to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13th Annual Biotech Conference in September. Conference details are as follows: B. Riley
Read more →NVAXNovavax Reports Second Quarter 2018 Financial Results Novavax Delivers on Key Milestones Supporting its 2018 Objectives Company to Host Conference Call Today at 4:30 pm ET Gaithersburg, MD
Novavax Reports Second Quarter 2018 Financial Novavax Delivers on Key Milestones Supporting Company to Host Conference Call Today MD, August 8, 2018 - Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter and six
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018
GAITHERSBURG, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August 8, 2018. Conference call details are as foll
Read more →NVAXNovavax Reports First Quarter 2018 Financial Results Gaithersburg, MD
Novavax Reports First Quarter 2018 Financial MD, May 9, 2018 (GLOBE NEWSWIRE) - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2018. Quarter and Subsequent Achievements: had an extremely productive first quarter, incl
Read more →NVAXNovavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine
Prepare trial is assessing the efficacy of Novavax’ RSV F Vaccine for infants via maternal immunization Enrollment of ~4,600 participants enables initiation of interim efficacy analysis Topline efficacy data from analysis expected in the first quarter of 2019 GAITHERSBURG, Md.
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018
GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018. Conference call details are as follows:
Read more →NVAXNovavax Announces Closing of Public Offering
GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced the closing of the underwritten public offering priced on Wednesday, Ap
Read more →NVAXNovavax Prices Public Offering of Common Stock
GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten public offering of 30,303,050 shares
Read more →NVAXNovavax Announces Proposed Public Offering of Common Stock Gaithersburg, MD (
Announces Proposed Public Offering of Common Stock Gaithersburg, MD (April 11, 2018)-Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it intends to offer to sell, su
Read more →NVAXNovavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
Update on RSV F Vaccine Phase 3 Prepare™ trial for infants via maternal immunization Results from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose flu vaccine GAITHERSBURG, Md., April 02, 2018 (GLOBE NEWSWIRE) -- Novava
Read more →NVAXNovavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer
GAITHERSBURG, Md., March 14, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the promotion of John J. Trizzino to Senior Vice President, Chief Business Officer (CBO) and Chief Financial Officer (CFO). Mr. Trizzino has been serving as Senior Vice President, C
Read more →NVAXNovavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results RSV Phase 3 Prepare Trial Outcome De-risked by Successful Informational Analysis NanoFlu Vaccine Demonstrates Improved Im
Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results MD, March 14, 2018 - Novavax, Inc., (Nasdaq: NVAX) today provided a corporate update and announced its financial results for the fourth quarter and twelve months ended December 31, 2017.
Read more →NVAXNovavax to Host Conference Call and Webcast to Provide Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
GAITHERSBURG, Md., March 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March
Read more →NVAXNovavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
Phase 2 trial of NanoFlu vaccine expected to begin in third quarter of 2018 Given strength of trial data, Novavax has submitted detailed results for publication in peer-reviewed medical journal Company management to discuss more complete trial results after publication GAITHER
Read more →NVAX` J.P.
` J.P. Morgan Healthcare Conference January 2018 2 Certain information, particularly information relating to future performance and other business matters, including expectations regarding clinical development, market opportunities and anticipated milestones constitute forward -
Read more →NVAXNovavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
RSV F Vaccine informational analysis completed in fourth quarter of 2017 RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees Filing of RSV F Vaccine BLA anticipated by late 2019 NanoFlu Vaccine data package to be completed and released in Februa
Read more →NVAXNovavax to Present at the Stifel 2017 Healthcare Conference
GAITHERSBURG, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference. Presentation details are as follows: Date: Wednesday, November 15, 2017 Time: 1:15 p.m. – 1:55 p.m. ET Location
Read more →NVAXNovavax Reports Third Quarter 2017 Financial Results Gaithersburg, MD
Novavax Reports Third Quarter 2017 Financial MD, November 7, 2017 - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results for the third quarter and nine months ended September 30, 2017. Quarter Achievements: were very pleased to initiate and fully enroll the Pha
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017
GAITHERSBURG, Md., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results following the close of U.S. financial markets on Tuesday, November 7, 2017. Conference call details are as follows:
Read more →NVAXNovavax Announces Leadership Change
GAITHERSBURG, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry
Read more →NVAXNovavax Announces Leadership Change GAITHERSBURG, Md.
Novavax Announces Leadership Change GAITHERSBURG, Md., October 13, 2017 -- Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. "Buck" Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded op
Read more →NVAXNovavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference
GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference. Presentation details are as follows: Date: Tuesday, September 26, 2017 Time: 11:00 – 11:25 am ET L
Read more →NVAXNovavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults
Recently published NanoFlu™ preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains Data from trial expected by the end of 2017 GAITHERSBURG, Md., Sept. 19,
Read more →NVAXNovavax to Participate in the Citi 12th Annual Biotech Conference
GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi’s 12th Annual Biotech Conference. Conference details are as follows: Date: Thursday, September 7, 2017 Location: Mandarin Oriental hotel, Bos
Read more →NVAXNovavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine
GAITHERSBURG, Md., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M™ adjuvant (NanoFlu™) have been published in the journal Vaccine. Nova
Read more →NVAXNovavax Reports Second Quarter 2017 Financial Results Gaithersburg, MD
Novavax Reports Second Quarter 2017 Financial MD, August 8, 2017 - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results for the second quarter and six months ended June 30, 2017. Quarter and Subsequent Achievements: has demonstrated considerable progress in our
Read more →NVAXNovavax to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on August 8, 2017
GAITHERSBURG, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operating results following the close of U.S. financial markets on Tuesday, August 8, 2017. Conference call details are as follows: D
Read more →NVAXNovavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs Phase 2 data in older adults (E205) demonstrate adjuvants and 2-dose regimens significantly incr
Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs Gaithersburg, MD, July 24, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced positive topline data from its Phase 2 safety and immunogenicity trial of
Read more →NVAXReminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immuno
Read more →NVAXNovavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunog
Read more →NVAXNovavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine
Novavax-RSV-F-Vaccine GAITHERSBURG, Md., June 7, 2017 /PRNewswire/ -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from the second of two Phase 2 trials of its RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of child bearing age have b
Read more →NVAXNovavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine
GAITHERSBURG, Md., May 11, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that Dr. James F. Cummings has been promoted to Vice President, Clinical Development and Translational Medicine. Dr. Cummings joined Novavax as Senior Director of Clinical Development
Read more →NVAXNovavax Reports First Quarter 2017 Financial Results Gaithersburg, MD
Novavax Reports First Quarter 2017 Financial MD, May 8, 2017 - Novavax, Inc., (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, Quarter Achievements: continued to make significant progress in the execution of our two key clinical trials
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter 2017 Financial Results on May 8, 2017
GAITHERSBURG, Md., May 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017. Conference call details are as follows: Da
Read more →NVAXNovavax Reports Fourth Quarter and Year-End 2016 Financial Results Gaithersburg, MD
Novavax Reports Fourth Quarter and Year-End 2016 Financial Results MD, February 27, 2017 - Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the fourth quarter and twelve months ended December 31, 2016. and Fourth Quarter Achievements: significant progre
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017
GAITHERSBURG, Md., Feb. 20, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017. Conference call detai
Read more →NVAXNovavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults
GAITHERSBURG, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). Th
Read more →NVAXNovavax to Present at the 35th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35th Annual J.P. Morgan Healthcare Conference. Presentation details are as follows: Date: Thursday, January 12, 2017 Time: 9:30 am U.S. Pacific
Read more →NVAXNovavax to Participate in the 4th Annual Guggenheim Boston Healthcare Conference
GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the 4th Annual Guggenheim Boston Healthcare Conference. Conference details are as follows: Date: Tuesday, December 13, 2016 Location: Intercontinen
Read more →NVAXNovavax to Participate in the Citi 2016 Global Healthcare Conference
GAITHERSBURG, Md., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the Citi 2016 Global Healthcare Conference. Conference details are as follows: Date: Wednesday, December 7, 2016 Location: New York Palace Hotel, N
Read more →NVAXNovavax to Present at the 28th Annual Piper Jaffray Healthcare Conference
GAITHERSBURG, Md., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. Conference details are as follows: Date: Tuesday, Novemb
Read more →NVAXNovavax Reports Third Quarter 2016 Financial Results Announces Corporate Restructuring and Cost Savings Highlights Strategic Focus and Development Activities for 2017 Gaithersburg, MD
Novavax Reports Third Quarter 2016 Financial MD, November 9, 2016 - Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the third quarter and nine months ended September 30, 2016, in conjunction with its Investor and Analyst Day update. Company presented a r
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016
GAITHERSBURG, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast after the close of U.S. financial markets on Wednesday, November
Read more →NVAXNovavax Reschedules 4th Annual Investor and Analyst Meeting
GAITHERSBURG, Md., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst update as part of its third quarter financial results conference call an
Read more →NVAXNovavax to Host 4th Annual Investor and Analyst Meeting
GAITHERSBURG, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY. Senior management will conduct a series of presen
Read more →NVAXNovavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults Topline data from the Resolve Phase 3 trial did not meet pre-specified efficacy objectives o The attack rate for the Phase 3 primary o
Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults Management will host a conference call at 5:00 pm ET time today Gaithersburg, MD., September 15, 2016 - Novavax, Inc., (Nasdaq: NVAX) today announced topline data from two clinical trials of its RSV
Read more →NVAXNovavax Reports Second Quarter 2016 Financial Results Gaithersburg, MD
Novavax Reports Second Quarter 2016 Financial MD, August 9, 2016 - Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2016. Second Quarter Achievements: is an incredibly exciting time for Novavax, as we near
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter Financial Results on August 9, 2016
GAITHERSBURG, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 201
Read more →NVAXNovavax Recognized by Washington Post as Top Workplace
GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016. “At Novavax, we strive to create an environment where teamwork and collaboration thrive bas
Read more →NVAXNovavax Announces New Seasonal Combination Respiratory Vaccine Program
Seasonal influenza nanoparticle approach replaces VLP program HHS BARDA contract will complete its term as scheduled in September 2016 Nanoparticle design builds on advances achieved with RSV F Vaccine Animal immunogenicity and efficacy data demonstrate broadly neutralizing an
Read more →NVAXNovavax Receives the Tech Council of Maryland’s Chairman’s Award
GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryla
Read more →NVAXNovavax to Participate in the 2016 Citi Midwest Healthcare Access Day
GAITHERSBURG, Md., May 11, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced management will participate in the 201
Read more →NVAXNovavax Reports First Quarter 2016 Financial Results Gaithersburg, MD
Novavax Reports First Quarter 2016 Financial MD, May 4, 2016 - Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016
GAITHERSBURG, Md., April 27, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 201
Read more →NVAXNovavax to Participate in the FBR New Prescriptions Conference
GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief
Read more →NVAXNovavax to Present at the 15th Annual Needham Healthcare Conference
GAITHERSBURG, Md., April 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief
Read more →NVAXNovavax Announces Management Promotion
GAITHERSBURG, Md., April 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Iksung Cho has been named Vice
Read more →NVAXNovavax Appoints Bob Darius Senior Vice President, Quality Operations
GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Bob Darius, Senio
Read more →NVAXNovavax Announces Management Promotions
GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Dr. Gregory M. Glenn has been n
Read more →NVAXNovavax Reports Fourth Quarter and Year-End 2015 Financial Results Gaithersburg, Md.
Novavax Reports Fourth Quarter and Year-End 2015 Financial Results Md., February 29, 2016 - Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today anno
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and
Read more →NVAXNovavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares
GAITHERSBURG, Md., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that, in connection with Novavax’ pre
Read more →NVAXNovavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023
GAITHERSBURG, Md., Jan. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the closing of its previously announc
Read more →NVAXNovavax Prices $300 Million of Convertible Senior Notes Due 2023
GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the pricing of $300 million aggregate
Read more →NVAXNovavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023
GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to
Read more →NVAXNovavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs
GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard,
Read more →NVAXNovavax to Present at the 34th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 3
Read more →NVAXNovavax Appoints Mark Twyman Vice President Marketing
GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Mark Twyman to the
Read more →NVAXNovavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults
GAITHERSBURG, Md., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced complete target enrollment of the piv
Read more →NVAXNovavax to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference
GAITHERSBURG, Md., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will participate in t
Read more →NVAXNovavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization
GAITHERSBURG, Md., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the enrollment of the first participa
Read more →NVAXNovavax to Present at the 27th Annual Piper Jaffray Healthcare Conference
GAITHERSBURG, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and C
Read more →NVAXNovavax to Make Multiple Presentations at RSV Vaccines for the World
GAITHERSBURG, Md., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Novavax representatives will be
Read more →NVAXNovavax to Present at the Stifel 2015 Healthcare Conference
GAITHERSBURG, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Barclay “Buck” Phillips, SVP, Ch
Read more →NVAXNovavax Reports Third Quarter 2015 Financial
Novavax Reports Third Quarter 2015 Financial Gaithersburg, Md., November 9, 2015 - Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its
Read more →NVAXNovavax Reports Third Quarter 2015 Financial Results
GAITHERSBURG, Md., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the third q
Read more →NVAXNovavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults
GAITHERSBURG, Md., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the initiation of a Phase 3 clinical
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2015
GAITHERSBURG, Md., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its third quarter 2015
Read more →NVAXNovavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults
GAITHERSBURG, Md., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase
Read more →NVAXNovavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
Read more →NVAXNovavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics
GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase
Read more →NVAXNovavax to Host 3rd Annual Analyst and Investor Meeting
GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, will host its 3rd annual Analyst and Investor Meetin
Read more →NVAXAnalyst & Investor Meeting September 2015 Safe Harbor Statement Certain information contained herein, particularly information relating to future financial or business performance, conditions or strategies and other fina
Analyst & Investor Meeting September 2015 Safe Harbor Statement Certain information contained herein, particularly information relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regardin
Read more →NVAXNovavax Announces Grant of up to $89 Million to Support Development of RSV F Vaccine to Protect Infants via Maternal Immunization Bill & Melinda Gates Foundation to support development of the RSV F Vaccine Program Gaithe
Announces Grant of up to $89 Million to Support Development of RSV F Vaccine to Protect Infants via Maternal Immunization Bill & Melinda Gates Foundation to support development of the RSV F Vaccine Program Md., September 29, 2015 - Novavax, Inc., (Nasdaq: NVAX) a clinical-stag
Read more →NVAXNovavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference
GAITHERSBURG, Md., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and
Read more →NVAXNovavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model
GAITHERSBURG, Md., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its RSV F-protein recombinant nanopa
Read more →NVAXNovavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease
GAITHERSBURG, Md., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the full data set from its clin
Read more →NVAXNovavax to Participate in Multiple Investor Conferences in September
GAITHERSBURG, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the Company will participate in the
Read more →NVAXNovavax Reports Second Quarter 2015 Financial Results Gaithersburg, Md.
Novavax Reports Second Quarter 2015 Financial Md., August 10, 2015 - Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial resu
Read more →NVAXNovavax to Present at the Wedbush PacGrow Healthcare Conference
GAITHERSBURG, Md., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and C
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter Financial Results on August 10, 2015
GAITHERSBURG, Md., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 201
Read more →NVAXNovavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP
GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 2
Read more →NVAXNovavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference
GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1
Read more →NVAXNovavax Appoints Gail Boudreaux to Board
GAITHERSBURG, Md., June 18, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Gail K. Boudreaux
Read more →NVAXNovavax Appoints Gail Boudreaux to Board Gaithersburg, Md.
Novavax Appoints Gail Boudreaux to Board Md., June 18, 2015 - Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Gail K
Read more →NVAXNovavax Reports First Quarter 2015 Financial Results Gaithersburg, Md.
Novavax Reports First Quarter 2015 Financial Gaithersburg, Md., May 7, 2015 - Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its fina
Read more →NVAXNovavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015
GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 201
Read more →NVAXNovavax to Present at the 14th Annual Needham Healthcare Conference
GAITHERSBURG, Md., April 8, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief
Read more →NVAXNovavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses
GAITHERSBURG, Md., March 28, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Gale Smith, Ph.D., Vice President, V
Read more →NVAXNovavax Appoints Brian Rosen as Vice President, Government Affairs
GAITHERSBURG, Md., March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Brian Rosen to th
Read more →NVAXNovavax Reports Fourth Quarter and Year-End 2014 Financial Results Gaithersburg, MD (
Novavax Reports Fourth Quarter and Year-End 2014 Financial Results Gaithersburg, MD (February 26, 2015) - Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuva
Read more →NVAXNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
GAITHERSBURG, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and
Read more →NVAXNovavax Announces Initiation of Ebola Vaccine Phase 1 Clinical Trial Supported by Non-Human Primate Challenge Data and Documented Rapid Manufacturing Capabilities
Initiation of Enrollment of Phase 1 Clinical Trial of Ebola GP Vaccine Non-Human Primate Challenge Data Signal Breakthrough in Ebola Vaccine Development Rapid Manufacturing Process of Ebola GP Vaccine Published in BioProcessing Journal GAITHERSBURG, Md., Feb. 12, 2015 (GLOBE N
Read more →NVAXNovavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, Presid
Read more →NVAXNovavax to Present at the 26th Annual Piper Jaffray Healthcare Conference
GAITHERSBURG, Md., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, Presi
Read more →NVAXNovavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP
GAITHERSBURG, Md., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun i
Read more →NVAXNovavax to Present at the Jefferies Global Healthcare Conference
GAITHERSBURG, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Stanley C. Erck, Presi
Read more →NVAXNovavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects
GAITHERSBURG, Md., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun i
Read more →NVAXNovavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
GAITHERSBURG, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Nova
Read more →NVAXNovavax Reports Third Quarter 2014 Financial Results Gaithersburg, MD (
Novavax Reports Third Quarter 2014 Financial Gaithersburg, MD (November 5, 2014) - Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today ann
Read more →NVAXNovavax to Host Conference Call to Discuss Third Quarter 2014 Financial Results on November 5, 2014
GAITHERSBURG, Md., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it will report its fin
Read more →NVAXNovavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia
First Ebola Vaccine Candidate based on the 2014 Guinea Ebola Strain Genetic Sequence Robust immune responses demonstrated in preclinical studies; exceptional responses when used with Novavax' Matrix-M adjuvant Non-human primate study initiated GMP manufacture initiated; Scaled
Read more →NVAXNovavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26
GAITHERSBURG, Md., Oct. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Gregory Glenn, M.D., S
Read more →NVAXNovavax to Present RSV Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26
GAITHERSBURG, Md., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Gregory Glenn, M.D., S
Read more →NVAXNovavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies
Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies Vaccine Induces Antibodies that are at Least as Protective as Palivizumab Palivizumab Competing Antibody Response from Vaccine Protects Against Both Homologous and Heterologous Disease Strains GAITHERSBURG,
Read more →NVAXNovavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects
GAITHERSBURG, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun i
Read more →NVAXAnnounces BARDA Exercise of Contract Option
Announces BARDA Exercise of Contract Option Gaithersburg, Md. - September 23, 2014- Novavax, Inc. (Nasdaq: NVAX) announced today that it has executed a contract modification with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Aut
Read more →NVAXNovavax Announces BARDA Exercise of Contract Option
Award of Option Period for 24 months Additional Option Period Funding Commitment of $70 million Clinical, Manufacturing and Product Development Activities Funded Up to Phase 3 GAITHERSBURG, Md., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today tha
Read more →NVAXNovavax' H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2 Clinical Data
Vaccine and adjuvant were well-tolerated, consistent with the company's prior studies with saponin-based adjuvants Hemagglutination-inhibiting antibody responses similar to prior Novavax studies of A(H7N9) with another saponin adjuvant Strong neuraminidase inhibiting antibody r
Read more →NVAXNovavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy Third-Trimester Pregnant Women
GAITHERSBURG, Md., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun
Read more →NVAXNovavax to Host 2nd Annual Analyst and Investor Meeting
GAITHERSBURG, Md., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that it will host its 2nd annual
Read more →NVAXNovavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC
GAITHERSBURG, Md., Sept. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today presented preclinical data demonstrat
Read more →NVAXNovavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC
GAITHERSBURG, Md., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will present data f
Read more →NVAXNovavax to Present at the Wedbush Securities Life Sciences Management Access Conference
GAITHERSBURG, Md., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Barclay "Buck" Phillips
Read more →NVAXNovavax Reports Second-Quarter 2014 Financial Results Gaithersburg, MD (
Novavax Reports Second-Quarter 2014 Financial Gaithersburg, MD (August 6, 2014) - Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today repo
Read more →NVAXNovavax to Host Conference Call to Discuss Second Quarter 2014 Financial Results on August 6, 2014
ROCKVILLE, Md., July 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will report its financ
Read more →NVAXNovavax Recognized as One of The Washington Post's Top Workplaces
GAITHERSBURG, Md., June 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, is pleased to announce that it has been rec
Read more →NVAXNovavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering Gaithersburg, MD (
Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering Gaithersburg, MD (June 11, 2014) Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinan
Read more →NVAXNovavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering
GAITHERSBURG, Md., June 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the closing of the underwri
Read more →NVAXLAUNCH PRESS RELEASE Novavax Announces Proposed Public Offering of Common Stock Gaithersburg, MD (
Novavax Announces Proposed Public Offering Gaithersburg, MD (June 4, 2014)-Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced t
Read more →NVAXNovavax Announces Proposed Public Offering of Common Stock
GAITHERSBURG, Md., June 4, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer to
Read more →NVAXNovavax to Present at the Jefferies 2014 Global Healthcare Conference
GAITHERSBURG, Md., June 2, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will present at the following event: Event: Jefferies 2014 Global Healthcare Conferenc
Read more →NVAXNovavax Reports First-Quarter 2014 Financial Results Gaithersburg, MD (
Novavax Reports First-Quarter 2014 Financial Gaithersburg, MD (May 7, 2014) - Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported
Read more →NVAXNovavax Reports First-Quarter 2014 Financial Results
GAITHERSBURG, Md., May 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the
Read more →NVAXNovavax Appoints Sven Andreasson as Senior Vice President, Corporate Development
GAITHERSBURG, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Sven Andr
Read more →NVAXNovavax to Report First Quarter Financial Results on May 7, 2014
GAITHERSBURG, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014 after the close of the U.S. financial markets. Following the earnings release, company management
Read more →NVAXNovavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age
Vaccine candidate was well-tolerated with no vaccine-related serious adverse events Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant Women with the lowest baseline levels of RSV neutralizing antibodies had the largest inc
Read more →NVAXNovavax Appoints Dr. Cindy Oliver as Senior Vice President, Process Development Operations
GAITHERSBURG, Md., April 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Cynthia
Read more →NVAXNovavax to Present at the 13th Annual Needham Healthcare Conference
GAITHERSBURG, Md., April 2, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on April 9, 2014 at 12:10
Read more →NVAXNovavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)
GAITHERSBURG, Md., March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for t
Read more →NVAXBarclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of its H7N9
SVP, Chief Financial Officer and Treasurer Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of its H7N9 Avian Influenza VLP Vaccine Candidate with Matrix-M Gaithersburg, MD (March 10, 2014) - Novavax, Inc. (Nasdaq
Read more →NVAXNovavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations
GAITHERSBURG, Md., March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of John J.
Read more →NVAXNovavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA
GAITHERSBURG, Md., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the execution of a contract modification to extend the base period of performance of its current contract with the U.S. Department of Health and Human Services, Biomedical Advanced Re
Read more →NVAXBarclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedn
Contact: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness with HHS-BARDA Gaithersburg, MD - (February 27, 2
Read more →NVAXNovavax to Report Fourth Quarter and Year-End 2013 Financial Results on March 10, 2014
ROCKVILLE, Md., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and webcast to report its fourth quarter and year-end 2013 financial results on Monday, March 10, 2014, at 4:30 p.m. ET. The dial-in number for the c
Read more →NVAXNovavax Announces Management Promotions to Support Expanded Clinical Activity in 2014
ROCKVILLE, Md., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced a number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015. Gregory M. Glenn, M.D. has been named Senior Vice President
Read more →NVAXNovavax Announces Continuation of RSV Vaccine Partnership With PATH
ROCKVILLE, Md., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced the continuation of their partnership with PATH to develop Novavax' RSV (respiratory syncytial virus) vaccine for maternal immunization. Under this amendment, PATH will provide Novavax approxi
Read more →NVAXNovavax to Present at the 25th Annual Piper Jaffray Healthcare Conference
ROCKVILLE, Md., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will present at the 25th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at
Read more →NVAXNovavax Reports Third-Quarter 2013 Financial Results
ROCKVILLE, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants, today announced its financial results f
Read more →NVAXNovavax to Report Third Quarter 2013 Financial Results on November 7, 2013
ROCKVILLE, Md., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial results on Thursday, November 7, 2013, at 4:30 p.m. ET. The dial-in number for the confer
Read more →NVAXNovavax Initiates Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate
ROCKVILLE, Md., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age. This randomized, blinded,
Read more →NVAXNovavax Completes $100 Million Public Offering of Common Stock
ROCKVILLE, Md., Sept. 27, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the closing of its previously announced underwritten public offering of 31,846,950 shares of its common stock, including 4,153,950 shares of common stock that were issued upon the exerc
Read more →NVAXBarclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Completes $100 Million Public Offering of Common Stock Rockville, MD (
Contact: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Completes $100 Million Public Offering of Common Stock Rockville, MD (September 27, 2013) Novavax, Inc. (Nasdaq: NVAX) today announced the closing of its previously ann
Read more →NVAXBarclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Prices Public Offering of Common Stock Rockville, MD (
Contact: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Prices Public Offering of Common Stock Rockville, MD (September 24, 2013) Novavax, Inc. (Nasdaq: NVAX) today announced that it has priced an underwritten public offerin
Read more →NVAXNovavax to Initiate Seasonal and Pandemic Influenza Trials in Collaboration With BARDA
Quadrivalent Seasonal Influenza Clinical Trial to start in 1Q2014 Pandemic Influenza Clinical Trial to start in the U.S. in 1H2014 Proprietary Adjuvant Matrix-M to be used in the Pandemic Clinical Trial ROCKVILLE, Md., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:N
Read more →NVAXNovavax to Host an Analyst and Investor Update Call With Webcast
ROCKVILLE, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine adjuvants, today announced that it will host the Analyst and Investor Update Call with Webcast o
Read more →NVAXNovavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)
Genocea Biosciences' Herpes Simplex Therapeutic Vaccine uses Matrix-M adjuvant Phase 1/2A U.S.-based clinical trial enrolled 143 volunteers with moderate-to-severe HSV-2 Two highest dose Matrix-M adjuvanted cohorts demonstrated statistically significant reductions in viral shed
Read more →NVAXNovavax to Present at the 2013 Stifel Nicolaus Healthcare Conference
ROCKVILLE, Md., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will present at the 2013 Stifel Nicolaus Healthcare Conference on Thursday, September 12, 2
Read more →NVAXJohn A. Herrmann VP, General Counsel and Secretary Novavax, Inc. 240-268-2000 Novavax Acquires Isconova; Extended Public Tender Offer Period Closed Rockville, MD (
Contact: John A. Herrmann VP, General Counsel and Secretary Novavax, Inc. 240-268-2000 Novavax Acquires Isconova; Extended Public Tender Offer Period Closed Rockville, MD (August 22, 2013)-/GlobeNewswire, Inc. /-Novavax, Inc. (Nasdaq: NVAX) announced today the number of sh
Read more →NVAXNovavax Reports Second-Quarter 2013 Financial Results
ROCKVILLE, Md., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines to address a broad range of infectious diseases, today announced its financial results for the second quarter
Read more →NVAXNOVAVAX to Present at the 2013 Wedbush Life Sciences Conference
ROCKVILLE, Md., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 2013 Wedbush Life Sciences Management Access Conference on We
Read more →NVAXNovavax to Report Second Quarter 2013 Financial Results on August 8, 2013
ROCKVILLE, Md., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its second quarter 2013 financial results on Thursdsay, August 8, 2013, at 8:30 a.m. ET. The dial-in number for the confere
Read more →NVAXNovavax Publishes Positive Preclinical Efficacy Data Against Influenza A(H7N9)
Positive efficacy data from its A(H7N9) vaccine published in the peer-reviewed scientific journal Vaccine Novavax vaccine-induced immunity provided 100% protection against lethal wild-type A(H7N9) influenza challenge versus 0% survival in control (H5N1) vaccine and placebo group
Read more →NVAXNovavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate
ROCKVILLE, Md., July 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 clinical trial of its monovalent virus-like particle (VLP) vaccine candidate for the prevention of disease due to A/Anhui/1/13-like A(H7N9) avian in
Read more →NVAXJohn A. Herrmann VP, General Counsel and Secretary Novavax, Inc. 240-268-2000 Novavax and Isconova to Combine; Novavax' Swedish Prospectus Approved Rockville, MD (
VP, General Counsel and Secretary Novavax and Isconova Novavax' Swedish Prospectus Approved Rockville, MD (July 8, 2013)-/GlobeNewswire, Inc. /-Novavax, Inc. (NASDAQ: NVAX) announced today the approval in Sweden of its prospectus related to its recommended offer to acquire a
Read more →NVAXNovavax Announces Positive Top-Line Results From Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly
Well-tolerated without any vaccine-related serious adverse events Adjuvant enhanced response seen in all dose levels Anti-F IgG antibodies to the F protein in serum rose 3.0-5.7 fold across all dose levels Palivizumab-like antibodies rose from undetectable levels to those prev
Read more →NVAXBarclay Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Announces Positive Top-Line Results from Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly Well-tolerated w
SVP, Chief Financial Officer and Announces Positive Top-Line Results from Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly Rockville, MD (July 2, 2013)-/GlobeNewswire, Inc. /-Novavax, Inc. (NASDAQ: NVAX) today announced positive top-line safety and immunogenicity da
Read more →NVAXJohn Herrmann VP, General Counsel and Corporate Secretary Novavax, Inc. 240-268-2000 Novavax Appoints Barclay "Buck" Phillips as Senior Vice President and Chief Financial Officer Rockville, MD (
Novavax Appoints Barclay "Buck" Phillips as Senior Vice President and Chief Financial Officer Rockville, MD (June 24, 2013)-/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Barclay A. "Buck" Phillips to the position of Senior Vice President and
Read more →NVAXNovavax Appoints Barclay "Buck" Phillips as Senior Vice President and Chief Financial Officer
ROCKVILLE, Md., June 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the appointment of Barclay A. "Buck" Phillips to the position of Senior Vice President and Chief Financial Officer, effective June 24, 2013. He will be responsible for managing Novavax'
Read more →NVAXUPPSALA, 17 June, 2013 Novavax to make initial Form S-4 registration statement filing Isconova AB (publ) ("Isconova") announces that Novavax Inc. ("Novavax") expects to make its initial filing today of a Re
UPPSALA, 17 June, 2013 Novavax to make initial Form S-4 registration statement filing Isconova AB (publ) ("Isconova") announces that Novavax Inc. ("Novavax") expects to make its initial filing today of a Registration Statement on Form S-4 with the U.S. Securities and Exchange
Read more →NVAXNovavax Produces MERS-CoV Vaccine Candidate
ROCKVILLE, Md., June 6, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it had successfully produced a vaccine candidate designed to provide protection against the recently emerging Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The vaccine can
Read more →NVAXIrrevocable Undertaking This irrevocable undertaking agreement (the "Agreement") has been made on [ ] June 2013, by and between: 1. Novavax, Inc., ("Novavax"); and 2. [ ] (the "Obligated Party"). Novavax and the Obligate
Irrevocable Undertaking This irrevocable undertaking agreement (the "Agreement") has been made on [ ] June 2013, by and between: Novavax and the Obligated Party are each referred to as a "Party" and jointly as the "Parties". also intends to make a private offer whereby holde
Read more →NVAXNovavax Announces Public Offer for All Outstanding Shares of Isconova
Adds proprietary nanoparticle matrix immune-modulating adjuvant technology to Novavax's recombinant vaccine development platform Total transaction valued at approximately $29.6 million USD Conference call with management to discuss acquisition at 10:00 a.m. EDT today ROCKVILLE
Read more →NVAXNovavax H7N9 VLP Influenza Vaccine Enters Animal Testing
Novavax H7N9 VLP vaccine produced, purified and entered into preclinical immunogenicity and efficacy studies in less than a month Production of GMP H7N9 clinical trial materials underway ROCKVILLE, Md., May 10, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announce
Read more →NVAXFrederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Reports First-Quarter 2013 Financial Results Key Highlights Phase II RSV clinical trial data achieve protocol sp
Novavax Reports First-Quarter 2013 Financial Rockville, MD (May 7, 2013)-/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2013. The company reported a net loss of $10.0 million, or $0.07 per share, for th
Read more →NVAXNovavax Reports First-Quarter 2013 Financial Results
Phase II RSV clinical trial data achieve protocol specified-objectives of safety and immunogenicity. Novel malaria vaccine candidate in India honored by the Vaccine World Summit India 2013 conference for having the "Most Promising Vaccine for Emerging Diseases in India." Positi
Read more →NVAXNovavax to Report First-Quarter 2013 Financial Results on May 7, 2013
ROCKVILLE, Md., April 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its 2013 first-quarter financial results on Tuesday, May 7, 2013, before the U.S. financial markets open. The announcement will be followed by a webcast and conferen
Read more →NVAXNovavax to Present at 12th Annual Needham Healthcare Conference
ROCKVILLE, Md., April 25, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present a company update at the 12th Annual Needham Healthcare Conference in New York at the Westin Grand Ce
Read more →NVAXNovavax to Review Recent Findings from Vaccine Programs at World Vaccine Congress and Expo in Washington, DC
ROCKVILLE, Md., April 15, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will review recent clinical results from the company's vaccine development programs at the World Vaccine Congress and Expo this week in Washington, DC. On April 16 at 5:55pm (E
Read more →NVAXNovavax Appoints Amy B. Fix Vice President of Regulatory Affairs
ROCKVILLE, Md., April 10, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the appointment of Amy B. Fix to the position of Vice President of Regulatory Affairs. She is responsible for directing regulatory strategy and coordinating the company's interactions w
Read more →NVAXNovavax Reports Positive Top-Line Results From Phase II Clinical Trial of RSV Vaccine Candidate in Women of Childbearing Age
Well-tolerated and without any vaccine related serious adverse events (SAEs) Anti-F IgG antibodies to the F protein in serum rose 6 to 16-fold across all doses (60 and 90 g). Addition of adjuvant enhanced response with both first and second vaccinations Neutralizing antibody re
Read more →NVAXNovavax Reports Progress on RSV Vaccine at the XV International Symposium on Respiratory Viral Infections
ROCKVILLE, Md., March 18, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) reported that David C. Flyer, Ph.D., Director of Preclinical Development at Novavax, presented recent preclinical findings from the company's respiratory syncytial virus (RSV) vaccine development progr
Read more →NVAXNovavax to Present at the 25th Annual ROTH Conference
ROCKVILLE, Md., March 13, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 25th Annual ROTH Conference at the Ritz-Carlton in Laguna N
Read more →NVAXNovavax, CPLB and ICGEB Collaboration Honored for Malaria Vaccine Progress at Vaccine World Summit India 2013
ROCKVILLE, Md., March 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that its collaboration to develop a novel malaria vaccine in India has been honored by the Vaccine World Summit India 2013 conference for having the "Most Promising Vaccine for Emerging
Read more →NVAXNovavax Reports Fourth Quarter and Year-End 2012 Financial Results
ROCKVILLE, Md., March 1, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the fourth quarter and year-ended December 31, 2012. For the fourth quarter of 2012, Novavax reported a net loss of $8.0 million, or $0.06 per share, compared to a
Read more →NVAXNovavax to Report 2012 Fourth-Quarter and Year-End Financial Results on March 1, 2013
ROCKVILLE, Md., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 fourth-quarter and year-end financial results on Friday, March 1, 2013, before the U.S. financial markets open. The announcement will be followed by a webcas
Read more →NVAXNOVAVAX to Present at the 15th Annual Bio CEO & Investor Conference
ROCKVILLE, Md., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W. Driscoll, Vice President and Chief Financial Officer of Novavax, will be presenting at the 15th Annual Bio CEO & Investor Conference in
Read more →NVAXNovavax' Phase I RSV Vaccine Data Published in Vaccine
Vaccine was well-tolerated with no evident dose-related toxicity or attributable SAEs Immunization induced significant increases in neutralizing antibody responses ROCKVILLE, Md., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that the journal Vacc
Read more →NVAXNovavax Publishes Preclinical Efficacy Study of its RSV Protein Nanoparticle Vaccine Candidate
ROCKVILLE, Md., Dec. 3, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that the journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0050852) published data from a preclinical study of its recombinant nanoparticle vaccine candidate against respiratory s
Read more →NVAXNovavax to Present at the 24th Annual Piper Jaffray Healthcare Conference
ROCKVILLE, Md., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 24th Annual Piper Jaffray Healthcare Conference on November
Read more →NVAXNovavax to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the Lazard Capital Markets 9th Annual Healthcare Conference on N
Read more →NVAXNovavax Reports Third-Quarter 2012 Financial Results
ROCKVILLE, Md., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the third quarter and nine months ended September 30, 2012. Third-Quarter 2012 and Subsequent Highlights: Reported positive top-line results from two Phase I clini
Read more →NVAXNovavax to Report Third Quarter 2012 Financial Results on November 2, 2012
ROCKVILLE, Md., Oct. 26, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 third-quarter financial results on Friday, November 2, 2012, before the U.S. financial markets open. The announcement will be followed by a webcast and confe
Read more →NVAXNovavax Announces $27 Million Equity Offering
ROCKVILLE, Md., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has raised a total of $27 million through the sale of 12,285,321 shares of its common stock to RA Capital Management, Camber Capital Management and Ayer Capital Management at a p
Read more →NVAXFrederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Announces $27 Million Equity Offering Rockville, MD (
Contact: Frederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 Novavax Announces $27 Million Equity MD (October 23, 2012)-/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX) today announced that it has raised a total of $27 million through the sa
Read more →NVAXNovavax Reports Positive Top-Line Results From Two Phase 1 Trials of Pandemic Influenza Vaccine
Vaccine candidates met safety and immunogenicity endpoints in both trials Trials' results support further development of vaccine in larger trials -- Adjuvanted candidates, at all doses of antigen tested including 3.75 g dose, achieved dose-sparing goals with seroconversion and
Read more →NVAXNovavax Initiates Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly Adults
ROCKVILLE, Md., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adults 60 years of age and older. This randomize
Read more →NVAXNovavax Initiates Phase 2 Clinical Trial of RSV Vaccine Candidate
ROCKVILLE, Md., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age. The study is being conducted in
Read more →NVAXNovavax Presents RSV Vaccine Data at the 8th Annual International Respiratory Virus Symposium
Data Reinforce Previous Clinical and Preclinical Studies Successfully Induced F-Protein Specific Neutralizing Antibody Response Phase 2 Studies to Begin in the Fourth Quarter of 2012 ROCKVILLE, Md., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced
Read more →NVAXNOVAVAX to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
ROCKVILLE, Md., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Septem
Read more →NVAXNOVAVAX to Present at the 2012 Stifel Nicolaus Healthcare Conference
ROCKVILLE, Md., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 2012 Stifel Nicolaus Healthcare Conference on September 6, 2
Read more →NVAXNOVAVAX to Present at the 2012 Wedbush Life Sciences Conference
ROCKVILLE, Md., Aug. 13, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 2012 Wedbush Life Sciences: Management Access Conference on
Read more →NVAXNOVAVAX Reports Second Quarter 2012 Financial Results
ROCKVILLE, Md., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2012. Second Quarter 2012 and Subsequent Highlights: Reported positive safety and immunogenicity top-line resu
Read more →NVAXNOVAVAX to Report Second Quarter 2012 Financial Results on August 3, 2012
ROCKVILLE, Md., July 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 second-quarter financial results on Friday, August 3, 2012, before the U.S. financial markets open. The announcement will be followed by a webcast and confer
Read more →NVAXNOVAVAX Provides Update on Influenza Programs
Primary Endpoints Achieved in Phase II Seasonal Influenza Trial Two H5N1 Pandemic Influenza Trials Fully Enrolled ROCKVILLE, Md., July 24, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today reported positive top-line results from the company's Phase II clinical trial of
Read more →NVAXNOVAVAX and PATH Announce Partnership on RSV Vaccine
Novavax initially awarded approximately $2 million by PATH Potential for future PATH funding of 50% of external costs to develop maternal RSV vaccine available for low-resource countries Novavax retains global rights to commercialize RSV vaccine ROCKVILLE, Md., July 18, 2012 (
Read more →NVAXNOVAVAX, CPL Biologicals and the International Centre for Genetic Engineering and Biotechnology Announce Collaboration to Develop New Malaria Vaccine With Funding From Government of India
ROCKVILLE, Md., July 16, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), CPL Biologicals (CPLB) and the International Centre for Genetic Engineering and Biotechnology (ICGEB), today announced that they have formed a new collaboration to develop a novel malaria vaccine in In
Read more →NVAXNOVAVAX Reports on Progress with RSV Vaccine at New International Conference on Modern Vaccines
ROCKVILLE, Md., July 5, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) reported this week that Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, reviewed recent preclinical and clinical findings from the company's respiratory syncytial virus (
Read more →NVAXNovavax to Review RSV Program at New International Conference on Modern Vaccines
ROCKVILLE, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, will make a plenary presentation on the company's respiratory syncytial virus (RSV) vaccine program
Read more →NVAXNOVAVAX to Present at Jefferies 2012 Global Healthcare Conference
ROCKVILLE, Md., June 4, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present a corporate update at the Jefferies 2012 Global Healthcare Conferen
Read more →NVAXNOVAVAX, Inc. Announces $12 Million Equity Offering
ROCKVILLE, Md., May 21, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that on Friday, May 18, 2012, it sold 10,000,000 shares of its common stock to RA Capital Healthcare Fund, LP at a price of $1.22 per share. The shares were offered under an effective she
Read more →NVAXNOVAVAX Launches Additional Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
ROCKVILLE, Md., May 9, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it has begun enrollment in a second Phase I clinical trial of its monovalent virus-like particle (VLP) vaccine candidate to prevent potential pandemic disease due to A/H5N1 avian infl
Read more →NVAXNOVAVAX Reports First Quarter 2012 Financial Results
ROCKVILLE, Md., May 4, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2012. The company reported a net loss of $7.3 million, or $0.06 per share, for the first quarter of 2012, compared to a net los
Read more →NVAXNOVAVAX Launches Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
ROCKVILLE, Md., May 2, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it has begun enrollment in a Phase I clinical trial of its monovalent virus-like particle (VLP) vaccine candidate to prevent a potential pandemic disease due to A/H5N1 avian influenza
Read more →NVAXNOVAVAX to Report First Quarter 2012 Financial Results on May 4, 2012
ROCKVILLE, Md., April 26, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 first-quarter financial results on Friday, May 4, 2012, before the U.S. financial markets open. The announcement will be followed by a webcast and conferenc
Read more →NVAXNOVAVAX to Present at the 11th Annual Needham Healthcare Conference
ROCKVILLE, Md., April 3, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W. Driscoll, Vice President and Chief Financial Officer of Novavax, will present at the 11th Annual Needham Healthcare Conference in New
Read more →NVAXNOVAVAX to Present Results From Phase I RSV Study at XIV International Symposium on Respiratory Viral Infections
ROCKVILLE, Md., March 22, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Louis F. Fries III, M.D., its Vice President, Clinical and Medical Affairs, will present results from the company's Phase I clinical trial of its recombinant nanoparticle vaccine c
Read more →NVAXNOVAVAX to Present at the 24th Annual ROTH Conference
ROCKVILLE, Md., March 12, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 24th Annual ROTH Conference in Laguna Niguel, California o
Read more →NVAXNOVAVAX Reports Fourth Quarter and 2011 Year-End Financial Results
ROCKVILLE, Md., March 9, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the fourth quarter and year ended December 31, 2011. For the fourth quarter of 2011, Novavax reported a net loss of $3.7 million, or $0.03 per share, compared to a
Read more →NVAXNOVAVAX Appoints John A. Herrmann III, Vice President and General Counsel
ROCKVILLE, Md., March 8, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Mr. John A. Herrmann III to the position of Vice President and General Counsel. Mr. Herrmann will have responsibility for the legal affairs of the company and will con
Read more →NVAXNOVAVAX Launches Phase II Clinical Trial of Seasonal Influenza Vaccine
ROCKVILLE, Md., March 1, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has begun enrollment in a Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate. This randomized, observer-blind, comparator-
Read more →NVAXNOVAVAX to Report 2011 Fourth-Quarter and Year-End Financial Results on March 9, 2012
ROCKVILLE, Md., Feb. 24, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2011 fourth-quarter and year-end financial results on Friday, March 9, 2012, before the U.S. financial markets open. The announcement will be followed by a webcas
Read more →NVAXNOVAVAX to Present at the 14th Annual Bio CEO & Investor Conference
ROCKVILLE, Md., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Frederick W. Driscoll, Vice President and Chief Financial Officer of Novavax, will be presenting at the 14th Annual Bio CEO & Investor Conference
Read more →NVAXNOVAVAX Appoints Mervyn L. Hamer, Vice President of Manufacturing
ROCKVILLE, Md., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Mr. Mervyn L. Hamer to the position of Vice President of Manufacturing. In this role, Mr. Hamer will have responsibility for manufacturing at both the Rockville and Gai
Read more →NVAXNOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals
Regulatory approval received for rabies vaccine toxicology studies in India Clinical study of influenza vaccine candidate planned for 2012 Validated manufacturing facility ready for clinical production Additional new vaccines in development for undisclosed targets ROCKVILLE,
Read more →NVAXNOVAVAX to Present at 23rd Annual Piper Jaffray Health Care Conference
ROCKVILLE, Md., Nov. 28, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 23rd Annual Piper Jaffray Health Care Conference in New York
Read more →NVAXNOVAVAX Acquires New Manufacturing and Office Facilities in Gaithersburg, MD
ROCKVILLE, Md., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has entered a long-term lease arrangement for 74,000-square-feet of manufacturing, lab and office space in two facilities in Gaithersburg, MD. The main facility, located at 20 Fi
Read more →NVAXNOVAVAX to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W. Driscoll, Vice President and Chief Financial Officer of Novavax, will be presenting at the Lazard Capital Markets 8th Annual Healthcar
Read more →NVAXNOVAVAX Appoints Russell "Rip" Wilson Senior Vice President of Business Development
ROCKVILLE, Md., Nov. 7, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Russell P. "Rip" Wilson as Senior Vice President of Business Development. Mr. Wilson will be responsible for developing business alliances, license arrangements, and pa
Read more →NVAXNOVAVAX Reports Third Quarter 2011 Financial Results
ROCKVILLE, Md., Nov. 4, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the third quarter ended September 30, 2011. Novavax reported a net loss of $3.2 million, or $0.03 per share, for the third quarter of 2011 compared to a net loss of
Read more →NVAXNOVAVAX Appoints Erica S. Shane, Ph.D., Vice President, Process Development
ROCKVILLE, Md., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Erica Shane, Ph.D., to the position of Vice President, Process Development. In this role, Dr. Shane will have responsibility for all process development activities for
Read more →NVAXNOVAVAX to Report Third Quarter 2011 Financial Results on November 4, 2011
ROCKVILLE, Md., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) will report financial results for the third fiscal quarter of 2011 on Friday, November 4, 2011, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call
Read more →NVAXNOVAVAX CEO Addresses U.S. Patent and Trademark Office (USPTO) on Behalf of the Biotechnology Industry Organization (BIO)
ROCKVILLE, Md., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that Stanley C. Erck, President and Chief Executive Officer of Novavax, testified this afternoon on behalf of BIO to support its initiative for reducing filing and prosecution costs for
Read more →NVAXNOVAVAX Announces Conference Call to Discuss Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate
ROCKVILLE, Md., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will conduct a conference call for invited analysts and institutional investors on October 13, 2011 at 10:30 am ET to review the recent top-line results from a Phase I clinical t
Read more →NVAXNOVAVAX Announces Contract Award from U.S. Department of Homeland Security to Develop Foot-and-Mouth Disease Vaccine
ROCKVILLE, Md., Oct. 5, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has been awarded a $1.3 million contract from the U.S. Department of Homeland Security to develop a virus-like particle (VLP) vaccine countermeasure to protect the United States f
Read more →NVAXNOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate
- Well-tolerated with no systemic side-effect trends - Highly immunogenic with an increase in anti-RSV antibodies in 100% of subjects in the highest-dose group - Oral and poster presentations to be made at 5th Vaccine and ISV Annual Global Conference in Seattle ROCKVILLE, Md.,
Read more →NVAXNovavax to Report Top-Line Results From Phase I Respiratory Syncytial Virus Vaccine Clinical Trial on October 3rd at 5th Vaccine and ISV Annual Global Conference
ROCKVILLE, Md., Sept. 26, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report top-line results from a Phase I clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in a presentation at the 5th Vaccine and ISV Annual Global
Read more →NVAXNOVAVAX Announces Publication of Results From H5N1 Influenza Virus-Like Particle Vaccine Phase I/IIa Clinical Trial
VLP vaccine candidate was well-tolerated, immunogenic and generated cross-reactive neutralizing antibodies ROCKVILLE, Md., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the publication of an article that reported new safety, immunogenicity and cro
Read more →NVAXNOVAVAX to Present at Stifel Nicolaus Healthcare Conference
ROCKVILLE, Md., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will be presenting at the Stifel Nicolaus Healthcare Conference on September 8,
Read more →NVAXNovavax to Present at the 2011 Wedbush Life Sciences Conference
ROCKVILLE, Md., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will be presenting at the 2011 Wedbush Life Sciences: Management Access Conferen
Read more →NVAXNovavax Reports Second Quarter 2011 Financial Results
ROCKVILLE, Md., Aug. 5, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the second quarter ended June 30, 2011. Novavax reported a net loss of $5.0 million, or $0.04 per share, for the second quarter of 2011 compared to a net loss of $8
Read more →NVAXNOVAVAX and the Mexican Social Security Institute Publish Results From H1N1 Influenza Vaccine Trial in Mexico
ROCKVILLE, Md., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) and Specialties Hospital of the National Medical Center, Mexico City, today announced the publication of safety and immunogenicity results from a clinical study of Novavax's A/H1N1 virus-like-particle (V
Read more →NVAXNovavax to Report Second Quarter 2011 Financial Results on August 5, 2011
ROCKVILLE, Md., July 29, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) will report financial results for the second quarter of 2011 on Friday, August 5, 2011, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call hosted
Read more →NVAXNovavax Appoints Dr. Timothy Hahn Senior Vice President of Manufacturing
ROCKVILLE, Md., June 28, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Timothy J. Hahn, Ph.D., as Senior Vice President of Manufacturing. Dr. Hahn will oversee production of the company's vaccines and vaccine candidates and be responsible
Read more →NVAXNOVAVAX to Present at the NOBLE FINANCIAL 7th Annual Equity Conference
ROCKVILLE, Md., May 13, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the NOBLE FINANCIAL 7th Annual Equity Conference on May 16, 2011 at 10:30
Read more →NVAXNovavax Named Biotechnology Firm of the Year by Tech Council of Maryland
ROCKVILLE, Md., May 11, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has been named Biotechnology Firm of the Year by the Tech Council of Maryland (TCM), the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. Novavax was
Read more →NVAXNovavax Reports First Quarter 2011 Financial Results
ROCKVILLE, Md., May 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2011. The company reported a net loss of $7.5 million, or $0.07 per share, for the first quarter of 2011, compared to a net loss o
Read more →NVAXNovavax to Report First Quarter 2011 Financial Results on May 9, 2011
ROCKVILLE, Md., May 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) will report financial results for the first quarter of 2011 on Monday, May 9, 2011, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call hosted by Stanle
Read more →NVAXNovavax Announces Senior Management Appointments
ROCKVILLE, Md., April 26, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointments of Louis Fries III, M.D., as Vice President, Clinical and Medical Affairs, and Jane Halpern, Ph.D., as Vice President of Regulatory Affairs. Before joining Novavax, Dr. Fr
Read more →NVAXNovavax Announces Change in Leadership
ROCKVILLE, Md., April 19, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Stanley C. Erck, its former Executive Chairman, has been appointed to the position of President and Chief Executive Officer and will remain as a member of the Board of Directors. In a
Read more →NVAXNovavax's VLP Influenza Vaccine Named One of Top 100 Drugs in Development Today Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine...
ROCKVILLE, Md., April 5, 2011 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tent
Read more →NVAXNOVAVAX Reports Fourth Quarter and 2010 Year-End Financial Results
ROCKVILLE, Md., March 28, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the fourth quarter and year ended December 31, 2010. Restated Financial Results: As will be filed in the Company's Annual Report on Form 10-K for the year ended Dece
Read more →NVAXNOVAVAX Announces Release Date of 2010 Year-End Financial Results and Investor Conference Call
ROCKVILLE, Md., March 23, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2010 year-end financial results in a press release to be issued after 8:00 a.m. local time Monday, March 28, 2011 and will then hold an investor conference call at
Read more →NVAXNOVAVAX to Present at BIT Life Science
ROCKVILLE, Md., March 22, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, will give a keynote address at the 3rd World Congress of Vaccine on March 23rd,
Read more →NVAXNOVAVAX to Present at the ROTH 23rd Annual OC Growth Stock Conference
ROCKVILLE, Md., March 11, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company, announced today that Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on March 14th, 2011 at
Read more →NVAXMaryland Governor Martin O
ROCKVILLE, Md., March 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Maryland State Governor Martin O'Malley will visit the company's headquarters in Rockville, Maryland, on Monday, March 7, to celebrate the recently announced contract valued at up to $
Read more →NVAXNovavax Inc. is Today's Focus Stock on MicroStockProfit.com
DALLAS, March 2, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decisio
Read more →NVAXNOVAVAX Awarded HHS-BARDA Contract Valued at up to $179 Million to Develop Pandemic and Seasonal Influenza Vaccines for U.S. Government Using Recombinant VLP Technology
ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded a contract valued at up to $179 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary
Read more →NVAXNovavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries
ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS). Under the agreement, LGLS receives an exclusive license t
Read more →NVAXNOVAVAX to Present at Citi 2011 Global Health Care Conference
ROCKVILLE, Md., Feb. 24, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Citi 2011 Global Health Care Conference on March 3rd, 20
Read more →NVAXNOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at t
Read more →NVAXNOVAVAX to Present at 13th Annual BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 13th Annual BIO CEO & Investor Conference on February 15
Read more →NVAXNOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle
Read more →NVAXNOVAVAX Launches Phase I Clinical Trial to Evaluate its Novel Vaccine Against Respiratory Syncytial Virus (RSV)
ROCKVILLE, Md., Jan. 4, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has begun patient enrollment in a Phase I clinical trial to assess the safety, immunogenicity and tolerability of a vaccine candidate against respiratory syncytial virus (RSV). In th
Read more →NVAXNOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
ROCKVILLE, Md., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus
Read more →NVAXNOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
ROCKVILLE, Md., Dec. 16, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Adm
Read more →NVAXNOVAVAX to Present at Piper Jaffray 22nd Annual Healthcare Conference
ROCKVILLE, Md., Nov. 29, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, will be presenting at the Piper Jaffray 22nd Annual Healthcar
Read more →NVAXNOVAVAX to Present at Lazard 7th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Lazard 7th Annual Healthcare Confere
Read more →NVAXNOVAVAX Reports Third Quarter 2010 Financial Results
ROCKVILLE, Md., Nov. 5, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2010. Novavax reported a net loss of $10.4 million, or $0.10 per share, for the third quarter of 2010 compared to a net
Read more →NVAXNOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
ROCKVILLE, Md., Nov. 4, 2010 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded approximately $978,000 in grants under the Internal Revenue Service's Qualifying Therapeutic Discovery Project ("QTDP"). This program was created under the Patient P
Read more →NVAXNovavax to Report Third Quarter 2010 Financial Results on November 5, 2010
ROCKVILLE, Md., Oct. 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Dr. Rahul Singhvi, President & Chief Executive Officer, and members of senior management will provide a corporate update and review of third quarter 2010 financial results via a we
Read more →NVAXNOVAVAX to Present at BIO Investor Forum
ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Mr. Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the BIO Investor Forum. The presentation will take pl
Read more →NVAXNOVAVAX to Present at Stifel Nicolaus Conference
ROCKVILLE, Md., Sept. 8 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Mr. Frederick Driscoll, Chief Financial Officer of Novavax will be presenting at the Stifel Nicolaus Conference. The presentation will take place on Friday,
Read more →NVAXNOVAVAX to Present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
ROCKVILLE, Md., Sept. 8 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the American Society for Microbiology (ASM) sponsored, ICAAC. The Conference will take place September 11-15, 2010 at the
Read more →NVAXNOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
ROCKVILLE, Md., Aug. 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) President and CEO Dr. Rahul Singhvi today attended the press briefing by U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials announcing a $2 billion plan to acc
Read more →NVAXNOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
ROCKVILLE, Md., Aug. 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the IMVAC Summit. The Conference will take place August 17-19, 2010 at the Royal Sonesta Hotel, Cambridge, MA. D
Read more →NVAXNovavax Reports Positive Results from Pre-Clinical Safety Study of Respiratory Syncytial Virus (RSV) Vaccine Candidate
ROCKVILLE, Md., Aug. 12 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus (RSV), showed the vaccine to be safe and well-tolerated at all doses tes
Read more →NVAXNOVAVAX Reports Second Quarter 2010 Financial Results
ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the second quarter ended June 30, 2010. Novavax reported a net loss of $9.4 million, or $0.09 per share, for the second quarter of 2010 compared to a net loss of $
Read more →NVAXNOVAVAX Elects Richard H. Douglas to its Board of Directors
ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Richard Douglas, Ph.D. to its board of directors. Dr. Douglas is currently Senior Vice President, Corporate Development at Genzyme Corp. As a leader of Genzyme's Corpo
Read more →Competitive Position
How NVAX ranks across every disease it competes inCompetitive Position is a premium feature
See how NVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial